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Abstract:
High resolution and colour vision is derived from cone photoreceptors within the retina of the
eye. These highly specialised neuronal cells convert energy from incident light into changes
in cellular membrane potential. Action potentials are then relayed and processed within the
inner retina and the cerebral cortex. Loss of function in the cone photoreceptors is the direct
cause of visual loss for millions o f patients. Yet for many of the most common causes of
blindness cone photoreceptor dysfunction occurs late on in the disease and is secondary to
inherited and/or environmental influences that primarily affect other cell types. Cone
photoreceptors are then secondarily affected and it is once their function is lost that the patient
becomes visually disabled.
The aim of this thesis was to evaluate therapies targeting the molecular steps of cone
photoreceptor death rather than the underlying pathology. If effective at slowing cone
photoreceptor degeneration and preserving function, such therapies could be applicable to
large numbers of patients with a variety of underlying defects. There will however be
continued stimuli for cell death as the primary defect has not been corrected and so it is
important to determine the magnitude and duration of any treatment effect. The experiments
of this thesis were performed in an animal model of inherited retinal degeneration derived to
allow repeated in vivo assessments of cone photoreceptor function and survival. Gene
therapy and intra-ocular injections were used to evaluate proteins with contrasting modes of
action.
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Chapter 1 Introduction
1.1 Overview
Retinal diseases severely impair vision for millions of people. For many of the
most common disorders, including rod-cone dystrophies and age-related macular
degeneration (AMD), the cone photoreceptors continue to function until the late
stages of the disease. However, in time the cone photoreceptors become
secondarily affected resulting in the loss of the high acuity central visual field,
and colour vision, on which normal functional lives are so dependent.
The recent trials of gene-replacement therapy for a form of Leber’s congenital
amaurosis have demonstrated that selected monogenic disorders can be treated
safely and effectively by targeting the underlying genetic mutation.1-6 However
genetic heterogeneity, early onset structural changes, gain of function mutations,
dominant negative mutations, and poorly characterised aetiology all present
significant challenges for similar treatments to be used for the majority of retinal
disorders.
In contrast ‘proof of concept’ experiments have been performed with
neuroprotective factors to show that targeting the process of photoreceptor death
may provide a treatment of widespread use regardless of the underlying disease.
Even a limited slowing of photoreceptor degeneration could give millions of
people valuable years of extra sight. CNTF, a cytokine with neuroprotective
effects, is currently in phase II clinical trials,7 though studies in animal models
have identified dose-related toxic effects on photoreceptors.8;9 Other means of
neuroprotection are also under investigation but important questions remain,
particularly as to whether any effect is sustained over time and whether rescuing
cone photoreceptors, with their importance for normal quality of life, is feasible
in the presence of established rod photoreceptor degeneration.
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1.2 The mammalian eye
The mammalian eye consists of three major anatomical layers, which are shown
in Figure 1-1. The outermost layer consists of relatively tough tissues, namely
the opaque fibrocollagenous sclera and the transparent cornea. The middle layer
in contrast consists of highly vascular tissues, known collectively as the uvea. In
the posterior segment of the eye the uveal tissue constitutes the choroid, which is
the major blood supply to this portion of the eye and is also known as the
choriocapillaris. Anterior to the choroid is the ciliary body and then iris. It is
within the ciliary body that the aqueous fluid filling the anterior portion of the
eye is continuously produced, and that the muscles are found which act to alter
the shape and hence refractive strength of the intraocular lens. The iris too
contains within it smooth muscle tissues and is the pigmented sphincter that
determines the pupillary aperture of the eye.
iris
lens
retina
sclera
cornea
optic nerve
RPE
vitreous gel
choroid
ciliary body
Figure 1-1 Cross section of the eye. The eye consists of 3 principal layers: 1: sclera and
cornea (labels in black); 2: choroid, iris and ciliary body (labels in red); 3: retina and
retinal pigment epithelium (RPE) (labels in grey). The vitreous gel, neighbouring the
innermost border of the neuroretina, is approximately 98% water and translucent in the
adult eye.
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The inner most layer consists of the retinal pigment epithelium (RPE) and
neuroretina, with the latter bordering the vitreous cavity. It is within the
neuroretina that incident light is absorbed, having been focussed by the cornea
and lens. The process through which photons stimulate a change in membrane
potential is known as phototransduction and this occurs in specialised neuronal
cells known as photoreceptors. Photoreceptor derived changes in membrane
potential are processed within inner retinal layers, and in turn lead to action
potentials within ganglion cells, the axons of which leave the eye within the optic
nerve to synapse in sub-cortical visual centres of the brain.
1.2.1 The neuroretina
The mammalian retina is a highly specialised multilayered tissue, as shown in
Figure 1-2, consisting of 6 major neuronal cell types. The photo-sensitive cells,
the sensory neurons of the visual system, are the rod and cone photoreceptors
whose nuclei reside in the outer nuclear layer (ONL). Extending in from the
ONL the photoreceptors have cellular processes that synapse in the inner
plexiform layer (IPL). Extending out from the ONL, into the sub-retinal space,
these cells have inner and outer segments.10 The outer segments of cone
photoreceptors are conical in shape, whilst those of rods are long, thin and
cylindrical (Figures 1-3 and 1-4). In both cases the inner segments are rich in
mitochondria and the cellular apparatus necessary for protein synthesis, whilst
the outer segments are densely packed with membranes in which the light-
sensitive photopigments are located. In cones the outer segment membranes are
formed by repeated invaginations of the cellular membrane, where as in rods
there are discrete intracellular membrane discs. The protein rich outer segment
membranes are continually renewed, with old membranes discarded for
degradation by the neighbouring retinal pigment epithelial (RPE cells).
Cone photoreceptors sub-serve high resolution and colour vision in high ambient
light conditions (referred to as photopic conditions). They are have much lower
light sensitivity than rod photoreceptors, but produce faster responses and adapt
to light more efficiently. This means that under natural light conditions cones do
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not become saturated, and provide greater temporal resolution vision than is
derived from rods. In humans there are three types of cone photoreceptor with
distinct opsin proteins bound to a common chromophore (11-cis-retinal) giving
the different absorption spectra for colour vision. Peak sensitivities are at
approximately 420nm, 530 nm and 560 nm for S- (short/blue), M- (middle/green)
and L- (long/red) cone photopigments respectively. M- and L-cone opsins have
about 96% amino acid sequence homology with each other and about 42%
sequence homology with S-cone and the rod opsin protein.11 Humans and
selected non-human primates have a specialised region at the posterior pole of
the eye known as the fovea which consists of densely packed cones, devoid of
rod photoreceptors or overlying blood vessels; it is this portion of the retina that
is used for fixation and for highest acuity vision.
In mice there are only two types of cone opsin (M- and S-). Most cones in mice
express both these opsins, but the degree of M-opsin expression varies across the
retina, being greatest in the superior retina and least in the inferior retina.12
Furthermore, in the mouse cones are evenly distributed across the retinal surface
without any specialised fovea.13;14 As in Figure 1-2 cone photoreceptor nuclei in
the mouse eye form a single row at the outermost edge of the ONL.
Rod photoreceptor cells, in both humans and rodents, are widely distributed
across the retina and far outweigh the number of cones (making up 97% of the
total photoreceptor population in mice13 and 95% in humans).15 In the rodent it
is the rod nuclei that form the bulk of the ONL, though in humans this varies
with position in the retina.15 Rods are extremely sensitive to light and able to
detect single photons. Peripheral vision in scotopic (i.e. low light level)
conditions is primarily mediated through rod photoreceptors, but their ability to
adapt to bright light is limited. The peak sensitivity of the rod pigment is
approximately 496 nm.
In the outer plexiform layer of the retina the photoreceptive rods and cones
synapse with the second order neurons of the visual system, the horizontal and
bipolar cells whose nuclei are found in the inner nuclear layer. The synapses
between these cells and amacrine cells allow intra-retinal processing of the inputs
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to the visual system.16 Within the inner plexiform layer cells of the INL synapse
with cells of the innermost layer, the ganglion cell layer. It is the axons of the
ganglion cells that pass into the optic nerve to form the afferent connection from
the retina to the brain.
In addition to the neuronal cells of the retina there are permanent populations of
glial cells. Mueller glia, the processes of which transverse the retina, provide
physical as well as physiological support to the other cells of the retina. Through
a network of adherens junctions the inner foot processes of glia cells form the
inner limiting membrane of the retina which separates the retina from the
vitreous cavity. The outer foot processes of the Mueller glia are aligned with the
photoreceptor inner segments, and likewise through inter-cellular junctions, form
an outerlimiting membrane that is of structural importance to the photoreceptors.
Of note in the context of cone neuroprotection, Mueller glia respond to a variety
of stimuli by releasing trophic factors that act directly to support photoreceptor
survival and function.17 Other factors and cytokines released by Mueller glia
influence vascular permeability and retinal homoeostatsis. They have also
recently been found to have a role in intra-retinal visual pigment recycling for
cones under bright daytime light conditions.18 Other glial cells found in the
retina include astrocytes and microglia. Astrocytes too are heavily involved in
retinal haemostasis, in part through interactions with intra-retinal blood vessels.
The retinal microglia, derived from circulating monocytes, are central to immune
responses and tissue repair; they are activated early on in retinal degenerations
and are seen to migrate to the ONL, though the extent to which they perpetuate
the processes of neuronal death, as opposed to being merely reactive, is less
clear.19
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Figure 1-2 Cross section of retina from a transgenic mouse with green fluorescent
protein (GFP) expressed in cone photoreceptors. The section has been stained with an
antibody for RG opsin, which is found in cone photoreceptor outer segments. DAPI has
been used to stain nuclei. The principal layers of the retina are evident: outer nuclear
layer (ONL), outer plexiform layer (OPL), inner nuclear layer (INL), inner plexiform
layer (IPL) and ganglion cell layer (GCL). The ganglion cell layer is the innermost, and
neighbours the vitreous cavity.
Figure 1-3 Field emission scanning electron microscope image of human retina showing
rod and cone outer segments. Image courtesy of Dr P Munro, Imaging Dept, UCL
Institute of Ophthalmology
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The retinal pigment epithelium
The RPE, on the outermost border of the neuroretina, consists of a single layer of
polarised and pigmented cuboidal epithelial cells (Figure 1-4 and Figure 1-5).
The melanin pigment within these cells reduces scattering of light within the
retina, and thus contributes to the high degree of spatial discrimination and acuity
that the visual system can achieve. The cells are also closely adherent to one
another through intervening tight, gap and adherens junctions and thus create a
physiological barrier between the choriocapillaris on one side and the neuroretina
on the other. By controlling the passage of water, ions and selected molecules
the RPE cell layer actively maintains the chemical environment and homeostasis
of the outer retina. Furthermore the apical surface of these cells consists of
microvilli that interdigitate between the photoreceptors of the outer neuroretina.
Through these close approximations the RPE cells assist in cellular functions and
produce neurotrophic factors required for photoreceptor cell viability. The RPE
cells also phagocytose outer segments membranes that are discarded by
photoreceptors in the process of continual renewal; degradation of these within
the RPE cells generates lipofuscin pigments as a by-product, accumulation of
which has been identified as an important pathological step in several inherited
retinal degenerations.
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Figure 1-4 RPE cells in relation to principal retinal cell types. RPE microvilli are seen
to interdigitate between photoreceptor outer segments. Adapted from Deubner, Journal
American College of Nutrition, 2000.
Figure 1-5 Scanning electron micrograph of the RPE monolayer. The RPE cells are
closely adherent to one another to form a continuous layer which regulates the passage
of water and metabolites to and from the retina. This image is taken from a macaque
eye that had undergone experimental surgery; the small spheres on the surface of some
RPE cells are residual heavy liquid following the surgery, and not a normal feature of
the RPE monolayer.
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1.2.2 Phototransduction
The process through which light stimulates a change in membrane potential is
known as phototransduction. Central to this is the light sensitive molecule,
known as a chromophore, 11-cis-retinal. On absorption of a photon the 11-cis-
retinal molecule undergoes a conformation change (a cis- to trans- isomerisation
resulting in straightening of the molecule) such that it becomes all-trans-retinal.
In mammalian photoreceptors the chromophore is bound through a covalent
Schiff-base linkage to a lysine reside in the seventh helix of an opsin molecule.
The opsin molecules all have seven transmembrane helices and the 11-cis-retinal
nests in between these. Variations in the opsin molecule sequence determine the
peak absorption spectrum of the complex.
The steps through which photo-isomerisation of the rod chromophore-opsin
complex leads to a change in membrane potential are shown in Figure 1-6. Of
note, prior to activation of the phototransduction process the cGMP-gated (CNG)
channel is open permitting a constant influx of cations; this is known as the ‘dark
current’. Activation of the phototransduction process results in closure of these
channels and membrane hyperpolarisation. This in turn leads to decreased
release of neurotransmitter at the OPL synapse.
In contrast to most neuronal cells where activation leads to an all or nothing
depolarisation, the hyperpolarisation and change in neurotransmitter release in
stimulated photoreceptors cells is graded and proportional to stimulus strength.
In part this is due to the phototransduction cascade activation being tightly
regulated by negative feedback mechanisms. In addition to the calcium
dependent feedback mechanisms shown and discussed in Figure 1-6, the cascade
is also terminated by phosphorylation of activated rhodopsin by rhodopsin kinase
and the subsequent binding of phosphorylated rhodopsin by arrestin. Also the
bound GTP promoting activation of the transducin -subunit is hydrolysed
resulting in the phosphodiesterase complex returning to its inhibited state.
Although the phototransduction process in cones is very similar to that shown in
Figure 1-6 for rods a number of the proteins involved are cell-type specific.
These differences are likely to account for the differences in response kinetics
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between rods and cones (cones are approximately 100 times less sensitive than
rods but their response kinetics are faster). The protein differences are also
important when considering disease mechanisms and the cells primarily affected
by a mutation. For example the cGMP-gated channel subunits in rods are
CNGA1 and CNGB1, whereas in cones the analogous subunits are CNGA3 and
CNGB3. Cones also have specific transducin and cGMP-PDE proteins, and
alternatives to the arrestin and recoverin molecules seen in rods (known as X-
arrestin and visinin in cones respectively).20;21
The number of different proteins involved in these high-energy pathways is a
factor in why there are so many disease-causing mutations involving
phototransduction proteins. In addition of course, the capacity for repair or
regneneration in these neuronal cells is limited. Indeed, by definition the IRD-
causing mutations that affect the phototransduction cascade lead not only to loss
of function, but also to photoreceptor death.
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Figure 1-6 Activation of the phototransduction cascade. 11-cis-retinal-
rhodopsin, bound to disc membrane in the rod outer segment, is activated by an
incident photon (hv). The activated rhodopsin (R+) in turn binds the
heterotrimeric G-protein, transducin (G), catalysing the exchange of GDP for
GTP and resulting in the formation of an activated -subunit (G+) bound to
GTP. Two activated G protein -subunits in turn bind and activate photoreceptor
cell specific phosphodiesterase (PDE6) (G+-E+), leading to hydrolysis of
cGMP (cG). The activation step involves the removal of inhibitory -subunits
from the active site of this enzyme. The consequent decrease in cytoplasmic
cGMP levels leads to closure of a cGMP gated cation channel and cessation of
the resting influx of sodium and calcium ions. The cell therefore hyperpolarises.
Feedback mechanisms are simultaneously activated in part through cytoplasmic
calcium levels. As a sodium/calcium exchanger continues to function the
cytoplasmic calcium levels decline and calcium is released from both the
guanylyl cyclase activating protein (GCAP) and membrane bound calmodulin
(CM); calcium free GCAP then binds and activates guanylate cyclase (GC),
leading to regeneration of cGMP. Calcium-free calmodulin dissociates from the
cGMP gated cation channels altering their affinity for cGMP. Calcium ions also
inhibit the phosphorylation of rhodopsin via the protein recoverin or S-modulin.
Adapted from Lamb and Pugh.22
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1.2.3 The visual cycle
Chromophore pigment is recycled in an enzyme cascade known as the visual
cycle, the key steps of which are shown in Figure 1-7. All-trans-retinol, obtained
either following phototransduction in photoreceptors or de novo from the blood
vessels is isomerised within the RPE to 11-cis-retinol. Cone photopigment
recycling is also performed in Mueller cells, which like the RPE cells, are in
close proximity.23
In addition to the steps and enzymes shown in Figure 1-7, two others are of note
because of their pathological significance:
1. RPE-retinal G-protein coupled receptor (RGR).
All-trans-retinol (vitamin A) is also delivered to the RPE cells from the
systemic circulation bound to serum retinol binding-protein. All-trans-
retinol binds to the RPE-retinal G-protein coupled receptor (RGR); like
rhodopsin this protein is a seven transmembrane domain receptor and
mutations within its gene (RGR) are a cause of RP.
2. Cellular retinaldehyde binding-protein (CRalBP)
Once all-trans retinal esters have been isomerised to 11-cis-retinol the latter
is bound to cellular retinaldehyde binding-protein (CRalBP) prior to binding
by 11-cis retinol dehydrogenase 5. Mutations in the CRalBP gene (RLBP1)
are also found in RP.
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Figure 1-7 The steps of the visual cycle. The activation of rhodopsin by light occurs
through the isomerisation of the bound chromophore, 11-cis-retinal, to all-trans-retinal.
This is then released from rhodopsin and reacts with the membrane lipid phosphatidyl-
ethanolamine (PE) before being transported back to the cytoplasm by ABCA4. After
modification to all-trans-retinol by retinol dehydrogenase (At-RDH) it is transported to
the RPE and trans-isomerised to 11-cis-retinal through the actions of LRAT, RPE65 and
RDH5. The reaction of all-trans retinal with PE also generates the precursors of
lipofuscin fluorophores (e.g., N-retinylidene-PE) which are taken up by the RPE through
phagocytosis to form lipofuscin fluorophores (e.g., A-2E). Abbreviations: At-RDH, all-
trans retinol dehydrogenase; LRAT, lecithin-retinol acyltransferase; RPE65, retinal
pigment epithelium-specific protein, 65-kDa; RDH5, 11-cis-retinol dehydrogenase 5; PE,
phosphatidylethanolamine; A-2E, N-retinylidene-N-retinylethanolamine. Adapted from
Pacione et al.24
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1.3 Inherited retinal degenerations
In the developed world inherited retinal degenerations (IRDs) are an important
cause of blindness in children and those of a working age, and at present no
curative treatments exist. Retinitis pigmentosa, the most prevalent form of IRD,
affects between 1/7000 and 1/3000 of the population, typically causing blindness
in the 4th or 5th decade of life.25-27 Other IRDs include X-linked retinoschisis,
Best’s disease, Stargardt’s disease and the progressive cone and cone-rod
dystrophies. Recently age-related macular degeneration (AMD) has been shown
to have an underlying genetic basis, but involving several genes (reviewed by
Zanke et al.)28
1.3.1 Classifications and Genotype-Phenotype Correlations
The classification of IRDs has historically been on the basis of clinical
characteristics and patterns of inheritance. However, since the 1980s there has
been a rapid increase in the understanding of the molecular basis for these
diseases with over 200 retinal disease loci, and 160 disease-causing genes
identified to date (Figure 1-8).29 Complexity arises however as the effect of a
specific mutation can vary markedly between individuals. In part this can be due
to the effect of other genes as is well illustrated with the Rdh8 and Abca4
double-knockout mouse.30 Absence of both of these genes, which are involved
in all-trans-retinal clearance from photoreceptors results in a fast retinal
degeneration whereas absence of either in isolation does not; the resultant retinal
degeneration can therefore be described as a digenic disorder. However, the
degeneration is not seen in all double-knockout animals and it has been found
that in part incidence is determined by which of two different alleles of Rpe65
are also carried. An allele variant with leucine (Leu) instead of methionine (Met)
at position 450 leads to greater diretinoid-pyridinium-ethanolamine (A2E)
accumulation.31 A2E is a by-product of all-trans-retinal metabolism and its
accumulation is toxic to RPE cells.32;33 A greater incidence of retinal
degeneration is therefore seen in mice that carry the Leu450 variant of Rpe65 in
addition to the Rdh8 and Abca4 double-knockout.
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In patients, digenic forms of retinitis pigmentosa are not common but are seen
with a protein-truncating or null-sequence change in ROM1 in conjunction with a
single mis-sense mutation in RDS.34;35 Both these genes encode structural
proteins required for the formation and maintenance of rod outer segment discs.
RDS mutations in particular are associated with variable phenotypes. Different
mutations within this same gene cause phenotypes including autosomal dominant
retinitis pigmentosa (adRP), fundus flavimaculatus, retinitis punctata albescens,
central areolar choroidal atrophy, diffuse choriocapillaris atrophy, cone–rod
dystrophy, age-related macular degeneration-like maculopathy, choroidal
neovascularisation, pattern dystrophy, butterfly-shaped pigment dystrophy and
adult-onset foveomacular dystrophy.36 In addition for some of the mutations
marked diversity is seen within families, where genetic diversity between
individuals will be limited. Although difficult to prove this is likely to be due to
environmental interactions as well as the influence of additional modifier genes.
The complexity of the underlying genetics means that in practice a careful
phenotypic description is as important as ever to help guide where to look for
mutations and how to interpret them.
Determination of the phenotype of patients with inherited retinal degenerations is
greatly aided by the use of the electroretinogram (ERG). In this procedure the
summed electrical responses of the retina to a stimulus are recorded with a
electrode in contact with the cornea. By varying the stimulus or background
light characteristics it is possible to specifically examine rod or cone
photoreceptor mediated responses. To examine rod-pathway responses the
patient can be dark-adapted and then dim light flashes are presented under
scotopic (dark-adapted) conditions. Conversely, to examine cone-pathway
responses the patient can be light-adapted to achieve bleaching of the rod
photoreceptors, and then whilst still exposed to bright background light (photopic)
conditions bright flashes are presented to the subject. Further cone-specificity
can be achieved using high frequency stimuli, as is the case in photopic flicker
ERG protocols. The initial response recorded under photopic or scotopic
conditions is a negative reflection (known as the a-wave) which is as a direct
result of cyclic nucleotide gated cation channels closing in photoreceptor outer
segments. Subsequently there is a larger positive displacement reflecting post-
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photoreceptor neuronal activity within the retina.37 By determining the extent of
functional impairment in specific photoreceptor populations the ERG can be used
as an objective means of detecting progression and allows detailed phenotypic
descriptions to be made. Furthermore, with limited adaptations similar protocols
can be used both in experimental animal models and in humans facilitating
research and genotype-phenotype correlations.
The combination of detailed history taking, clinical examination and clinical
testing, coupled with molecular genetics gives a powerful tool to diagnose
patients and give appropriate prognoses and genetic counselling. Only by
knowing which variant of a disease or syndrome the patient is suffering from can
health services move towards individualised care. Furthermore, the associated
understanding of the disease pathology and mechanisms has driven research into
potential therapies.
Figure 1-8 The number of mapped and identified retinal disease genes from 1980 to
2010. Graph from the Retinal Information Network provided by the University of
Texas-Houston Health Science Centre (www.sph.uth.tmc.edu/RetNet)
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1.3.2 Retinitis Pigmentosa
The term ‘retinitis pigmentosa’ (RP) is used to describe a heterogeneous group of
inherited disorders in which there are shared clinical features and hence a
common phenotype. The underlying biological pathways and disease
mechanisms giving rise to that phenotype are however highly variable. Typically
patients with RP have a progressive rod-cone dystrophy and so the early
symptoms are related to rod dysfunction in the peripheral visual field. This may
not be noticed until advanced or tested for, but the peripheral rod photoreceptor
loss results in nyctalopia (poor night vision) and reduced sensitivity in the
peripheral visual field (tunnel vision) that will in time render the patient
ineligible for driving. The loss of photoreceptors is associated with disruption of
cells in the retinal pigment epithelium and the release of pigment granules and so
one of the characteristic clinical signs is the development of peripheral sub-
retinal pigment deposits.38 These are shown in Figure 1-9 and are most marked
alongside blood vessels forming perivascular clusters known as bone-spicules
due to their morphological appearance.39 The rod photoreceptor loss is
progressive from the retinal periphery towards the macula, and so an abnormal
retinal reflex may sometimes be seen as ring at the advancing edge of the area of
pigmentation. In time there follows a secondary loss of cone photoreceptors and
it is this that has the greatest impact on the patients. Patients with early RP, as
with those with congenital stationary night blindness in which there is only rod
photoreceptor loss, commonly continue to work and live mobile and independent
lives. In the early stages they can continue to hold a full driving licence.
However in RP patients the cone photoreceptors become secondarily affected in
time leading to a deterioration in central visual acuity and colour vision. It is this
loss of cone-based vision that is of greatest functional significance to patients and
ultimately leads to patients being registered as blind.
Although most case of RP are characterised by the typical rod-cone loss, there
are multiple variants, including those where the loss of cone photoreceptors is
simultaneous to that of rods.40;41 These are referred to as cone-rod degenerations
and have symptoms of cone loss from early on in the disease.
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The clinical signs seen in RP in addition to bone-spicule formation also relate to
photoreceptor loss. Retinal blood vessels are subject to autoregulation, so as
photoreceptors loss progresses and oxygen demand diminishes the retinal arteries
are seen to become attenuated. The reduced blood flow also gives the optic disc
an altered appearance, described as ‘waxy’ in colour. This is in contrast to the
pale disc of arteriolar occlusions as in RP the inner retina is preserved42 and so
there is not the axonal loss seen in other causes of reduced nerve head perfusion.
In advanced RP the macula itself may be seen to be abnormal with atrophic or
cellophane features. Cystoid macular oedema may occur as a further
complication. Loss of retinal thickness can also lead to a relative unmasking of
the large choroidal vessels that can not ordinarily be seen.39
The timecourse of disease progression in RP is very variable, again reflecting
that it is now known to be a heterogeneous group of conditions with a large
variety of underlying genetic mutations and additional influences. In general
though, symptoms or signs of the disease typically present during the 2nd or 3rd
decade of life, with legal blindness following in the 4th to 5th decades once cone
photoreceptor function is also affected. X-linked, autosomal recessive and
autosomal dominant cases generally have their age of onset at successively
greater ages, though there is considerable overlap. Leber’s congenital amaurosis
is a severe congenital form and syndromic cases usually present in infancy.
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Figure 1-9 Collage of fundus photographs showing typical features of retinitis
pigmentosa. In the retinal periphery there is evidence of bone spicule formation.
Retinal blood vessels are attenuated and the optic disc has a waxy pallor appearance.
Prior to the onset of genetic tests patients were described on the basis of the
phenotype and pattern of inheritance. These distinctions are still used both
clinically and to sub-classify the large variety of identified mutations as in Table
1-1.29 The major sub-classifications and figures for their approximate prevalence
are shown in Figure 1-10. Autosomal dominant RP (AdRP), autosomal recessive,
and x-linked RP encompass approximately 30%, 20% and 15% of non-
syndromic cases respectively. Alternatively these may be described in terms of
total RP cases, in which case the prevalences are 20%, 13% and 8%.
Approximately 5% of the non-syndromic cases are early-onset forms of RP that
are termed recessive Leber congenital amaurosis (LCA). The remaining 30% of
non-syndromic cases are of sporadic or unknown inheritance and these will
include undiagnosed recessive mutations as well as de-novo dominant mutations.
In addition to the non-syndromic cases of RP there are also the syndromic forms
which involve other organs in addition to the eye. For example, in Usher
syndrome the development of RP is preceded by congenital hearing impairment.
In Bardet-Biedl syndrome ophthalmic features are accompanied by polydactyly,
obesity, renal abnormalities, and mental retardation. Multiple other, and
relatively rare, systemic associations also exist.29 Prevalence estimates vary with
the population studied and due to variations in how diagnostic criteria and
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definitions are applied.27 The percentages given in Figure 1-10 are therefore
approximations.26
Figure 1-10 Estimated prevalence of retinitis pigmentosa sub-types. Clinically cases of
RP are described in terms of a syndromic or non-syndromic phenotype if this can be
determined. The non-syndromic cases are then described in terms of inheritance.
Autosomal-domiant RP (AdRP) represents the most prevalent single sub-type,
representing approximately 30% of all non-syndromic cases (and 20% of all RP cases).
The most common single cause of syndromic RP is Usher syndrome. Estimates of
prevalence are adapted from Daiger et al.26
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1.3.3 Gene mutations in RP
The progress in molecular genetics and diagnostic services available means that
in practice the responsible mutation can be identified in about 50-60% of adRP
patients and 30% of those with recessive RP.43 In all over 45 different genes
have been identified as causing RP, and further loci have been linked though the
responsible genes have yet to be identified (Table 1-1).29
RP sub-type Mapped and identified genes
Autosomal
dominant
CA4, CRX, FSCN2, GUCA1B, IMPDH1, KLHL7, NR2E3, NRL,
PRPF3, PRPF8, PRPF31, PRPH2, RDH12, RHO, ROM1, RP1,
RP9, SEMA4A, SNRNP200, TOPORS
Autosomal
recessive
ABCA4, C2ORF71, CERKL, CNGA1, CNGB1, CRB1, EYS,
IDH3B, LRAT, MERTK, NR2E3, NRL, PDE6A, PDE6B, PRCD,
PROM1, RBP3, RGR, RHO, RLBP1, RP1, RPE65, SAG,
SPATA7, TULP1, USH2A
X-linked RP2, RPGR
Table 1-1 Mapped and identified genes for the major sub-types of RP. Source RetNet
online database, accessed September 2010.29
The majority of genes in which mutations causing RP are found are directly
involved in phototransduction. Other genes mutated in RP are for proteins
involved in the visual cycle, photoreceptor structure and additional cellular
functions. The fact that there are so many different disease causing mutations in
photoreceptor related genes may reflect the complexity of these cells, their high
energy requirements and that damaged cells are not replaced in the mature
retina.44;45
Phototransduction proteins
The gene for rhodopsin (RHO) was the first to be associated with RP46;47 and
mutations in this gene remain the most common single cause of RP, accounting
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for approximately 25% of autosomal dominant cases48 as well as autosomal
recessive and sporadic cases.49-51 A large variety of disease-causing mutations
are found within the gene; to date more than 120 point mutations alone have been
identified,29 about 60% of which localise to the transmembrane domain of the
protein and 35% to the extracellular loops; only rarely are mutations affecting the
intracellular loops pathogenic.52 Rhodopsin mutations are commonly described
in terms of classes based on their behaviour in tissue culture experiments.53;54
Class II mutations are the most common and are thought to result in defective
folding such that there is abnormal protein aggregation. Such proteins are then
usually marked for degradation within the cell. Class I mutations cause
abnormal trafficking of the mutant rhodopsin protein within the cell.
Mutations in the genes for the  catalytic unit and  subunits of PDE6 (PDE6A
and PDE6B respectively), the  subunit of the rod cyclic nucleotide gated
channel (CNGA1), and arrestin (SAG) have also been identified as causes of RP
(reviewed by Phelan and Bok).38 Mutations in these phototransduction-related
genes are also important causes of other inherited retinal degenerations in
addition to RP, including congenital stationary night blindness and cone
dystrophies.
Visual cycle proteins
The second most common group of genes mutated in RP are those encoding
proteins involved in the visual cycle. The genes encoding RPE65 (RPE65),
CRalBP (RLBP1), RGR (RGR) and ABCR (ABCA4) are all known to be mutated
in cases of RP.38 Of these the ABCA4 gene is of note because of the wide variety
of phenotypes that can be caused by mutations in the gene.55 The first phenotype
to be associated with ABCA4 mutations was that of Stargardt macular dystrophy
and fundus flavimaculatus. Since then mutations in the gene have also been
identified as the most common cause of autosomal recessive cone-rod dystrophy,
56 in addition to being a cause of autosomal recessive RP.57;58 Mutations in the
ABCA4 gene were also initially described as a cause of AMD, but repeated
studies since have not validated that claim, and have instead highlighted the
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challenges of ascribing pathological significance to changes in such a large gene
(50 exons) in which sequence changes are so common in the general population
(reviewed by Lotery and Trump).59
Structural proteins
Peripherin/RDS and ROM1 are proteins with four transmembrane domains that
are of integral structural importance for rod outer segment discs, though they
may also have additional functions. The proteins are encoded by the genes RDS
and ROM1 respectively. Mutations in RDS alone cause RP60;61 and mutations in
the combination of RDS and ROM1 are a cause of digenic RP.34;35 However
there is also evidence that ROM1 mutations in isolation are causative of RP.62-64
Transcription factors
Mutations of the photoreceptor cell transcription factors NRL (NRL) and CRX
(CRX) interfere with photoreceptor development and later in life cause retinal
degeneration. NR2E3 mutations are best known as a cause of enhanced S cone
syndrome, in which there is photoreceptor death but a relative increase in the
number and function of short-wavelength cones.65 They are also however
causative of RP.66
Mutatations in syndromic RP
In contrast to the non-syndromic RP mutations affecting photoreceptor or RPE-
specific proteins, the causative mutations in syndromic RP typically affect
proteins of systemic importance. For example in Bardet-Biedel syndrome (BBS)
causative mutations affect proteins related to the primary cilium, a microtubule-
based organelle that protrudes from the surface of almost all human cell types
and which is of importance in extracellular signalling pathways.67 Patients with
mutations in such proteins are characterised by obesity, renal dysfunction, retinal
degeneration, cognitive impairment, and polydactyly. Likewise in Refsum’s
disease mutations in PEX1 affect cellular degradation pathways in a variety of
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cell types,68 in Usher syndrome a myosin mutation (MYO7A) leads to impaired
organelle motility within cells,69 and in Stickler syndrome the function of
collagen proteins are compromised throughout the body leading to joint, hearing
and cleft abnormalities in addition to retinopathy.29;70
1.4 Photoreceptor cell death in inherited retinal
degenerations
In most cases of RP the disease-causing allele is expressed exclusively in rod
photoreceptors, and not in cone photoreceptors. Examples include mutations in
rhodopsin,46;47;71 or rod-specific cyclic GMP.72;73 Early stages of the disease are
therefore characterised by rod dysfunction and subsequently by rod
photoreceptor cell loss. However, a common feature of the disease is that the
mutation-dependent rod photoreceptor death is then followed by a secondary
degeneration of the previously healthy cone photoreceptors.74 This secondary
loss of cone photoreceptors occurs regardless of the underlying mutation and
furthermore it is this loss of cone photoreceptors that leads to the greatest
reduction in quality of life.
Another common feature, regardless of the underlying mutation, is that the
photoreceptor death progresses in a controlled manner without significant
inflammation or disruption to the inner retina. Common molecular pathways of
cell death are employed, again despite the large variety of causal mutations.
Studies to elucidate these mutual mechanisms leading to secondary cone
photoreceptor degeneration, and orderly photoreceptor cell death have furthered
understanding of the disease. They have also permitted identification of potential
therapeutic targets which are of relevance to large numbers of RP patients,
regardless of their precise genotype.
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1.4.1 Secondary loss of cone photoreceptors
To date, there is no known form of retinal degeneration in humans or mice where
rod photoreceptor death is not followed by cone photoreceptor death.75 In
contrast there are well described progressive cone dystrophies (PCDs) in which
the functional deficit is confined to the photopic system, at least until late stages
of the disease. These include patients affected by mutations in the GUCA1A
gene, which encodes the phototransduction protein guanylate cyclase activating
protein-1 (GCAP1), and patients with CNGA3 and CNGB3 mutations, which
encode the - and - subunits of cone cGMP-gated cation channels. CNGA3 and
CNGB3 mutations are more commonly associated with achromatopsia (a
stationary cone dysfunction) but are also seen in PCDs (reviewed by Michaelides
et al.).56 There is good circumstantial evidence therefore of a cone dependency
on rod photoreceptor survival which is not reciprocal.
Studies in murine models in particular have helped identify multiple molecular
mechanisms and pathways that contribute to the dependency of cones on rods for
survival. Although mice do not have a fovea the relative numbers of rods and
cones in the peripheral retina is similar to that in humans, and there are many
similarities in the nature of rod-cone degenerations in humans and mice.13;15
Ultimately however, the challenge is to detect how such mechanisms cause a
slow and progressive degeneration in human cones for years after the rods have
almost completely degenerated, and to identify therapeutic targets. Even a
partial slowing of this secondary cone loss could yield valuable years of extra
sight for millions of people.
Rod-derived paracrine effects
Transplantation studies in the rd1 mouse demonstrated limited morphological
rescue of degenerating cone photoreceptors following the injection of rod
photoreceptors into the sub-retinal space.76 This suggested that the rods
themselves released a diffusible factor causative of the preservation seen. Indeed
co-culture experiments were supportive of this hypothesis77 and subsequently
Leveillard et al. isolated a protein produced by rods that promoted short-term
Chapter 1: Introduction
41
cone survival in vitro and in vivo in the rd mouse.78 The protein was called Rod
derived cone viability factor (RdCVF) and is encoded by the Nxnl1 (Txn16)
gene.79 The principal limitation of such studies in the rd mouse is however, that
the speed of degeneration is such that the rods are degenerating before the mouse
photoreceptor layer is fully developed.80 Developmental factors are therefore
still likely to be of influence and the course of degeneration contrasts with that in
most patients.
In further experiments RdCVF has been evaluated in the P23H rat.81 This is a
better model of rod-cone degeneration, in which a mutated mouse rhodopsin
gene (P23H) is expressed under the control of the rhodopsin promoter.82 The
mutation is clinically relevant (causing 12% of autosomal dominant RP in the
United States)71 and produces a rod-cone degeneration in the heterozygous rats.
The authors demonstrated that repeated injections into the subretinal space did
produce morphological and functional preservation of cones, compared to PBS-
treated and control eyes, at a single late timepoint. The absolute values of cone
numbers preserved and improvement in ERG function were small compared to
normal values in non-degenerate retina. This was despite the injections being
administered at timepoints when rod loss was almost complete and endogenous
levels of RdCVF in the degenerate retina were presumably minimal. It will be
interesting to see if greater efficacy, supporting a major role for this protein, is
achieved with more sustained expression (eg with a viral vector). However, at
present the data is more suggestive of a supportive role for this protein as
opposed to being the dominant rod-cone influence. This function is further
supported by the work of Punzo et al. which found that in multiple murine
models of RP the cones survive prolonged periods after the rods after almost
completely degenerated.75 This is similar to observations in humans and
indicates that some cones do survive prolonged periods even when the number of
surviving rods, and so presumably concentration of rod-derived trophic factors, is
minimal.83
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Toxins and microglia
The death of rods may be associated with the release of toxic factors, and
mobilisation of microglia, that could themselves damage cones.84 Kedzierski et
al. studied a hemizygous-transgenic rds mouse in which the rds transgene had
been integrated into the x-chromosome.85 The authors noted that in contrast to
the random mosaic pattern of photoreceptor degeneration that could be expected,
the degeneration was noted to occur in patches involving both cells that were
expressing the transgene and others that were not. This could be explained by
the spread of some disease causing factor from genetically damaged cells to the
neighbouring genetically healthy cells. Such a factor could travel through the
extracellular space or through connecting gap junctions; the latter method is
referred to as the ‘bystander effect’ and is reviewed by H.Ripps.86 Gupta et al.
proposed a related theory in which rod death activates mobile microglia which in
turn also destroy cones.84
Where as a diffusible factor or inflammatory reaction would be expected to cause
a fairly uniform effect across the retinal surface, in practice sharp demarcation
lines are commonly seen between diseased and normal retina. This is evident for
example, on the borders of sectorial defects or at the edge of the retained central
island of preserved cone function in patients with advanced RP.87-89 In addition,
in many patients the cone cell death occurs slowly over many years or decades
after the rods have almost entirely disappeared. Detailed studies in a variety of
animal models have characterised the timings further and found that cone cell
death only commences after the major phase of rod death is largely complete.75
Toxic factors and microglia may play a role, but were they the dominant initiator
of cone cell death one would expect to see a closer temporal relationship between
the peak of rod photoreceptor and commencement of cone photoreceptor death.
Loss of structural support
In the mouse retina, and in peripheral areas of the human retina, the ONL is
predominantly made up of rod photoreceptors. It had been suggested that a lack
of surrounding rods could lead to a lack of physical support for the cone
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photoreceptors, and subsequently to their loss of function and death. This seems
plausible for the murine retina, where for example in the rhodopsin knockout the
outer nuclear layer diminishes from 8-10 nuclei thick to 1 nuclei thick within the
space of 10 weeks.90 However this would not explain cone loss in the human
fovea. Furthermore this theory ignores the physical support Mue ller cells and
RPE cells provide cone photoreceptors.91-92
Oxidative stress
Photoreceptors have a very high rate of oxygen consumption, and this is
supported by the highly vascular choroid. Choroidal blood vessels however lack
the capacity for autoregulation in response to tissue oxygen levels. It is therefore
argued that rod photoreceptor death, and hence reduced oxygen comsumption,
leads to an increase in oxygen tension in the outer retina and damage to cones
through reactive oxygen species. This theory could also explain the retinal blood
vessel constriction that is seen as a characteristic feature of RP, as retinal vessels
do have the capacity for autoregulation. The theory would also explain why the
peripheral retina, with its high rod/cone ratio, is first to be affected whilst the
cone-dense fovea is not affected until late on. Intra-retinal oxygen levels have
been found to be significantly increased in the RCS93 and P23H rat94 in
association with rod degeneneration. It is however challenging to demonstrate
that hypoxia is the cause of subsequent cone-photoreceptor loss.
Shen et al. used immunofluorescent markers in a procine model of RP to
demonstrate evidence of lipid peroxidation, and other makers of oxidative
damage, in degenerating cone photoreceptors.95 It has also been demonstrated by
Okoye et al.96 and Yamada et al.97 that subjecting mice to hyperoxia leads to
photoreceptor loss and marked thining of the outer nuclear layer.
The hypothesis would be strengthened further if it could be demonstrated that
expression of antioxidants, specifically in the photoreceptor layers, did slow the
secondary cone loss in models of RP. Peter Campochiaro’s group have
attempted this by generating rd10 mice with increased expression of superoxide
dismutase ( SOD2) and catalase in the photoreceptors.98 Both these molecules
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are normal components of the cellular antioxidant defence system and their
expression was shown to reduce levels of free radicals in the outer retina of rd10
mice and reduce levels of protein markers for oxidative damage. Interestingly
expression of these two molecules did not cause any apparent reduction on rod
cell death as measured by ONL thickness at 2 timepoints; the first was at P25
when rod degeneration was well in progress and the second at P325 when the rod
degeneration is ordinarily near completion. However, it was found that cone cell
numbers and function were preserved. Cone numbers were determined with
PNA staining, which binds to the extracellular matrix comprising the cone cell
sheath,99 and so does not itself necessarily indicate increased cone survival; an
increase in photopic b wave was however demonstrated, following comparison to
null-rd10, SOD2-rd10 and Catalase-rd10 controls. It was only the rd10 mice
which expressed both SOD2 and catalase that had the increased response. This
suggests that SOD2 and catalase can protect against cone photoreceptor loss. As
rod photoreceptor loss was not reduced it does not appear that these molecules
are acting just by non-specifically slowing apoptosis. Instead the study suggests
oxidative damage was specific to cone photoreceptors.
Nutrition
In their study of the kinetics of cone photoreceptor death Punzo et al. evaluated
four different mouse models with mutations in rod-specific genes (the P23H, rd,
rhodopsin knockout and PDE- knockout mouse models).75 In each of these
models the major phase of cone cell death was coincident with upregulation of
genes involved in cellular metabolism, and specifically in the mammalian target
of rapamycin (mTOR) pathway. Furthermore the surviving cones had signs of
autophagy, a self-digestion process, and molecular markers of cellular starvation.
Rd mice treated with insulin had prolonged cone survival, whereas depletion of
endogenous insulin (using streptozotocin injections that kill insulin-producing
beta cells of the pancreas) had the opposite effect. These authors therefore
presented multiple lines of evidence that the degeneration of cones is through
molecular pathways at least in part related to shortage of nutrients.
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The exact mechanism of how nutrient shortage would be triggered by the loss of
rods has not been established. The authors hypothesised however that the cones
could be dependent on rod-rpe interactions for the flow of nutrients into the
retina.75 In their experiments detailing the kinetics of cone photoreceptor loss
Punzo et al. noted that the major phase of cone photoreceptor loss started only
once rod degeneration was advanced to the extent that the ONL was just one cell
thick. Possibly this could represent a threshold at which the number of outer
segment-rpe interactions fall below a critical level and nutrient flow becomes
insufficient. This could explain the apparent mutation-independent timing at
which cone photoreceptor loss commences.
1.4.2 Molecular mechanisms of photoreceptor cell death
Despite the large variety of underlying mutations and primary pathologies
causing RP it is evident that photoreceptor death, in most cases, is through
common molecular pathways. These pathways therefore, like the mechanisms
for secondary cone involvement, represent a shared feature for large numbers of
patients with RP and thus would represent an attractive therapeutic target.
The classical pathways through which cells die are shown in Figure 1-11.
Necrosis, the least controlled of the 3 major pathways, describes a form of cell
death which is primarily externally driven. It is in effect a passive process of
which the cell is not in control. The hallmarks of necrosis include osmotic
swelling, precipitation of proteins and cell lysis. This results in unprocessed
proteins being released into the extracellular space, an inflammatory reaction and
damage to surrounding tissues. This is not a feature of retinitis pigmentosa
where inflammation is limited and cells of the inner retina are largely
preserved.83
In contrast, cell death in RP is ‘programmed’. The process involves an orderly
sequence of events driven by the cell which is in the process of demise. Through
this process the cell degenerates with limited impact on adjacent healthy tissue.
There are both autophagy and apoptotic programmed cell death pathways which
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share common features. Elements of the autophagy pathway (also known as the
lysosomal pathway) are part of the cell’s normal homeostasis mechanisms and
involved in organelle turnover. The pathway is characterised by the formation of
large vacuoles, some of which expand to capture intracellular organelles – hence
the term autophagic vacuoles. Cathepsins and proteasomal enzymes are features
of the autophagy pathway. Cells undergoing autophagy may subsequently
undergo apoptosis.100-101
Apoptosis, like autophagy, is an active process requiring protein synthesis and
mitochondrial function.102 In developing cells genes for the apoptosis effector
proteins such as ubiquitin are up-regulated as part of the process but in adult cells
they are commonly ordinarily present but in an inactive state.103-105
Extrinsic and intrinsic pathways are described, on the basis of whether the trigger
is activation of a cell surface receptor or mitochondrial depolarization
respectively. Apoptotic pathways most often involve a family of cysteine
proteases, known as caspases, that cleave key cellular targets leading to death of
the cell.106 There are also caspase-independent apoptosis pathways.107-108
Photoreceptor death in inherited retinal degenerations is primarily through
apoptosis, which can be detected using features summarised in
Table 1-2.44;109-114 Inhibitors of apoptosis have therefore gained interest as
potential therapies.115-119 However other factors, atypical for classical apoptosis,
have also been implicated in photoreceptor cell degeneration particularly from
studies in the rd mouse.120-123 In particular calpain enzymes,122 poly(ADP-ribose)
polymerase,124 and cathepsin activity 125-126 have all been implicated in
photoreceptor death in the rd mouse. A complicating factor with studies in this
mouse model is that the photoreceptor degeneration commences before the retina
is fully developed and so will be concurrent with normal developmental patterns
of cell death.102 This can make tissue-based detection methods challenging to
interpret. None the less the implication of alternative cell death mechanisms
raises questions as to how effective potential therapies will be that target single
pathways, particularly in the presence of persistent cell death stimuli.
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Figure 1-11 Classical pathways of cellular death. Cell death can proceed in an
uncontrolled manner driven by external influcences and known as necrosis, or in a
controlled fashion known as programmed cell death (PCD). The latter achieves
demise of the cell with minimal inflammatory reaction and disruption to surrounding
tissues. It is an active process driven by the cell itself that is undergoing
degeneration. Necrosis can also involve some enzyme activity (eg calpain enzymes)
hence the term “necrosis-like PCD”. PCD primarily involves authophagy and
apoptotic pathways which share some features and cells can readily move between
these two pathways.
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Indicator of Apoptosis Means of Detection
 Cell shrinkage & membrane blebbing
 Budding of whole cell to produce membrane-
bound bodies in which organelles are initially
intact.
 Fragmentation of nuclei
 Condensation & margination of chromatin
Microscopy
 Exteriorization of phosphatidylserine Annexin V binding
 DNA cleavage & fragmentation Electrophoresis, in-situ
end labelling, TUNEL
 Caspase enzyme activation Immunohistochemistry
Table 1-2 Markers of apoptosis. The terminal deoxynucleotidyl transferase dUTP
nickend labelling (TUNEL) method is a particularly well known means of characterising
apoptotic cell death. It is however not totally specific as in the advanced stages of cells
undergoing apoptosis and necrosis can have overlapping features.127-128
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1.5 Therapeutic approaches for retinal diseases
At present there are no effective treatments for inherited retinal degenerations.
However, the identification of the underlying genes and molecular pathways for
many of these diseases has provided a major impetus for research into treatments.
Unsurprisingly some conditions are likely to be more amenable to treatment than
others, and importantly different approaches are better suited in certain situations
than others (Figure 1-12).
1.5.1 Gene replacement therapies
In many monogenic autosomal or X-linked recessive disorders the clinical
phenotype results from absence of function of a specific gene. For such
conditions expression of a wild-type version of the mutated gene offers the
potential for a curative approach.2;129
Viral vector mediated gene replacement therapy in the rds mouse was the first
study to demonstrate restoration of photoreceptor structure and function in a
model of retinal degeneration.130 Mice homozygous for a null mutation in Prph2
lack photoreceptor discs and outer segments and loose photoreceptors by
apoptosis such that by 2 months there is minimal retinal function. In this study,
subretinal injections of recombinant adeno-associated virus (AAV) encoding a
Prph2 transgene resulted in the formation of near normal outer segments
sufficient for photoreceptor function.
Since then restoration of RPE or photoreceptor structure and function has been
achieved in a number of animal models of RP using rAAV-mediated gene
replacement therapy,1;131-133 and clinical trials have followed.2-5 However,
interestingly in the majority of these trials the gene replacement therapy was not
sufficient to significantly delay photoreceptor death. In part this may be related
to strength of transgene expression as recent studies with more efficient viral
vectors and promoters have demonstrated long-term prevention of photoreceptor
loss, even in the presence of fast degenerations.131;133 It is also likely however
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that the function of some genes is more readily replaced than others, due to levels
or timing of expression for example.
1.5.2 Gene silencing
Other retinal degenerations are caused by a gain of function mutation having a
toxic effect on the cell. Many of these are inherited as autosomal dominant traits.
Inserting an additional wild-type version of the mutated gene for these disorders
will not alone counter the effect of the existing mutated gene; instead a means of
gene silencing is required. This can be achieved using a number of different
molecular approaches including the use of single-stranded antisense
oligonucleotides that are complimentary in sequence to the mutant transcript, or
by expressing catalytic ribozymes specific to the mutant transcript. The latter
technique was reported to delay photoreceptor degeneration in the P23H
transgenic rat, with functional rescue demonstrated for up to 6 months.134-135
However these results have not been repeated or replicated in other models since.
Of greater interest recently has been the discovery of the RNA interference
pathway through which short double-stranded RNA molecules can selectively
degrade messenger RNA (mRNA) thereby suppressing translation and gene
expression. Of note, a single molecule of short interfering RNA (siRNA) can
initiate the degradation of multiple copies of mRNA. siRNA delivering therapies
are already under evaluation in clinical trials for AMD 136-137 and have been
evaluated in pre-clinical studies for specific models of retinal degeneration.138
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Figure 1-12 Therapeutic Strategies for IRDs. The majority of causative mutations for
RP affect genes solely expressed in rods; a minority are expressed in RPE cells. Cone
cell loss, and hence loss of central vision, visual acuity, colour perception and contrast
sensitivity follows as a secondary consequence. Research into potential therapies can be
regarded as focussing on 5 principal steps in the pathogenic pathway, namely: 1.
Targeting the genome and inserting a ‘correct’ version of the mutated gene. 2.
Targeting down-stream by silencing molecular expression of the gene. Further down the
pathway the secondary consequence of photoreceptor death can be targeted (3), or
subsequently attempts can be made to replace cells that have died (4). The end point of
the pathway is irreversible visual loss, at which point supportive treatments or artificial
vision are the principal focus of research.
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1.5.3 Neuroprotection
Various approaches have been used to target the process of photoreceptor death,
rather than addressing the underlying defect. Photoreceptors, as with other cell
types, can tolerate some degree of insult and damage but there is a threshold
above which apoptosis is more likely to follow. The idea behind neuroprotection
is to raise the threshold required for the initiation of apoptosis, or interfere with
the process of apoptosis so that completion becomes delayed or less likely.
Theoretical advantages of neuroprotection
As shown in Figure 1-13 there are a number of potential advantages that would
make a neuroprotective approach an attractive alternative to means of addressing
the underlying genetic or molecular defect. These are discussed in relation to the
most prevalent causes of blindness:
Neuroprotection
Conceptual Advantages
• Potential for established pathology
• Delay as good as cure for slowly-
progressive disease
• Applicable even if correction of the
underlying defect is not feasible
Issues to be resolved
• Is beneficial effect clinically
relevant?
- sufficient functional benefit?
- maintained in time?
• Generic Potential
Figure 1-13 Summary of principal advantages and issues to be resolved regarding
neuroprotection
Chapter 1: Introduction
53
1. Applicable for late presentation (eg once cell death / structural changes already
established)
Most inherited retinal degenerations are slow processes that are typically well
established by the time patients present with symptomatic visual loss. Targeting
the underlying genetic mutation is often not feasible once the disease is
symptomatic as rod photoreceptor loss is already well established. Targeting the
later processes of the disease instead (i.e. secondary cone photoreceptor death) is
more clinically relevant, and possibly more feasible, for patients with established
pathology as it is specifically the loss of cones that precipitates loss of reading
and driving vision, and the onset of legal blindness. Furthermore, substantial
vision can remain even when most of the cone population has been lost139 giving
hope that even in advanced disease a slowing of cone cell death would prevent
large numbers of people becoming blind.140
2. For slowly progressive diseases cure may not be necessary or clinically
relevant
The slow time course of visual loss in most inherited retinal degenerations, often
over decades, means that even a relatively subtle slowing of the process may be
all that is needed to preserve useful vision for the patient’s lifetime – as long as
the protective effect is maintained. Glaucoma is treated in much the same way,
where the aim of treatment is not to stop ganglion cell death altogether, but
instead treatment is titrated to limit loss just enough to minimise handicap for
that patient’s expected lifespan.
3. Applicable if correction of the underlying defect is not feasible
– rare
– unknown
– polygenic
– dominant mutation
Chapter 1: Introduction
54
One of the principal challenges of treating IRDs is the extensive genetic
heterogeneity.141 Gene replacement therapies are inherently gene specific, and
gene silencing techniques are sometimes mutation specific as well. Developing
specific therapies for each mutation, or mutated gene, is not feasible in the near
future. One of the attractions of neuroprotective therapies therefore, is that by
targeting the the final common pathways of IRDs (regardless of the underlying
mutation) they may offer the potential for a more widely applicable generic
treatment. Indeed, a neuroprotective treatment could also be applicable to the
large numbers of patients in which photoreceptor death results from other
pathologies, such as age-related macular degeneration (AMD), which affects a
substantial percentage of the population in developed countries over the age of
60.142 For many patients the underlying genetic mutations and molecular
pathways are yet to be characterised. Mutation specific treatments may be
decades away from fruition, if at all. In the meantime, more generic
neuroprotective treatments could be more feasible for many such patients.
Limitations of neuroprotective factors
Before entering mainstream use it will have to be demonstrated that any
neuroprotective agent has a beneficial clinical effect. For this the maintained
neuronal cells will have to be functional, not just surviving. Furthermore, to be
clinically relevant the effect will need to be maintained for a valuable period of
time, and not rapidly over ridden by continuing cellular stresses secondary to the
persistent underlying pathology. In the original description of an effect of
fibroblast growth factor on photoreceptor degeneration it was evident that the
effect was indeed diminished with time. Faktorovich et al. injected a single
bolus into eyes of the RCS rat.143 At one month post-injection photoreceptor
numbers in the treated eyes were similar to pre-treatment, where as in control
eyes most had been lost. However at two months following injection the number
of photoreceptors in the treated eyes was diminished, as compared to treated eyes
one month before. Previously preserved cells were therefore dying. Further
assessments would be required to determine the rate of the photoreceptor death,
and whether numbers would soon be as in untreated eyes, or whether there would
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be a longer-lasting effect. This concept is illustrated in Figure 1-14.
Furthermore, the treatment effect may depend on the speed of the degeneration
and nature of the underlying defect. It will therefore be of interest to see to what
extent neuroprotective agents are indeed of generic, and mutation-independent,
potential.
Figure 1-14 Duration of a neuro-protective effect. In this graph total cone numbers is
shown on the y-axis. There is a normal age-related decline (top line) but within a
patient’s lifetime the number of cones is ordinarily adequate for ‘normal’ vision. In
patients with RP there is a more rapid loss of cones such that there are insufficient
functioning cones for nomal vision, typically in the 4th decade of life. A transient
therapeutic effect (red solid) could lead to a subsequent increased rate of photoreceptor
loss such that soon cone numbers are as in untreated eyes. Alternatively, without a
catch-up phase of increased cell death there would be a lasting benefit (red dotted line).
The latter could lead to extra years of nomal sight (red double arrows).
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Neuroprotective factors for RP
The principal neuroprotective agents under investigation can be grouped together
as trophic factors, anti-apoptosis factors, calcium channel blockers and vitamin A
supplements. The understanding of how these agents modulate the photoreceptor
microenvironment to promote survival is variable, and as the photoreceptor cell
death mechanisms in IRDs are better understood additional approaches can be
expected.
1. Trophic Factors
Proof of principle for the efficacy of trophic factors in IRDs comes from studies
of fibroblast growth factor-2 (FGF-2, also variably referred to as bFGF). FGF-2
was initially found to act as a neurotrophic agent after axonal injury in several
regions of the central nervous system,144-146 and is also found naturally in the
retina.147-148 Supplementing this molecule has been found to induce histological
photoreceptor rescue in the RCS rat and in a transgenic rat model with a
rhodopsin mutation (the TgnS344ter-4 rat).143;149 However, it was also found to
induce pathological neovascularisation and cataract formation and so interest has
since focussed on finding alternatives.150
Ciliary Neurotrophic Factor (CNTF) supplementation has also been shown to
induce morphological photoreceptor rescue in a number of animal models. Its
use is currently being investigated in clinical trials for RP and non-neovascular
AMD.7;151 However animal model studies for this agent too have shown
significant side-effects with a paradoxical negative effect on the ERGs of treated
eyes.152-155 Glial cell line derived Neurotrophic Factor (GDNF) has also been
shown to slow photoreceptor rescue in animal models, but apparently without
significant negative side-effects.80;154;156-160 Furthermore GDNF has already
entered the clinical domain as a CNS-delivered medication for Parkinson’s
disease,161;162 and so if it is effective for IRDs it would be an attractive
neuroprotective agent with which to start clinical trials.
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Whilst most neurotrophic agents are believed to target both rods and cones, Yang
et al. evaluated the effect of RdCVF specifically on cone photoreceptor survival
in the P23H rat.81 Sub-retinal protein injections repeated at 3 timepoints led to a
preservation of cone cell numbers in this model of RP and a relative preservation
of function on the ERG. Further studies are ongoing to evaluate the effect with
more sustained, and clinically applicable delivery methods.
2. Anti-apoptosis Factors
Regardless of the underlying mutation, the final common pathway and key step
prior to irreversible visual loss, is photoreceptor death involving the apoptosis
pathway.44;112;113;163 Indeed, inhibiting apoptosis with the protooncogene bcl-
2,115-118 the peptide inhibitor of caspase-3 114 or expressing the x-linked inhibitor
of apoptosis (XIAP) 119 have all been shown to delay photoreceptor degeneration
in rodent models of IRD. The oncogenic potential of these agents will raise
concerns over their potential for clinical use, but if expression can be targeted
specifically to a non-dividing cell population (such as photoreceptors) any
oncogenic potential is likely to be significantly diminished.
3. Vitamin A
In a randomized, controlled, double-masked clinical trial oral vitamin A was
found to slow, on average, the rate of retinal degeneration in patients with RP.164
The mean rate of ERG decline was less in the treated group. The number of
patients with known mutations was too small to assess from this study whether
the effect varied with genotype, but work from mouse models does suggest that
selected patients may benefit more than others.165 Tiansen Li et al demonstrated
that vitamin A supplementation preserved photoreceptor survival and ERG
function in the T17M mouse, in which the degeneration results from mutant
rhodopsin protein with reduced stability in vitro (a class II rhodopsin mutation).
Vitamin A supplementation is believed to increase the bioavailability of the
chromophore, 11-cis-retinal within photoreceptors, and binding of 11-cis-retinal
to the mutant rhodopsin confers increased stability. In contrast treatment had no
effect in an alternative mouse model (the P346S mouse) in which the primary
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pathology is aberrant transport of the protein (a class I rhodopsin mutation).
There were however other differences between the murine models treated,
including speed of degeneration and stage of degeneration at the time of
treatment, and so other mechanisms of action remain possible.
Even if a sub-population of patients could indeed be identified that gain a more
predictable and significant effect from vitamin A supplementation there are
concerns that long-term high doses of the drug could induce hepato-toxicity.
Furthermore, in the presence of ABCA4 mutations (seen in atypical RP, cone-rod
dystrophy and Stargardt disease) vitamin A supplementation may increase
potentially harmful lipofuscin accumulation.166
4. Calcium channel antagonists
Increased calcium levels are implicated in IRD photoreceptor death partly as a
trigger for apoptosis, but also as a consequence of the raised cGMP levels found
in at least some forms of RP.167 cGMP activates the cationic membrane channels
permeable to sodium and calcium, which ordinarily mediate the depolarizing
current in photoreceptors responding to light stimuli.168;169 Excess activation of
these channels, and a subsequent rise in intracellular calcium, may be related to
the toxic effect of increased cGMP levels seen in the photoreceptors of the rd
mouse170;171
The function of cGMP gated cation channel is inhibited by diltiazem,172 a
calcium channel blocker commonly used in the treatment of ischaemic heart
disease, hypertension and cardiac arrhythmias. Frasson et al. therefore
administered high doses of this drug systemically to rd1 mice, and reported
reduced rates of photoreceptor degeneration in the treated group.173 However,
the rescue effect was transient with preservation of the ERG for only up to 12
days, and in healthy retinas diltiazem leads to a considerable reduction in
photoreceptor function (as measured by ERG b-wave amplitude). Furthermore
the rescue effect described has not been a consistently repeatable result either in
the same animal model 174 or in large animal studies.175
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1.5.4 Cell replacement therapies
Until recently sourcing sufficient numbers of non-immunogenic replacement
cells has been one of the major limitations for cellular transplantation approaches
to retinal diseases. The use of autologous cells for focal diseases 176 or cells from
embryonic sources have been investigated, but have been met with significant
practical and ethical challenges. The generation and subsequent neuronal
differentiation of induced pluripotent stem (iPS) cells has however removed
many of these limitations, raising the possibility that patients could be treated
with replacement RPE or photoreceptor cells derived from a readily available
source of their own such as fibroblasts or skin cells.177-180
Transplantation of replacement RPE cells has attractions for the treatment of
AMD, where RPE compromise precedes the photoreceptor degeneration.
However, to maintain differentiation the transplanted cells must bind to a suitable
substrate and so replacing Bruch’s membrane, which is also compromised with
age alone and in AMD, presents one of the remaining problems for this field of
stem cell research.181 Transplantation of photoreceptors for inherited retinal
degenerations for example, would not only require that the transplanted cells
survive and maintain their differentiation, but also that they form appropriate
synapses. To an extent this has been achieved with transplantation of
photoreceptor precursor cells, which led to a restoration of some basic visual
function in a murine model of RP.182 It however remains to be convincingly
demonstrated with embryonic stem cell-derived transplants.183 Restoration of
synapses presents an even greater challenge for attempts to replace ganglion cells
which have proximal connections within the retina, as well as distal connections
a relatively long distance along the optic nerve, the myelin in which is a known
impediment to axonal growth.184
An alternative to transplanting cells to restore their normal function is to use cell
transplantation as a means of restoring beneficial paracrine effects. Cells
transplants can be used as a means of achieving sustained local delivery of
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benefical trophic factors. Recently oligodendrocyte precursor cells 185 and
Mueller cell-derived stem cells 186 have been used to slow optic nerve
degeneration by integrating into the degenerating nerve fibre layer in the rat
glaucoma model. Mohand-Said et al. transplanted sheets of rods into the sub-
retinal space of mice with a retinal degeneration;77;187 although these rods did not
integrate, and were in a non-physiological location, their presence did have a
beneficial effect on cone survival which additional studies clarified was due to a
positive paracrine effect.77;188
1.6 Sustained delivery of therapeutic proteins to the
retina
Systemic therapies typically only deliver low drug levels to the retina due to the
blood-retinal barrier (formed by the endothelial cells of retinal blood vessels and
RPE cells) and are often limited by the potential for systemic side-effects. The
penetration of topical treatments such as eye drops is largely limited to the
anterior chamber. Therefore current retinal treatments are commonly
administered by intra-vitreal or peri-ocular injections. These are invasive
procedures, and at present most of the drugs used have short half-lives but are
being used to treat sub-acute or chronic diseases. Repeated injections are
therefore commonly required. The large number of patients receiving anti-
VEGF treatments for AMD, are usually injected every 4-6 weeks for the duration
of their treatment. This is not without significant risk to the patient and
challenges for health care providers. In the MARINA study assessing
ranibizumab the rate of presumed intraocular infection, a potentially blinding
complication, was 0.05% per injection. This risk is cumulative, and so over the 2
years of the study the risk was 1%.189
Novel methods of achieving sustained delivery of therapies to the retina are now
entering the clinical domain. Of note these include gene therapy to induce local
expression of therapeutic proteins and implantable devices to effect the slow
release of agents down a concentration gradient. In the future it may also be
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possible to chemically modify selected drugs to facilitate topical or systemic
delivery,190 or even selectively disrupt the blood-brain barrier.191 The key
requirements for all these approaches is to deliver the medicinal agent at
therapeutic levels, which are sustained over time, to the required cell type or
tissue without significant side-effects.
1.6.1 Direct gene transfer
Gene therapy is at present the only way to achieve sustained and intracellular
expression of a therapeutic protein following a single procedure. As many of the
cells within the retina are non-dividing the treatment gene need not be
incorporated into the host genome in order to achieve long term expression, thus
avoiding the risks of insertional mutagenesis.
The ideal recombinant vector used to introduce the therapeutic transgene should
be non-pathogenic, non-immunogenic and effective at transducing the desired
cell type.129;192 For these reasons recombinant adeno-associated virus (rAAV) is
the most commonly used vector for retinal gene therapy at present, and was used
in all 3 of the landmark clinical trials for RPE65 mutations. rAAV effectively
transduces both rod and cone photoreceptors and the RPE.129;193 Serotype 2
(AAV2) is the most common serotype found in humans and many of the viral
vectors in use now use the genome from this serotype. However by varying the
capsid proteins in which the genome is packaged the transduction kinetics and
specificity for different cell types can be varied; this process is known as
pseudotyping and so for example combining the genome of AAV serotype 2 with
the capsids from serotype 8 gives a viral vector (AAV2/8) with increased
transduction efficiency in rod and cone photoreceptors.194-196 Other pseudotyped
AAV vectors in common use include AAV2/5, AAV2/1 and AAV2/4 with the
latter two being used to transduce RPE cells specifically.195 Ocular gene therapy
with AAV vectors results in sustained transgene expression for many years
following a single injection in animal models,197;198 and now has an established
safety and efficacy profile in humans.2;199
Chapter 1: Introduction
62
Despite the success with viral vectors the reliable production presents technical
challenges and concerns remain over insertional mutagenesis and inflammatory
responses. Experimentally, a number of non-viral delivery systems are also used
including the use of polymers such as polyethylenimine (PEI), nanoparticles or
electroporation.200 Bejjani et al. reported short-term gene expression in RPE
cells following intravitreal injection of plasmid-laden biodegradable nanospheres
into the rat eye.201 However, at present in vivo transduction efficiencies and
longevity of expression are far from comparable with those already established
for viral vectors, and the treatment effects demonstrated with these technologies
have been limited.200;202
1.6.2 Vitreous implants
Drugs that have good long-term stability such as dexamethasone, a synthetic
corticosteroid, may be incorporated into vitreous implants. These can be
biodegradable or non-biodegradable, with the latter usually requiring removal
after a period of time. Ozurdex is a sustained-release dexamethasone implant
manufactured by Allergan, and is licensed by the Federal Drugs Administration
for treatment of retinal vein occlusion. The implant is biodegradable, and
inserted into the vitreous cavity with a simple injection procedure.
Dexamethasone is released into the vitreous cavity for 6 months following
implantation, with peak concentrations during the first 2 months.203
Delivering proteins or nucleic acids in this manner has been more problematic
however, because they are particularly vulnerable to endogenous proteases or
nucleases. One approach has been to embed amino or nucleic acids into
polymers and carrier matrices that offer protection from endogenous enzymes.
190;204 The conformational structure of many small molecule therapeutics is
essential for function, and so the challenge will be to preserve the structure and
biological activity in the synthetic polymers.
An alternative approach for proteins has been to implant cells genetically
engineered to continually produce the therapeutic agent. These have been used
to investigate the effects of CNTF, GDNF and BDNF over relatively short-
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timescales.7;156;157;205 If the cells are sequestered within a vitreous capsule the
potential for removal remains but as with the slow release capsules any drug
specificity must be inherent in the drug, as the delivery mechanism is itself non-
specific. To achieve long-term expression the implanted cells must be protected
from the host’s immune system, but still receive oxygen and nutrients to
maintain survival.
1.7 Rodent models of RP
The development of treatments for human retinal degenerations relies heavily on
the use of animal models. Their use is a prerequisite for the development of stem
cell and gene therapies where there is a significant risk of harm as therapies are
developed, and where in vitro studies are insufficient to justify clinical
investigations.
The widespread use of genetic modification with mice has allowed a broad
selection of murine models of IRD to be established and well characterised.
Many closely mimic the human pathology with an analogous retinal degeneration
and similar pathophysiological defects. Those referred to extensively throughout
this thesis are summarised in Table 1-3 and Table 1-4.
One of the challenges of translational research is to appreciate the significance of
differences between the animal models in which disease mechanisms are studied
and therapies developed, and the potential patients in which the therapies are to
be used. Some of the more pertinent differences in relation to studies of RP are
discussed below.
1. Anatomy. The principal anatomical difference between rodents and man
with regard to the retina, lies in the fact that the rodent retina lacks a
macula. This presents a challenge for the assessment of cone-related
outcome measures in rodent models, and complicates studies related to the
mechanisms of rod-cone degeneration. It is also true however that the
macula in humans is only affected late on in RP and outside the macula
the distribution of rods and cones in humans is similar to that in mice.
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2. Timings and stage of disease. Experimental treatments tend to be
evaluated in young animal models and in early stage of the disease.
Differences in life-span and metabolic rate between animal models and
humans are largely predictable and can be adjusted for, but it is matching
the stage of disease that is of greatest relevance. In advanced disease
accumulated cell damage (related to the disease process or ageing), cell
death or cellular stress responses can all affect the response to
interventions. This was well demonstrated in one of the RPE65 gene
studies where a dog aged 30 months was treated, and in contrast to the
younger animals, did not gain any functional improvement despite
evidence of transgene expression.206
3. Type of mutation. The retinal degeneration (rd) and retinal degeneration
slow (rds) murine models have mutations in genes that are commonly
affected in patients with RP and have proved valuable models to study
disease mechanisms and potential therapies. Of note however, both these
models have null mutations, where as in patients missense mutations are
more common. This causes differences in the phenotype severity and rate
of progression. In addition the disease mechanisms and responses to
interventions may also differ. Null mutations lead to the gene not being
transcribed into RNA, or the transcript not being translated into a protein
product. In contrast, missense mutations can lead to mutant protein
accumulating in a cell, from where they can induce a variety of cellular
responses including apoptosis, impact on gene expression and potentially
compete with iatrogenically introduced therapeutic copies of the
gene.207;208
4. Heterogeneity. Colonies of animal models are typically extensively
inbred and thus relatively genetically homogenous. For digenic conditions,
or others heavily influenced by modifier genes, this could account for
differences in phenotypes and responses to treatments between animal
models and corresponding patients. Likewise environmental (including
dietary) influences are similarly homogenous in experimental animals but
much more variable for patients.
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Murine models of retinal degeneration
rd1or rd rd10 rds/ Prph2rd2/rd2
M
ut
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n
Null mutation in Pde6b209;210
Missense mutation in exon
13 of Pde6b.211
Null mutation in Prph2
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Lack of functional rod PDE72
leads to a toxic accumulation
of cGMP and rod
photoreceptor death .167;170;171
112;113;163 Rapid loss of rods
begins postnatal day 10 and is
almost complete by PN20.212
There follows a slower loss of
cones between PN60-PN180,
though 5% of cones last over
6 months.213
Photoreceptor loss is slower
than that in the rd mouse.
Rod loss commences at P14
and is maximal at P28.214
By P30 rod function is
decreased by 70%, and cone
function by 50%.211 Rod
degeneration is largely
complete by P40,211 but
cones last up to 9 months of
age.214
Absence of normal
peripherin/RDS means outer
segments fail to develop. 215-
217 ERG function is greatly
diminished, and almost
completely lost by P60.
Photoreceptor cell loss is
maximal between P11 & P28
but then followed by a slower
phase that lasts 8 to 11
months.218
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PDE6B mutations in patients are a cause of autosomal-
recessive RP.72;219 They have also been associated with
dominant congenital stationary night blindness.220;221 The
rd10 mouse however, with a missense mutation and slower
degeneration, is the more representative of the human disease
than the rd1 mouse.
PRPH2 mutations are a cause
of AdRP, (accounting for
approximately ~5% human RP
patients), but can also cause a
large variety of other
phenotypes including cone-
rod dystrophies.56;60;61;222;223
However, as for the rd mouse,
the null mutation and failure
of normal photoreceptor
development is not
representative of typical RP.
Table 1-3 Summary of relevant murine models of retinal degeneration. Timings are
approximate as there is variation between strains in different research institutions; those
for the rd10 mouse are quoted for the mutation on a C57BL/6J background.
Descriptions are for mice homozygous for each mutation.
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Rat models of RP
P23H S334ter4
M
ut
at
io
n
This transgenic carries a rhodopsin
transgene with a single amino acid
substitution at amino acid position
23 (histidine for praline) 224
This transgenic carries a rhodopsin transgene
with a premature termination codon at residue
334 of the opsin transgene
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Experimental animals are typically
heterozygotes. These have a slow
rod degeneration with initially
normal cone function.225 P23H is a
class II rhodopsin mutation. The
mutant protein is mis-folded
leading to aggregation and
subsequent degradation via the
cellular ubiquitin proteosome
system.226;227
Experimental animals are typically
heterozygotes. The retinas typically develop
normally and then have a degeneration that
starts at P15 and is fast until about P60. This
is followed by slower progression.
S334ter4 is a class I mutation. Rhodopsin
protein formed from the transgene lacks 15
carboxy-terminal amino acids that are
ordinarily involved in protein trafficking to
the outer segments and in the deactivation of
the rhodopsin protein after light absorption.228
229
R
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s Same mutation is causative in most
prevalent form of adRP in north
America. ~12% human cases.225
Multiple mutations within the C terminus have
been identified in patients. Class I mutations
are however less common than class II
rhodopsin mutations.
Table 1-4 Commonly used rhodopsin transgenic rat models of RP. As expected for
transgenics, the rate of variation varies considerably between different lines.
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1.8 Thesis aims
Cone photoreceptor death, secondary to disease in another cell type within the
retina, is an important cause of blindness. A treatment to slow or prevent the
secondary loss of cone photoreceptors could benefit millions of people by
delaying or preventing the onset of legal blindness.
Therapies targeting cell death pathways have shown promise in animal model
studies. However, it remains unclear why healthy cones degenerate following a
rod degeneration and whether their sustained survival is possible without
restoring the rod photoreceptor population. Furthermore to be clinically valuable
any treatment would need to produce a sustained protective effect on cone
numbers and function.
The aim of this thesis is to investigate neuroprotective treatments as potential
therapies to preserve cone-mediated vision. A novel murine model of rod-cone
degeneration will be used to enable study of specifically the cone photoreceptor
population at repeated time points. This will allow evaluation of whether any
treatment effect is preserved with time.
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2.1 Buffers & media and solutions
Buffers were prepared in dH2O and autoclaved. Antibiotics were added
following autoclaving, and once solutions had cooled to less than 50C.
Buffer/Medium Constituents
Blocking solution
(immunohistochemistry)
1% bovine serum albumin (BSA), 3% normal goat serum
(NGS), 0.1% triton
Blocking solution
(western blot)
1x phosphate buffered solution (PBS), 3% dried milk
powder (fat-free), 0.5% tween
Church mix 0.24M SDS, 0.5M EDTA, 0.34M Na2HPO4, 0.16M
NaH2PO4
D10 Dulbecco’s Modified Eagle’s Medium (DMEM)
supplemented with 10 % heat inactivated foetal bovine
serum (FBS), 100 U/ml penicillin and 0.1 mg/ml
streptomycin.
ELISA blocker 1x PBS, 1% BSA, 5% sucrose, 0.05% NaN
G10 growth medium BHK-21 media supplemented with 10 % FBS, 100 U/ml
penicillin and 0.1 mg/ml streptomycin, 5 % tryptose
phosphate broth, 2 mM L-glutamine and 0.25 mg/ml
geneticin G418.
2x hepes buffered saline
(HBS)
280 mM NaCl, 10 mM KCl, 1.5 mM NaH2PO4, 12 mM D-
(+)-Glucose, 50 mM HEPES
Laemmli buffer (2x) 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004%
bromophenol blue, and 0.125 M Tris HCl
LB broth Prepared using 25g/l of LB-Broth preparation (Sigma-
Aldrich, Gillingham, UK). Preparation contains Casein
enzymic hydrolysate 10 g/l, yeast extract 5g/l and NaCl 10
g/l)
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Table 2-1 Buffers, Media & Solutions
Buffer/Medium Constituents
LB culture plates 15g/l of agar (VWR International, Leicestershire, UK) was
added to LB medium prepared as above. Ampicillin (100
g/ml) was added following autoclaving and then the LB-agar
mix was set in 9cm diameter plates and stored at 4C.
PBS 8g NaCl, 0.2g KCl, 1.44g of Na2HPO4, 0.24g, KH2PO4 in 1
litre distilled water.
PBS-MK 1xPBS, 2.5mM KCl, 1mM MgCl2
POROS buffer A 20 mM Bis-Tris Propane, 20 mM Tris Base
POROS 10% buffer B 20 mM Bis-Tris Propane, 20mM Tris Base, 0.3M NaCl
POROS 100% buffer B 20 mM Bis-Tris Propane, 20mM Tris Base, 3M NaCl
Proteinase K buffer 100 mM Tris (pH7.4), 50mM EDTA, 0.5% SDS
Running buffer 182g/L Tris Base and 4g/L SDS. This solution was filtered
(0.45m) and HCl was added drop wise to give a pH of 8.8
Sodium phosphate
buffer (1M)
97.1 g/L Na2HPO4 and 43.6 g/L NaH2PO4. pH 7.2
TD buffer 140mM NaCL, 5mM KCl, 0.7 mM K2HPO4, 3.5mM MgCl2,
25 mM Tris.
TE buffer 10 mM Tris (pH 8.0) + 1 mM EDTA in dH2O.
TBE buffer (10x) 108g Tris base, 55g Boric acid, 9.3g Na4EDTA
Transfer buffer Running buffer + 20% methanol
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2.2 Molecular biology
2.2.1 mRNA extraction
To prepare mRNA from retinal tissue enucleated eyes were rapidly dissected and
the retina snap frozen in liquid nitrogen. Samples were stored at -80C prior to
further steps. At the time of mRNA extraction 1ml of Trizol (Invitrogen) was
added to each frozen retina in order to preserve mRNA integrity during cell
membrane disruption. The retina and trizol mix was pipetted up and down, and
vortexed, to achieve tissue homogenization. 200l of chloroform was
subsequently added followed by centrifugation (15 minutes at 14 000g) to
separate the mixture into an aqueous phase (containing the mRNA) and an
organic phase (which is discoloured and of greater density relative to the aqueous
phase). The aqueous phase, mixed with an equal volume of isopropanol was
frozen at -20C overnight to achieve mRNA precipitation. An mRNA pellet was
isolated by centrifugation (14 000g for 10 minutes), and the supernatant removed.
This was followed by an ethanol wash (1ml 70% ethanol was added and the
mixture centrifuged at 14 000g for 5 minutes) followed by air drying (for 5
minutes). The resultant pellet was then resuspended in RNase-free water or EB
buffer (QIAGEN Ltd., UK, 10 mM Tris-Cl, pH 8.5). The resuspension volume
was typically 50l. In the event of poor re-suspension the solution was heated to
55C for up to 10 minutes to aid the process. An alternative means of mRNA
isolation was to use the RNeasy Mini Kit (QIAGEN Ltd., UK). RNA samples
were quantified by measuring absorbance at 260 nm (A260) in a
spectrophotometer, and purity was estimated by comparing the ratio of readings
at 260nm and 280 nm (Nanodrop® apparatus, LabTech International). Samples
were stored at -80C prior to further use.
2.2.2 Generation of cDNA
Complimentary DNA (cDNA) was generated from RNA samples using the
Quantitect Reverse Transcription kit (Qiagen, Crawley, UK). RNA samples
were first treated to remove contaminating genomic or viral DNA by incubation
for 2 minutes at 42C with diluted Qiagen gDNA wipeout Buffer. Reverse
transcription was then performed in a mix containing the Quantiscript reverse
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transcriptase enzyme (an RNA-dependent DNA polymerase, 1l), Quantiscript
RT buffer (4l), primer mix (1l) and 1g of the purified RNA sample (in 14l)
(total volume 20l). The reaction was allowed to run for 15 minutes at 420C
before the enzyme was inactivated by incubation at 95C for 3 minutes. cDNA
was stored at -20C.
2.2.3 Plasmid preparation
Maps for the plasmids used and produced are shown in the supplementary data
chapter.
GDNF plasmids
Murine GDNF cDNA was subcloned from an existing plasmid into the pd10
backbone with a CMV promoter. The sequence of the cloned plasmid was
confirmed with restriction enzyme digests, and by sequencing using a CMV
forward primer and a GDNF forward primer.
XIAP plasmids
Human XIAP cDNA was obtained from a plasmid kindly provided by Professor
Catherine Tsilfidis (University of Ottawa, Canada). PCR reactions were
performed to insert the ApaI and BsrG1 restriction enzyme sites at the 5’ and 3’
ends of the XIAP cDNA respectively. This permitted subsequent ligation into a
pre-existing pd10 plasmid containing a CMV promoter. The PCR primers used
were manufactured to order by Sigma-Aldrich (Dorset, UK) and used in the PCR
mix shown in Table 2-2. The KOD polymerase enzyme was used because of its
proof reading properties and low PCR error rate. The sequences of the 5’ and 3’
primers used are CC GAG CTC GGG CCC ATG ACT TTT AAC and G GGC
CCT GTA CAT GCA TGC TCG respectively.
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µl
10x Reaction Buffer 5
dNTPs 5
MgSO4 3
Primers (10 µM) 1 each of forward & back
DNA 1
H20 33
KOD polymerase 1
Table 2-2 KOD polymerase PCR reaction
Following an initial denaturation step (5 minutes at 95C) 30 cycles of PCR were
performed using the following conditions:
- Denaturation: 30 sec at 95C
- Annealing: 30 sec at 50-60C
- Extension: 2 minutes at 65C
- Final extension: 5 minutes at 68C
The PCR products were sized by electrophoresis and digested prior to ligation
into a CMV-containing pd10 plasmid. Sequencing of the entire CMV and XIAP
containing regions was performed to confirm accuracy of the PCR reactions and
cloning.
Rhodopsin plasmid
cDNA for human rhodopsin was subcloned into a pd10 plasmid containing the
bovine rhodopsin promoter sequence using the AfeI and SexAI restriction
enzyme sites. The latter is sensitive to dcm methylation and so DNA was
prepared in methylation deficient E.coli cells. Restriction enzyme digests and
DNA sequencing was used to confirm the plasmid sequence. The insertion of an
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SV40 intron sequence, and modifications to the transgene sequence to optimise
protein expression, were performed commercially by Genscript, New Jersey,
USA.
2.2.4 Electrophoresis, gel extraction & ligation of DNA
DNA products were separated on agarose gels containing ethidium bromide (1 µl
of 10 mg/ml concentration per 50 ml of gel) in order to visualise nucleic acid
bands. Bands were sized by comparison with commercial DNA ladders
(Promega, UK), and both the DNA samples and the ladders were loaded with 6x
loading dye (Promega, UK) to allow visualisation of the bands under UV light.
In most instances 1% agarose (w/v) gels were used but for more detailed
examination of small or large fragments the agarose percentage was increased or
decreased respectively.
The gels were prepared by adding the agarose (VWR International, UK) to 0.5%
TBE (Table 2-1). The mixture was heated in a microwave and intermittently
mixed until the agarose was completely dissolved. Following cooling the
ethidium bromide was added and the gel set in a plastic mould. Gels were run at
180V until the required bands could be resolved (typically 60-90 minutes).
DNA bands were excised from the agarose gel use a clean scalpel under a UV
light. DNA was isolated using a QIAquick® Gel Extraction Kit (Qiagen,
Crawley, UK). The protocol entailed dissolving the agarose-based fragment in
buffer at 55C. Following addition of isopropanol the solution was passed
through a binding column followed by washes to remove traces of agarose and
high salt concentration contaminants. DNA was then eluted in a tris buffer. The
size and quality of collected DNA was determined by spectrophotometric
analysis (using Nanodrop® apparatus, LabTech International) to determine the
concentration and pattern of absorbance, and by running a sample on an agarose
gel. DNA samples were stored at -20C.
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2.2.5 Amplification of DNA in bacteria
Transformation of competent cells
Chemically competent cells (-Select gold efficiency, Bioline, London, UK)
were preferentially used to transform cloned cDNA into bacterial cells. In
selected instances dam and dcm methylation deficient E.coli cells (dam-/dcm-
competent E.coli, New England Biolabs) were used instead to grow plasmids
free of Dam and Dcm methylation. This was necessary when plasmids were to
be digested using restriction enzymes sensitive to methylation (as was the case
for the rhodopsin plasmid).
Competent cells were stored at -80C. Prior to use cells were thawed on ice, and
incubated with plasmid DNA for a further 15 minutes on ice. The cells were heat
shocked for 45 seconds at 42C using a pre-warmed heat block. The cells were
immediately transferred back to ice for a further 3 minutes. 100l of SOC
medium (Sigma-Aldrich, UK) was added and the cells incubated at 37C for 1
hour to maximise transformation efficiency, before being spread onto an LB-agar
plate. In cases where a blue-white colony selection was required (i.e. when using
the pGEM®-T Easy system for sub-cloning) 50l of X-gal solution (20mg/ml)
was spread over the plate before addition of the transformation mix. Plates were
incubated overnight at 37C to allow growth of bacterial colonies.
Amplification and recovery of recombinant plasmid DNA
Bacterial colonies were inoculated into 5ml of LB medium containing 100g/ml
of ampicillin, and incubated at 37C with shaking for 12-16 hours.
For small-scale preparations, DNA was isolated using a GenEluteTM Plasmid
Miniprep Kit (Sigma-Aldrich, UK) using the standard protocol. This entailed
harvesting a pellet of E.coli cells by centrifugation of the inoculated LB medium;
the pellet was then resuspended and the cells lysed by alkaline lysis to release the
plasmid DNA into solution. A neutralisation and binding solution was added to
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precipitate unwanted cell debris, which was then separated from the supernatant
by centrifugation. The supernatant was passed through a primed DNA-binding
column and subsequently washed with an ethanol based solution to remove
residual salts and contaminants. DNA was harvested from the column by
passing through a small volume of elution solution.
For larger preparations 200l of the 5 ml LB culture following transformation, or
a pipette tip dipped in frozen glycerol stock, was used to inoculate a further litre
of LB, which was incubated as above. For these larger preparations plasmid
DNA was recovered using a GenEluteTM Plasmid Mega Kit (Sigma-Aldrich, UK);
this uses a similar protocol to above. Bacterial cells were isolated by
centrifugation, then resuspended and lysed. Again the genomic DNA, proteins
and cell debris was precipitated and separated from the suspended plasmid DNA
by centrifugation. The supernatant was passed through a primed anion-exchange
resin column which binds DNA, and subsequently washed. DNA was eluted in a
high salt buffer and precipitated using isopropanol to concentrate the DNA and
separate it from residual salts and buffer. The DNA pellet was washed in 70%
ethanol in endotoxin-free water and redissolved in EB-buffer (Sigma-Aldrich,
UK).
The size and quality of collected DNA by either technique was determined by
spectrophotometric analysis (using Nanodrop® apparatus), agarose gel
electrophoresis and with selected restriction enzyme digests. The
spectrophotometer was used to determine the ratio of absorbance at 280nm and
260nm, with 1.7 to 1.9 being considered the acceptable range. DNA samples
were stored at -20C.
2.2.6 Restriction enzyme digests
Restriction enzymes were purchased from Promega (WI, USA) and New
England Biolabs (NEB) (Hitchin, UK). Digests were typically performed using
1.0 g of plasmid DNA, 1l of enzyme and the appropriate concentration of the
manufacturer’s recommended buffer for 1-4 hours at either 25 or 37C. Digests
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were terminated, and salt in the buffers removed by DNA precipitation.
Restriction enzyme products were analysed using agarose gel electrophoresis and
comparison of fragment size with a commercial DNA ladder (Bioline, London,
UK)
2.2.7 DNA precipitation
DNA was precipitated following restriction enzyme digests by adding 1/10th
volume of 3M Sodium Acetate (pH5.2) and 2.5x volume of 100% ethanol. The
mixture was then kept at -20C for 30 mins prior to centrifugation at maximal
speed for a further 10 minutes. The supernatant was removed by pipetting
following repeated spins allowing a DNA pellet to be precipitated; the pellet was
then resuspended in sterile water or elution buffer.
2.2.8 DNA Sequencing
DNA plasmids were sequenced commercially by Eurofins Laboratories Ltd.
(Acton, U.K.) or Beckmann Coulter Genomics (Takeley, U.K.).
2.3 Cell culture
Baby Hamster Kidney (BHK) and HEK-293T cells were used for rAAV 2/2 and
rAAV 2/8 production respectively. BHK, HEK-293T cells and HELA cells were
used for in vitro testing of plasmids, and BHK and HELA cells were used for in
vitro testing of rAAV 2/2 viruses. All cell lines were grown in incubators
maintained at 37C with 5% CO2, and steps were performed in sterile tissue
culture hoods. The media used for each cell line are shown in Table 2-3.
Confluent cells were split approximately 1:3 every 48 hours, or 1:5 every 72
hours to maintain healthy growth.
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Cell line Growth Medium Used
BHK G10 (see Table 2-1)
HEK-293T D10 (see Table 2-1)
HELA D10
Table 2-3 Growth media used for cell culture
2.4 rAAV production
Recombinant adeno-associated viral (rAAV) vectors, containing single-stranded
DNA, were used to transduce cells in vitro and in vivo. AAV viruses are
replication-deficient and so are dependent on co-infection with “helper” viruses,
such as adenovirus or herpes simplex virus, to effect the steps of viral replication,
genome packaging and to an extent host cell lysis. Recombinant AAV vectors
additionally lack the normal rep and cap genes of the AAV genome. In wild type
AAV the rep gene is required for integration, replication and packaging, and the
cap gene encodes the three proteins (VP 1-3) that form the normal 20nm
icohosahedral AAV capsid.
To produce rAAV vectors in vitro host cells were transfected with the
“transgene” plasmid (containing the gene of interest, a promoter and the viral
inverted terminal repeats (ITRs) required for viral replication) and a plasmid
containing the AAV rep and cap genes. To produce rAAV2/2, the transfected
cells were also infected with a helper virus (Figure 2-1). To produce rAAV2/8,
the host cells were instead co-transfected with a further plasmid containing
genes required by the host cell to perform the helper virus functions. Helper
virus infection was therefore not required for rAAV2/8 production.
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Figure 2-1 In vitro rAAV2/2 vector production. Host cells were transfected with
plasmids containing the AAV rep and cap genes that are absent in recombinant viruses,
and the “transgene” plasmid which contained cDNA for the gene of interest and the
AAV inverted terminal repeats (ITRs) required for viral replication. For rAAV2/2
production BHK cells were co-infected with helper virus. rAAV2/8 production is
similar, except that the host cells are 293T cells and they are co-transfected with a helper
plasmid instead of being infected with helper virus. Plasmid DNA entry into cells was
achieved using transfection complexes; the constituents of these complexes varied with
the cell type being targeted.
Chapter 2: Materials and Methods
80
2.4.1 rAAV 2/2 production
rAAV 2/2 was produced using protocols based on previously published
methods.131;133;230 20 plates of BHK cells were used per batch of virus. Virus
particle production was achieved using rep and cap genes from the replicating
Herpes Simplex virus (HSV) amplicon pHAV7.3 in association with disabled
infectious single cycle HSV (DISC-HSV) helper virus.
Transfection
Transfection was performed when the plates of BHK cells were approximately
60% confluent (giving approximately 107 cells per 150mm plate); this was
achieved by splitting plates of confluent cells 1:2 the day prior to transfection.
A transfection mix was prepared in the ratios shown in Table 2-4 and and added
to the BHK cells for a period of 4 hours before being removed and replaced with
fresh B10 medium containing the helper virus (DISC-HSV) in the ratio of 10
infectious units per cell. The cells were then left for a further 36 hours for rAAV
production.
Component Quantity per 150mm plate of BHKcells
Optimem medium 15 mls
Peptide 6 ((K16)GACRRETAWACG)
(an integrin-targeting peptide) 250 g
Construct DNA 30g
pHAV7.3 DNA 30g
Lipofectin reagent 45l
Table 2-4 Transfection mix for AAV2/2. The peptide 6 has a lysine tail contributing to
the peptide having a positive charge of +17 which aids binding to DNA; peptide 6 also
binds to cell surface integrin proteins. Lipofectin reagent (purchased from Invitrogen,
Paisley, UK) is lipid based and aids binding of the transfection complex to cell surface
membranes and subsequently the endosomal membrane prior to release of DNA from
the endosome.
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Harvesting and Purification
After 36 hours of virus production cells were scraped off the plates and aspirated.
Following centrifugation isolated cell pellets were resuspended in 1ml per plate
of Optimem, and subjected to 3 freeze-thaw cycles (at -80C and 37C
respectively) with vigorous vortexing in between to ensure lysis of the cells.
The cell lysate was treated with 50 units per ml of Benzonase (Sigma, Dorset,
UK) and incubated at 37C for 30 minutes to remove cellular DNA. This was
then spun at 4000g until the supernatant was clear (typically 30 minutes). The
supernatant, containing the virus, was then further cleaned by adding 0.5%
deoxycholic acid (DCA, Sigma-Aldrich, Dorset, UK) and incubation at 37C for
a further 30 minutes. The DCA also aids subsequent binding of vector particles
to the heparin columns. The supernatant was then filtered through 5m and then
0.8m syringe filters (Millipore, Watford, UK) to remove cellular debris. rAAV
particles were then purified using a heparin-agarose column (Sigma-Aldrich,
Dorset, UK) and pre-washed with 10 ml PBS-MK (Table 2-1).231 The column
with the bound virus is then washed with 10 ml PBS-MK + 0.1M NaCl before
being eluted in 6 ml of PBS-MK + 0.4M NaCl (the first 2mls of which are
discarded due to the dead-space of the column).
The virus elute was concentrated by applying to Amicon Ultra-4 filter columns
(Millipore, Watford, UK) and centrifugation at 5000x g until the residual volume
was less than 200l. The virus was then washed by adding a further 2 mls of
PBS-MK to the concentrated virus in the Centricon columns, and spinning in the
centrifuge at 5000x g until the residual volume of PBS-MK containing virus was
approximately 100l. This was then aliquoted and frozen at -80C.
2.4.2 rAAV 2/8 production
rAAV2/8 was produced by transfecting HEK-293T cells. The cone arrestin-GFP
vector was produced following a transfection using a calcium chloride. For all
other rAAV2/8 vectors cells were transfected using polyethylenimine (PEI). In
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both cases the transfection mixture was added to the cells once they were
approximately 70-80% confluent. 20 plates (of 150mm diameter) were typically
used per batch of virus. To ensure the cells are growing at the time of
transfection the plates were split on the day prior to transfection.
Calcium chloride transfection
The calcium chloride-based transfection mix used is shown in Table 2-5.
Particular care was needed when making this mix to avoid protein precipitation.
Under sterile conditions the required volumes of plasmid DNA were first mixed
in a sterile flask, before adding the dH2O and then finally CaCl2. The flask
containing this mixture was then continually vortexed whilst 2xHBS (which had
been fully equilibrated to room temperature) was added slowly drop by drop.
The transfection mix was left to stand at room temperature for 30 minutes, during
which time complexes formed giving it a partially opaque appearance. The
required volume of D10 medium was added, which stops the complexing
reaction, before the mixture was added to the 293T cells (5mls per plate). The
transfection mix was left on the cells for approximately 24 hours before being
replaced with fresh D10 medium.
Component per 20 plate transfection
Transgene plasmid DNA 200g
AAV packaging plasmid (rep and cap
genes) 200g
Helper Plasmid 600g
2xHBS 25 mls
2.5M CaCl2 2.5 mls
dH2O (autoclaved) 22.5 mls
D10 Medium 50 mls
Table 2-5 rAAV2/8 calcium chloride transfection mix
PEI transfection
To transfect cells using PEI transgene, AAV8 packaging and helper DNA were
prepared in the ratio 1:1:3. A total of 50g of DNA was used per plate of cells.
Plasmid DNA was added to DMEM (2.5mls/plate) and then PEI was added last
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(2.25g of PEI per g of DNA). The transfection mix in DMEM was gently
mixed and left still for ten minutes for the formation of PEI-DNA complexes.
The transfection mix was added to cells for 24 hours before being replaced with
fresh D10 medium.
293T cell harvesting
Cells were harvested 72 hours following transfection or earlier if they were on
the verge of lysis (as evidenced by the cells adopting a rounded morphology and
starting to lift off the cell culture plates). Harvested cells were concentrated by
centrifugation (5 minutes at 2000 rpm) before the cell pellet was resuspended in
1xTD buffer. Cell pellets were stored at -80oC prior to purification.
Vector purification
As for AAV2/2 production, cell lysis was achieved with repeated (typically 4)
freeze-thaw cycles with vigorous vortexing in between cycles. The cell lysate
was then treated with a detergent (1% Triton), before being incubated with
Benzonase at 37C for 30 minutes to breakdown any residual free DNA. The
sample was then repeatedly spun down and then filtered to separate cell debris.
After each spin the supernatant was removed and the cell debris pellet discarded
prior to the next step. The spin / filter protocol was as follows: spin at 3220g 10
minutes, respin supernatant at 7500g 15 minutes, pass through 5M filter, spin at
7500g 15 minutes, filter through 0.45M and 0.22M filters and finally 2 final
spins as 20 000g for 30 minutes each. These final spins were repeated if
necessary until there was no debris pellet visible in the tube at the completion of
the spin. The additional two-phase separation step described below was
performed at this stage when used.
Residual supernatant containing the suspended virus was then concentrated and
purified in a 2 step process using a Sephacryl column for size exclusion, and then
passage through an anion exchange column. Flow through the columns was
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driven by a fast protein liquid chromatography (FPLC) machine (GE Healthcare,
UK)
A Sephacryl S300 column was first prepared by equilibration with 50% Poros
buffer B (Table 2-1). This was run at 5-10 mls/minute until the conductivity and
UV spectrophotometer readings had equilibrated (which typically took up to 2
hours). The filtered lysate was then loaded on to the column which separates the
lysate by size with larger items being impeded less by the medium and hence
coming off first. 50% Poros buffer B was also used to push the lysate through
the column.
The passage of virus was detected on the UV spectrograph, and pooled into
distinct collection tubes. These were then diluted 1 in 4 with Poros Buffer A
(Table 2-1) and stored at +4C until ready for use, whilst the Sephacryl column
was re-equilibrated using 50% Poros buffer B and then washed with 20% ethanol.
The diluted virus containing lysate was then loaded onto the Poros anion
exchange column, which had been equilibrated with 15% Poros buffer B. The
virus was washed through with further 15% Poros buffer B and then eluted with
60% Poros buffer B. Eluted virus was concentrated using Vivaspin 4 10kDa
concentrator tubes and centrifugation; for this, the eluted virus was loaded onto
the concentrator tube and spun until the residual volume was less than 200l.
Concentrated virus was washed with 2mls PBS-MK by adding the PBS-MK to
the concentrate in the Vivaspin tube and spinning at 5000g until all but 50-100l
had passed through the filter. This residual volume was placed in a sterile
eppendorf whilst the concentrator tube was washed with a further 100l of PBS-
MK. The virus-containing PBS-MK samples were pooled, aliquoted and stored
at -80C.
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Two phase separation for ultra pure virus
When used this additional step was performed following the spin / filtering
protocol for lysed virus samples, and prior to passage through the size exclusion
and anion exchange columns.
Viral suspension was added to approximately 5mls of a 1M ammonium sulphate
and 20% PEG4000 mix. This was left to settle for over 3 hours at room
temperature before being spun at 1000g for 5 minutes. The mix was left
overnight at 4C for separation of the 2 phases. The lower (aqueous) phase was
drained and passed through a 0.22M filter before a further spin at 20000g for 30
minutes. Collected supernatant was concentrated from approximately 5mls to 1-
2mls by spinning in a 300kDa Vivaspin column, before being suspended in
approximately 6mls of TD buffer for passage through the size and anion
exchange columns.
2.4.3 Vector genomic titres
Vectors were quantified by determining the number of genome copies per ml of
the vector preparation, using dot-blot assays and a probe specific for a segment
of the genomic DNA. In brief vector DNA was first extracted from the rAAV
particles by enzymatic digestion of the capsid, and then quantified relative to
serial dilution of a known concentration of plasmid DNA. The number of DNA-
containing particles is calculated based on the fact that each virion carries one
single-stranded DNA molecule. This ‘physical’ method of quantification has
advantages over ‘biological’ assays of infectivity which are highly dependent on
vector properties and laboratory conditions (such as promoter strength as well as
the cell type and helper virus used for infection).
Generation of Biotinylated Probe and Dilution Series
A segment of the plasmid DNA used to make the virus was cut using restriction
enzyme digests, and isolated by agarose gel electrophoresis and gel extraction.
In order to tag the probe DNA with biotin the double-stranded molecule was first
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denatured (95C for 2 min then cooled on ice) before being mixed as follows:
34l of denatured probe DNA, 10l of 5x labelling mix (contains random
octomers), 5l dNTP mix (containing biotin-dATP) and 1 l Klenow (all
reagents purchased from New England Biolabs, Herts, UK). The biotinylation
mixture was incubated for in excess of 1 hour at 37C, and then the reaction was
terminated with 5l of 0.2M EDTA (pH8). Biotinylated probe was then
precipitated by mixing with 5l NaOAc (3M) and 150 l of 100% ethanol and
incubating at -20C for 20 minutes, followed by centrifugation at 14000 rpm for
10 min. Precipitated DNA was washed with 70% ethanol and resuspended in
20l of TE buffer (Table 2-1).
The precise concentration of the plasmid DNA used for the standard was
determined using Nanodrop® apparatus (LabTech International); knowing the
concentration and size of the plasmid DNA (ng/l) allows calculation of the
volume required to give a specific number of molecules per well of the dot-blot
apparatus. (This is calculated knowing that 1 mole of any nucleotide weighs
325g, and that 1 mole consists of 6x1023 molecules (Avogadro’s constant)). The
plasmid DNA used for the standard was subsequently pipetted out to give a
dilution series between 1012 and 105 molecules per well.
Virus DNA extraction
1l and 5l samples of virus were digested with proteinase K enzyme using the
protocol shown in Table 2-6.
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l
Virus 1 or 5
Proteinase K Buffer (2x) 100
dH2O 99 or 95 (for 1l and 5l samples respectively)
Proteinase K enzyme 1
Table 2-6: Proteinase K digest of rAAV. The proteinase K enzyme and buffer was
manufactured by Sigma-Alrich, Dorset, UK. The digest was incubated at 56C for 30
mins.
To precipitate out the genomic DNA the digested virus was mixed with 20g
glycogen, 21l of NaOAc (3M), 260l of EtOH and incubated at -20C for 30
minutes, prior to centrifugation at 14000 rpm for 10 min. Precipitated viral DNA
was washed with 70% ethanol and centrifuged for 5 mins at 14000 rpm, before
being resuspended in 200l of 0.4M NaOH and 10mM EDTA. The DNA was
denatured as above (2 min at 95C then cooled on ice).
DotBlot Assay
A nylon transfer membrane (Amersham Biosciences, Bucks, UK) was placed in
a Dotblot apparatus (BioRad). Wells to be used were filled with 200l dH2O and
a vacuum applied to the apparatus. The prepared samples and standards were
pipetted in the wells, and drawn into the membrane under vacuum. Wells were
washed with 200l 0.4M NaOH + 10 mM EDTA, also drawn into the membrane
under vacuum.
DNA cross-linking to the membrane was induced by drying the membrane
between sheets of Whatman paper (VWR, Leicestershire, UK) at 37C for in
excess of 20 mins.
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The membrane was soaked in ddH2O and transferred to a hybridisation bottle
with 50 ml of hybridization buffer (Church mix, Table 2-1). Both the bottle and
buffer are pre-warmed in advance to 65C. The bottle, mix and membrane are
kept in a rotating hybridisation oven for 30 minutes, which comprises the pre-
hybridisation step of the protocol. 5l of the denatured biotinylated probe is
added, and the bottle and blot are left in the oven overnight for the hybridisation
reaction to occur.
The membrane was then washed 3 times (each using 50ml of 33mM sodium
phosphate buffer) for 5 minutes per wash. The membrane was then processed
using the Phototope-Star Detection kit (New England Biolabs, Herts, UK) using
the protocol summarised in Table 2-7.
Step Procedure
A. Blocking Membrane soaked in blocking solution (5% SDS,
125mM NaCl, 25 mM sodium phosphate, pH7.2) for 5
minutes with shaking.
B. Incubation 1 Streptavidin (1:1000 in blocking solution) applied for 5
minutes with shaking
C. Washes 2 x 5 minutes washes with Wash Solution I (=block
solution diluted 1/10)
D. Incubation 2 Biotinylated Alkaline phosphatase (1/1000 in blocking
solution) applied for 5 minutes with shaking
E. Washes x 1 with block solution then x 2 with wash solution II
(10mM Tris-HCL, 10 mM NaCl, 1 mM MgCl2, pH
9.5). Each wash for 5 minutes
F. Substrate
application
CDP-Star reagent (1:1000) applied to membrane for 5
minutes without shaking
Table 2-7: DotBlot Labelling protocol
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The membrane was read using an X-ray film or a chemifluorescence imager.
Digital scanning and densitometry (AIDA Image Analyzer, Raytest,
Straubenhardt, Germany) was used to compare signal intensity from the virus
samples with that from points on the standard curve. Titres were described in
terms of numbers of viral genomes per ml (vg/ml). This is preferable to methods
of quantifying vector particles per ml (vp/ml) as it avoids including empty, and
hence non-functional, vector capsids.
2.4.4 Polyacrylamide gel electrophoresis (PAGE) and protein
stain
Sodium dodecyl sulphate (SDS)-PAGE and a fluorescent protein stain were used
to examine the protein content of vector preparations. Vector samples were first
incubated with Laemmli buffer (which contains -mercaptoethanol and SDS,
Table 2-1) so that proteins are denatured and their positive charges neutralised;
this allows proteins to be sorted specifically by size and not by shape or charge.
1-3l virus samples were mixed with 5l Laemmli buffer (2x) , and the final
reaction volume made up to 10l with dH20, before being incubated at incubated
at 37C for 30 minutes.
Samples were loaded into a 10% w/v reducing SDS polyacrylamide
electrophoresis gel (prepared in advance with 2.5mls Protogel (Bisacrylamide
0.8%, acylamide 30%), 1.875mls Tris/SDS running buffer (Table 2-1), 3.125mls
dH2O, 35.25l 10%APS and 7.05l Temed (Tetramethylethylenediamine,
Sigma). A commercial protein ladder was run alongside (Bio-rad). Bands were
run to establish protein band separation over approximately one hour at 120 volts.
The gel was washed and fixed with 2 half hour washes in gel fixing solution
(50%Methanol, 7%Aceitic acid in distilled water). The washed gel was stained
overnight with Spyro Ruby protein gel stain (Invitrogen), before further washes
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in the same wash solution (for 1 hour) and in distilled water to decrease
background fluorescence.
The Spyro Ruby protein gel stain has excitation peaks at 280 nm and 450 nm and
an emission maxima close to 610 nm. The stained gel was therefore visualised
using a UV transilluminator.
2.4.5 Transmission electron microscopy
Viral vectors were examined using transmission electron microscopy and a
protocol based on previously published methods.232 Purified rAAV virus was
placed on a 300 mesh electron microscopy grid pre-coated with carbon and 1%
formvar. Grids were then washed with PBS-MK (3x 30 second washes) and
stained with 4% uranyl acetate for 1 minute. Excess uranyl acetate was removed
by placing the stained grid onto a drop of ddH20, and then blotting away residual
fluid with filter paper followed by air drying. Virus particles were observed
using a JEOL 1010 transmission electron microscope (Jeol Ltd, Akishima, Japan)
with an accelerating voltage of 80kV.
2.5 PCR
2.5.1 Primer design and manufacture
Primers were designed manually from the sequence or using commercial
software (eg the Roche website). Prospective primers were evaluated for
melting temperatures and the risks of forming primer dimers or secondary
structures using primer select software (Lasergene). Primers were manufactured
to order by Sigma-Alrich, UK.
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2.5.2 Standard PCR
PCR reactions using the human and murine XIAP primers were run using 0.5l
of sample cDNA or linearised plasmid DNA, 10l of Roche mastermix, 1l each
of the forward and reverse primers at a concentration of 20M, and 7.5l of
water to give a total reaction volume of 20l. The PCR reaction was run
following 3 minutes of initial denaturation at 94C. There then followed 40
cycles of 15 seconds at 94C followed by 1 minute at the desired temperature
(62C, unless otherwise stated) and a final extension step of 5 minutes at 72C.
The murine and human xiap primers used gave amplicons of 110 and 445 bp
respectively. The products of these pcr reactions were therefore detected and
sized by running on a 2% agarose gel with a 100bp commercial dna ladder.
2.5.3 Real-time PCR
cDNA from each sample was loaded into a 96 well plate along with FastStart
TaqMan® Probe Mastermix (ROX) (Roche, UK), forward and reverse primers
for amplification of the gene of interest, a hydrolysis probe that binds the
amplified area and dH2O to make the final reaction volume up to 30 µl. For
quantification of XAF1and -actin expression, primers were used at a final
concentration of 900 nM each, and the hydrolysis probe at a final concentration
of 250 nM. Quantitative real-time PCR was run on an ABI Prism 7900HT Fast
Real-time Sequence Detection System (Applied Biosystems, UK). The reaction
cycle at which the fluorescence signal in each reaction reached a defined level,
known as the “threshold cycle” (Ct) was determined using the manufacturer’s
software (SDS 2.2.2). The relative expression between comparable samples in
relation to the expression of genes of interest was calculated using the
“Comparative Ct” method and formulae provided by the manufacturer (Applied
Biosystems).
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2.6 Testing of plasmid and vector transgene expression
in vitro
293T cells were used preferentially because of their high susceptibility to
plasmid transfection or infection by AAV2/2 virus. Cells were seeded on to a 24
well plate 24 hours prior to transfection or infection, such that there were
approximately 75 000 cells per well (as determined using a haemocytometer).
2.6.1 Cell culture transfection with plasmids
Transfections were performed using either a peptide-lipofectin-DNA complex or
using Polyethylenimine (PEI).
Lipofectin transfection mixes were prepared as in Table 2-8. The transfection
mix was used to replace the normal growth medium for a period of 4 hours
before being removed, and replaced with D10 until cell or supernatant harvesting
after approximately 48 hours.
Per single well (of 24 well plate)
Lipofectin (1g/l) 0.75l
Peptide 6 42l
Plasmid DNA (added last) 1g
Medium 500l of Optimem (no additives)
Table 2-8 Lipofectin Transfection mix
PEI transfection mixes were prepared as in Table 2-9 and left still to complex for
10 minutes before being added to the cell culture. In contrast to the lipofectin
transfection mix, this mix was not changed until supernatant or cell harvesting.
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Per single well (of 24 well plate)
Plasmid DNA 3.3g
Medium 0.756mls of DMEM (no additives)
Polyethylenimine (PEI) 36.8g
Table 2-9 PEI Transfection mix
2.6.2 Cell culture infection and superinfection with AAV2/2
The 293T cell line consists of human kidney cells transformed with adenovirus 5
DNA (ATCC Product Information Sheet for CRL-11268). The cells can
therefore be infected in the absence of additional helper virus. However, to
increase infection efficiency, and increase the chance of detectable levels of
transgene expression before cell culture overgrowth, in vitro infections can be
performed with concomitant adenovirus application; this technique is known as
‘superinfection’.
Standard infections were performed by adding 1l of AAV2/2 (with a titre of
approximately 1x1012) to each well of cells. For superinfections adenovirus was
added concomitantly at a ratio of between 10-20 virus particles per cell (i.e.
multiplicity of infection (MOI) of 10-20).
2.7 In vivo procedures
All animal procedures were approved and licensed by the Home Office.
2.7.1 Anaesthesia and recovery
The general anaesthetic used for mice procedures consisted of Dormitor (1mg/ml
medetomidine hydrochloride, Pfizer Pharmaceuticals, Kent UK), Ketamine (100
mg/ml, Fort Dodge Animal Health, Southampton, UK) and sterile water for
injection prepared in the ratio of 1.0 : 0.6 : 8.4 respectively. 0.10-0.15 ml of the
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anaesthetic was administered by a single intra-peritoneal (i.p.) injection to adult
mice; for pups <14 days old 0.1ml of anaesthetic diluted 1/5 was used.
Mice were recovered by an equal-volume i.p. injection (0.15ml) of recovery mix
(containing 0.25ml Antisedan (5mg/ml Atipomezole hydrochloride, Pfizer
Pharmaceuticals, Kent UK) per 12 ml sterile water for injection). During
recovery mice were kept warm using heat pads and free access to water and food
was ensured.
Chapter 2: Materials and Methods
95
2.7.2 Electroretinogram
Electroretinogram (ERG) recordings can be used to study specifically rod or
cone function by varying the background light intensity, and the intensity and
frequency of flash stimuli.233 In the dark-adapted scotopic state any ERG
response to dim stimuli is exclusively from rod photoreceptors.234 In contrast
following light adaptation and under bright background (photopic) conditions the
rod pathway is suppressed and the ERG response is mediated by cone
photoreceptors.235
ERGs were recorded from anaesthetised mice using the commercially available
Espion E2 system with a ColorDome Ganzfeld Stimulator (Diagnosys, UK). A
purpose built platform, with moveable stands for the positioning of electrodes,
was used to position the mouse (Figure 2-2). Following the onset of general
anaesthesia the pupils of both eyes were dilated with a single drop of 1%
tropicamide. 2% hydroxyl-propyl-methyl-cellulose (HPMC) was then placed
onto each cornea to maintain hydration for the duration of the procedure and
improve electrical contact with the electrode.
The anaesthetised mouse was placed onto a heat pad aligned with the middle of
the ganzfeld bowl, and a rectal thermometer inserted. The heat pad and
thermometer were part of the commercially available Homeothermic Blanket
system manufactured by Harvard Apparatus Ltd (Edenbridge, Kent, U.K.). This
system was set up such that the mouse body temperature was maintained within
1 degree of 36.90C throughout the electrodiagnostic assessment.
Corneal contact electrodes, a midline subdermal ground electrode (placed above
the base of the tail) and a sub-lingual reference electrode were placed and the
impedance of the contacts checked; electrode contacts were adjusted to ensure
that the impedances for each recording channel (1 for each eye) were equal, and
low (between 5 and 8 KOhm). The electrodes were fashioned in house from
platinum wire.
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Figure 2-2 ERG recording apparatus. A custom built platform was used to position the
mouse in the centre of the Ganzfeld recording bowl. A heat pad was positioned between
the mouse and the platform surface. Mounts on the platform were used to position
electrodes. The recording apparatus was all within a metal Faraday box to help control
ambient light levels and reduce electrical interference.
Scotopic series were performed in animals that had been dark adapted over the
preceding 16 or more hours. Red LED headtorches (Silva, Sollentuna, Sweden)
were used to prepare the animal for scotopic examinations so as to avoid
compromising the dark adaptation prior to recordings. Responses to stimuli over
a 4 log unit range (0.001 to 10 cd.s/m2) were recorded, with 10 trials averaged at
each step. Each trial was recorded over 400ms, and the recordings were filtered
from 0-1KHz with a sampling frequency of 5kHz to reduce interference from the
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mains electrical supply. The first 10ms of each recording were used to establish
the baseline prior to stimulus presentation.
Prior to photopic examinations the animal was light adapted for 10 minutes with
a background white-light stimulus of 20 cd/m2 intensity. In the photopic flash
protocol responses were recorded to stimuli of increasing intensity, with 25 trials
averaged at each step. Example traces are shown in Figure 2-3.
Figure 2-3 Example of photopic flash traces. Averaged recordings from a series of
flash intensities are shown for the right (OD) and left (OS) eyes.
Photopic flicker examinations were performed in light-adapted animals,
following the photopic flash protocol. Responses were examined to standard
white light flashes of 0.5, 2.0, 5.0, 10.0, 15.0 and 30.0Hz frequency, all at an
intensity of 3 cd.s/m2. Analysis of amplitudes and implicit times was performed
on the averaged trace of 25 recordings from the 10Hz stimulus, as this response
typically shows the greatest amplitude in mice.236
Analysis of recordings was performed using the Espion E2 software. The
principal variables studied were A and B waves which were recorded relative to
the baseline and A wave trough respectively (Figure 2-4).
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Figure 2-4 The a and b waves demonstrated on a typical ERG
waveform to a bright flash from the rhodopsin knockout
2.7.3 Sub-retinal and intra-vitreal Injections
Sub-retinal injections were performed under general anaesthesia and following
pupil dilation with 1% tropicamide. HPMC and a coverslip were placed onto the
cornea to maintain clarity of view and to protect the cornea from drying. Under
direct retinoscopy through an operating microscope the tip of a 1.5 cm 34-gauge
hypodermic needle (Hamilton) was guided under the coverslip and then
tangentially through the sclera to produce a self sealing wound tunnel. The
needle tip was slowly advanced so as to rest between the retina and retinal
pigment epithelium. 0.5-1.5 l of virus suspension was then injected to produce
a bullous retinal detachment (typically covering 30-40% of the fundus), and care
was taken to minimize reflux on withdrawal of the needle.
Intra-vitreal injections were performed as above but with the site of injection 1
mm posterior to the limbus. The needle was advanced posteriorly towards the
optic disc under direct visualisation to avoid damage to the retina or lens.
To perform injections in mice before separation of the eyelids, the eyelids were
divided using a sharp needle and manual retraction.
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2.7.4 Confocal scanning laser ophthalmoscopy
Confocal scanning laser ophthalmoscopy (cSLO) allows high quality retinal
images to be obtained quickly in patients and in animal models. With this
technology, a laser is used to illuminate the retina and the reflected image is then
captured through a fine pinhole (approximately 400µm in diameter). The small
aperture of the pinhole ensures that scattered light, or light from outside the focal
plane, is excluded. The image formed on the detection unit is therefore
exclusively from a single focal plane illuminated by the stimulating laser (hence
the term confocal), resulting in high contrast optimally focussed images (Figure
2-5). To image across the retinal surface the emitted laser beam is redirected
horizontally (in the x-axis) and vertically (in the y-axis) along a plane of focus
perpendicular to the optic axis (conventionally the z-axis). This is performed
using oscillating mirrors, and allows the illuminating and confocal detection
system to effectively scan across an area of the retinal surface. As only a limited
area is imaged at any one time the illumination used can be brighter than would
be tolerated with conventional photography, which also contributes to the images
obtained being more clearly defined.
In these experiments cSLO was performed with the Heidelberg Spectralis
hardware and software (Heidelberg Engineering, Dossenheim, Germany). This
was used as is it is in hospital clinics, except that the chin rest was replaced with
a custom-made platform and heat pad on which to position mice. (Figure 2-6). In
the human eye this system can achieve a detection resolution of 5µm
(www.heidelbergengineering.com), though the different optics of the murine eye
will be likely to affect this. In these experiments the infra-red and fluorescein
angiography modes were used for cSLO, which use the 820nm and 488nm
stimulating lasers respectively.
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Figure 2-5 Schematic diagram of a confocal scanning laser system. From
www.heidelbergengineering.com.
Figure 2-6 The Heidelberg Spectralis adapted for use with animal models.
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Prior to imaging mice were anaesthetised with a general anaesthetic and the
pupils dilated with 1% tropicamide. Drops of Hypromellose (0.3%) (Tubilux
Pharma, Pomezia Italy) were applied to the corneas of anaesthetised animals to
prevent drying during the imaging procedure.
Infra-red cSLO was employed in order to focus on the retina and orientate the
imaging unit and mouse eye such that the optic disc was in the centre of the
image and that are far as possible the image clarity was equal across the field of
view (Figure 2-7). Imaging with infra-red has many advantages over
conventional ophthalmoscopy; of particular relevance for imaging the mouse eye
the infra-red illumination is better able to penetrate unclear media, and high
quality images are less dependent on the extent of pupillary dilation. We have
previously found that the combination of general anaesthetic, pupillary dilation
and corneal exposure readily predispose to corneal opacity in the mouse eye,
which can be challenging to prevent even with the frequent application of
lubricating drops. The use of infra-red ophthalmoscopy therefore assisted in
obtaining high quality images. In addition, the absence of a bright flash light
reduces stimulation of the subject being imaged.
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Figure 2-7 In vivo infra-red imaging of the murine retina.
To detect GFP the fluorescein angiography mode was used for cSLO; in this
mode a 488 nm laser is used to illuminate the retina, and a 500nm barrier filter is
inserted prior to the detection unit. Clinically this setting is used to image
fluorescence from pre-injected fluorescein dye, and so image retinal vasculature
and detect leak of the dye from vessels. The peak of the fluorescein absorption
spectrum is approximately 490 nm, and the peak of the emission spectrum is
approximately 521 nm. By detecting only light of a wavelength greater than 500
nm reflected 490 nm light is excluded. Fluorescence by fluorescein is however
still detected and so the morphology and leakiness of retinal vasculature can be
visualised in detail. GFP has similar peaks of absorption and emission spectra
(475 and 509 nm spectrum), and so can be imaged using the same settings. In
these experiments cSLO with the 488 nm laser was used to image in-vivo GFP
expressed in transgenic mice, and in wild type mice following gene therapy. To
achieve consistency between different images sensitivity settings were kept
constant (4.7 scans/second, 100% laser power, 100% sensitivity, high resolution
setting selected). Saved images were an average of 33 frames each.
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For analysis of cone cell densities images were subsequently analysed using
Photoshop (Adobe) and Image Pro-Plus (Media Cybernetics) software. In a
separate and overlying image individual hyperfluorescent spots were marked,
and the area corresponding to 75% of the field of view centred on the disc was
also delineated. The hyperfluorescent spots within this defined area were then
counted using Image Pro-Plus.
2.7.5 Optical coherence tomography
Optical coherence tomography (OCT) is a means of obtaining detailed cross-
sectional images from analysis of scattered light in vivo. 3D reconstructions can
then be created. Long wavelength (near-infrared) light is used which is able to
penetrate into ocular tissues, and so from the pattern of scatter the composition of
retina, RPE and choroid can be examined repeatedly in living subjects.
Spectral (or Fourier)-domain OCT (SD-OCT) technologies are able to
simultaneously measure multiple wavelengths of reflected light, hence the name
spectral-domain. These have largely superseded previous time-domain OCT
(TD-OCT) technologies that used a moving reference mirror to measure the time
taken for light to be reflected, and produced lower quality images.
The SPECTRALIS system used in these experiments integrates SD-OCT with
cSLO, to allow eye tracking and reduced motion artefact. In addition noise
artefact is reduced by averaging repeated scans at precisely the same location,237
and in humans the system has been demonstrated to have very high repeatability
and reproducibility with a repeated thickness measurements varying by less than
1 μm.238 Although the tracking laser is not known to pose any safety hazards, the
imaging time for a single session is limited to 300 seconds. This was found to be
more than enough to obtain high quality images in mice.
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2.8 Immunohistochemistry
2.8.1 Tissue preparation
Animals were sacrificed according to Schedule 1 of the Animals (Scientific
Procedures) Act 1986. The superior aspect of each eye was marked by cautery
of the peri-limbal tissues prior to enucleation or by placing a suture under the
superior rectus muscle.
For the preparation of flatmounts enucleated eyes were dissected whilst in 1%
PFA under the operating microscope. Whole retinas were carefully separated
from underlying RPE, choroid and sclera and incised with 3-4 radial incisions to
allow flattening of the retinal sheet. The superior incision would approximate
closest to the optic disc to allow subsequent orientation. The retinal sheet was
then transferred onto a glass slide using a Pasteur pipette and 1% PFA. To fix
the retina as a flat sheet a cover slip was gently applied over the retina and 4%
PFA applied around the edges which subsequently fixes the tissue by capillary
action.
For the preparation of frozen sections the cornea, iris and lens was removed from
enucleated eyes whilst immersed in 1% PFA. The remaining eye-cups were then
fixed for 15 minutes to 1 hour in 4% PFA. Cryo-protection, when used, was
performed by incubation in 10% sucrose solution overnight. Eyes were then
embedded in O.C.T (R A Lamb, East Sussex U.K) with care to maintain track of
the orientation. Eyes were then frozen in iso-pentane which had been pre-cooled
in liquid nitrogen. Specimens were stored at -20C and prior to examination 12-
20 µm thick sections cut using a Bright cryostat.
2.8.2 Antibody staining
Tissue, from flatmounts or frozen sections, was immersed in blocking solution
(Table 2-1) at room temperature for 2 hours prior to immunohistochemistry. The
tissue was incubated overnight at 4C with the primary antibody (Table 2-10)
diluted in blocking solution.  3 washes in PBS were performed (each ≥ 15 
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minutes) before incubation with secondary antibody for 2 hours at room
temperature.  Further washes in PBS were performed (3, each ≥ 15 minutes).  
Secondary antibodies (goat anti-rabbit, goat anti-chicken and goat anti-mouse)
were purchased from Invitrogen and used at 1/1000 concentration in blocking
solution unless otherwise stated. For rhodopsin immunohistochemistry the goat
anti-mouse secondary was used at 1/250, for caspase 3 staining the rabbit anti-
mouse secondary was used at 1/200, and for PNA staining the streptavidin-546
secondary was used at 1/200.
To stain nuclei sections were counterstained with 4',6-diamidino-2-phenylindole
(DAPI); this binds strongly to DNA, preferentially within AT-rich regions, and
has a blue fluorescence.239
Epitope Background Manufacturer
Concentration used
at (in Blocking
solution)
a-subunit
of cone transducin
(Gt2)
Rabbit
Santa Cruz
Biotechnology
1/500-1/1000
Caspase 3 (active) Rabbit AbCam 1/20
Cone Arrestin Rabbit Gift 1/2000
Cone-opsin (red-
green)
Rabbit Chemicon 1/1000
Cone-opsin (blue) Chicken Gift 1/4000
Cone-opsin (short) Rabbit Chemicon 1/1000
Hemagglutinin
(HA) tag
(polyclonal)
Rabbit Abcam 1/200-1/1000
Rhodopsin Mouse Gift 1/100
Peanut agglutinin
(PNA)
Goat
Vector
laboratories
1/200-1/1000
Table 2-10 Primary Antibodies
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2.8.3 Histology
Lectin
Lectin staining (Lectin from Bandeiraa simplicifolia, TRITC conjugated, Sigma,
UK) was used for orientation of retinal flatmounts by staining the vasculature.
Fixed retinal sheets were immersed in lectin (0.1mg/ml in PBS) at 4C for 12-16
hours, prior to repeated washes in PBS (6x 1 hour washes). Prior to mounting on
microscopy slides, retinal flatmounts and sections were stained with the Hoechst
33342 DNA stain (used at 1/1000 dilution in PBS). In addition DAPI (1/100
w/w) was added to the fluorescent mounting medium used (DAKO, Ely, UK).
Haematoxylin and Eosin (H&E)
Prior to staining cryosections were washed in running water to remove OCT
medium; paraffin sections were instead washed in xylene to remove the wax,
followed by alcohol and water washes to rehydrate the tissue. Slides were
immersed in Hematoxylin (Fisher Scientific, Loughborough, UK) for 5 minutes
to over-stain the tissue, before 2 minute rinses in water and acid alcohol (1%HCL
in 70% alcohol) to differentiate the staining by removing Haematoxylin from
non-basic tissue components. Following a further wash in water the slides were
immersed in ammonia water (1ml NH4OH in 1L H20) to alkalinise the tissue
and turn the Haematoxylin blue. Slides are washed in water and rehydrated with
95% alcohol prior to staining with Eosin (Fischer Scientific). The staining is
differentiated by immersion in 95% alcohol to remove excess eosin. Finally the
slides are immersed for 2 minutes in Xylene to aid fixation of the aqueous based
dyes, before being mounted in a Xylene-based mounting medium (DEPEX, BDH
chemicals, distributed by VWR International Ltd, Lutterworth, Leicestershire).
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2.9 Protein Detection
2.9.1 Evaluation of Protein Concentration
Total protein concentrations were determined by examining samples in triplicate
with a commercial calorimetric protein assay (DC protein assay kit, Biorad,
Hemel Hempstead UK). Sample concentrations were compared to a bovine
serum albumin standard curve and diluted in assay buffer to bring the
concentration to within the linear portion of the standard curve for quantification.
Bovine serum albumin used for the standard curve was supplied at 10mg/ml
(Promega, Madison, WI, USA). Measurement of optical density was performed
using the Emax ELISA reader (Molecular Devices Ltd, Berkshire, UK) to
quantify absorbance at 650 nm.
2.9.2 ELISA
GDNF and XIAP proteins were detected, and concentrations determined, using
commercial immunoassays manufactured by R&D Systems Europe Ltd., Oxford,
U.K. (human GDNF ELISA DuoSet and total human XIAP Duoset). Kits
were used according to manufacturer’s instructions. A 96 well plate was first
coated with ‘Capture’ antibody. A high-protein blocking solution was then used
to bind to any remaining areas of plastic on the 96 well plates. Samples were
then applied for 2 hours incubation at room temperature prior to washing with
wash buffer (0.05% (v/v) Tween® 20 in PBS) . A biotyinylated ‘Detection’
antibody was then applied for a further 2 hours prior to repeated washes.
Samples were incubated with streptavidin conjugated to horseradish-peroxidase
and detected using a chromogenic substrate. The colour change was measured at
450 nm using a spectrophotometer (Immunoscan, Cellular Technology Ltd).
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2.9.3 Western Blotting
Cells from in vitro and in vivo samples were lysed in a commercial RIPA buffer
with added protease inhibitor (both from Sigma Aldrich, Gillingham, UK). Cell
membranes were disrupted using a sonicator (Soniprep 150, MSE London UK)
with the samples maintained on ice, prior to storage in aliquots at -800C.
Equal amounts of protein were loaded into wells of a reducing SDS
polyacrylamide electrophoresis gel (typically 9% w/v) and run to establish
protein band separation over approximately one hour at 120 volts. Bands were
then transferred to a PVDF membrane (Millipore Watford UK) and blocked in
5% milk for one hour at room temperature with mixing. Primary and secondary
antibodies were used as in Table 2-11 prior to imaging of the membrane with a
chemifluorescence reader or x-ray developer.
Concentration used Incubation Conditions
Primary Antibodies
- anti HA 1/2000 Overnight at 4C
- anti XIAP 1/500-1/1000 Overnight at 4C
Secondary Antibodies
- anti Rabbit secondary 1/5000 in TBS Tweenand 2% goat serum
2 hours at room
temperature
Table 2-11 Antibodies used for Western Blotting
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Chapter 3 A novel model for the in-vivo
study of rod-cone degeneration
3.1 Introduction
A challenge to the study of cone photoreceptors in the mouse is that they
constitute only 3% of the total photoreceptor population, and are diffusely spread
throughout the retina.13;14 Retinal sections are therefore dominated by rod
photoreceptors, and the magnitude of cone-specific functional responses is small
in comparison to rod responses in wild-type mice.
A novel mouse model was therefore generated to facilitate the study of
specifically cone photoreceptor survival and function in the course of a rod-cone
retinal degeneration. The mouse model is a double transgenic, homozygous for a
targeted disruption of the rhodopsin gene and heterozygous for green fluorescent
protein (GFP) expression driven by a cone specific promoter. The rhodopsin
knockout mutation gives the mouse model a rod-cone degeneration analogous to
that seen in patients, in which a mutation expressed specifically in rods leads first
to rod photoreceptor death and then to a subsequent secondary loss of healthy
cone photoreceptors. The advantage of using this specific rhodopsin mutation is
that it renders the rods non-functional and so specifically cone function can be
assessed with confidence. The advantage of the cone promoter driven GFP
expression is that it permits in vivo, and hence repeated, quantification of cone-
photoreceptor survival during the course of the degeneration.
The mouse line was derived by inter-breeding the pre-existing ‘Rhodopsin
Knockout’ and ‘Opn.gfp’ strains.
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The Rhodopsin Knockout Mouse
This mouse line, with a targeted disruption of the rhodopsin gene, was generated
by Humphries et al. and has been a widely used since as a model of human
retinitis pigmentosa.90 The gene was disrupted by generating a vector that
incorporated a neomycin cassette at codon 135 in exon 2 of the rhodopsin gene.
Southern blots were used to identify embryonic stem cell clones and
subsequently chimeric mouse off-spring with DNA containing the targeted
disruption. In addition absence of rhodopsin expression in ocular tissues was
confirmed with reverse transcriptase PCR, with primers spanning the insertion in
exon 2, and rhodopsin immunohistochemistry. These experiments confirmed
that there was no rhodopsin in the homozygous knockouts (Rho-/-), in contrast to
the heterozygotes and wild types (Rho +/- and Rho+/+ respectively).
Rhodopsin has structural roles essential for photoreceptor morphogenesis, in
addition to its role in phototransduction,240 and so rhodopsin knockout mice lack
rod outer segments.90 The outer nuclear layer however, which is principally rod
photoreceptor nuclei,13;241 is nevertheless still about 80% of its normal thickness
at 24 days of age; this degenerates with time such that by 48 days it has
decreased in thickness by 50%, and by 90 days the ONL is just one cell thick
indicating that rod photoreceptor degeneration is essentially complete. In
keeping with the histological findings ERG analysis shows no evidence of a rod
response in the Rho-/- animals.90;242 In contrast, the cone ERG response is
initially equal to that in wild type mice, until about P47 when it then
progressively declines to reach 1-2% of the wild type response by P80. Punzo et
al. characterised the course of cone loss using quantitative real-time PCR to short
wavelength sensitive opsin transcript, and using whole-mount
immunohistochemistry to medium wavelength sensitive opsin and peanut
agglutinin lectin (PNA).75 Cone photoreceptor loss was found to commence only
once the rod loss was largely complete and the ONL just one cell thick. Cone
loss commenced in the central retina and was only complete across the whole
retinal surface by about 80 weeks of age.
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The Opn.gfp mouse
This mouse strain was purchased from the Mutant Mouse Research Resource
Centre (www.mmrrc.org) and is referenced by the strain name of “B6.Cg-
Tg(OPN1LW-EGFP)85933Hue/Mmmh”. The mutant mice contain a
modification of the Aequorea victoria jellyfish green fluorescent protein (GFP)
transgene under control of the human long-wavelength-sensitive cone opsin
promoter (OPN1LW-human). GFP, and in particular the variant used in this
mouse strain known as enhanced green fluorescent protein (eGFP), is a valuable
cellular and protein marker due to it being both highly fluorescent and soluble.
The strain was initially developed by Fei and Hughes 243 by injecting a plasmid
DNA construct into the pronuclei of F1 mouse embryos; transgenic mice were
identified using PCR, epifluorescence microscopy and immunohistochemistry.
Fei and Hughes found that only cone photoreceptors contained detectable levels
of GFP. No GFP was found in the RPE, suggesting that the GFP released during
disc shredding is rapidly degraded or looses its fluorescence due to the pH of the
endosomal pathway. 244 The effect is that the GFP expression is found very
specifically in cones, and not in the RPE cells or macrophages even though they
are involved in cone photoreceptor outer segment phagocytosis.
Fei and Hughes also found that
- The subset of the cone population that express GFP are found in greatest
density in the dorsal retina, and were relatively sparse in the more
peripheral ventral retina (in a similar pattern to M opsin expression).
- The level and distribution of expression was stable through successive
generations. Only heterozygotes for the transgene were studied (personal
communication).
- The cells (on the basis of histological appearance) appeared healthy and
normal despite the quantities of GFP seen.
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3.2 Colony Generation and Maintenance
Mice homozygous for the rhodopsin disruption were selected for by performing
scotopic ERGs following 12 hours of dark adaptation (example traces shown in
supplementary data chapter). In contrast to wild types or heterozygotes,
homozygous rhodopsin knockout mice are distinctive in having no a-wave;90;242
this is likely to be because the a-wave is a direct measure of the photoreceptor
response, and in mice lacking functional rods the a-wave generated by the
relatively sparse cones is too small for detection using standard ERG protocols.
Selection for retinal GFP expression was achieved by fundal imaging of
fluorescence using the scanning laser ophthalmoscope.
Experimental animals were all bred from crosses where one parent had no GFP
expression to ensure that only Opn.gfp heterozygotes were used. This was to
avoid variability in levels of GFP expression that could potentially result from
including Opn.gfp homozygotes. Breeding pairs were confirmed to be
homozygous for rhodopsin gene disruption and so all GFP-expressing off-spring
(i.e. the experimental animals) had the Rho-/-Opn.gfp+/- genotype.
Experimental animals, with this geneotype, are here-in referred to using the
“Rho-/-Opn.gfp” abbreviation.
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3.3 Cone-specific GFP expression
In order to confirm the cell population in which eGFP is expressed Rho-/-
Opn.gfp animals were culled at 6 weeks of age, and cryosections prepared along
the superior-inferior axis.
These showed the eGFP to be strongly expressed in specifically cone
photoreceptors, as determined by cellular morphology, location and counter-
staining with cone-specific antibodies (Figure 3-1 to Figure 3-3). eGFP is
excluded from nuclei and so in Figure 3-1 part B a negative image of the lobular
nucleus can be seen, which is a characteristic features of cone photoreceptors.13 It
can also be seen that the cone photoreceptors are localised to a single plane at the
outer edge of the outer nuclear layer; this means that a single confocal image,
with the focal plane at this level, can be expected to detect a high percentage of
the cone photoreceptors.
Also in Figure 3-1 the eGFP is seen to be strongly expressed throughout the cone
photoreceptor except in the outer segment where expression was reduced. An
antibody to red/green opsin was used to delineate cone outer segments. As
expected eGFP expression driven by the human long-wavelength opsin promoter
largely corresponds to cone outer segments expressing red/green opsin.
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Figure 3-1 GFP expression in cone photoreceptors of the Rho-/-Opn.gfp mouse. A cryosection
of adult retina has undergone immunohistochemistry for opsin protein (A and B). Strong GFP
expression is seen in cone cell bodies, synaptic end plates and inner segments (shown at low
power, high power and schematically in panels A, B and C respectively). The typical cone
photoreceptor morphology, with multi-lobed nuclei localised to the outer limit of the outer
nuclear layer (ONL), is well demonstrated in this figure. Red-green opsin expression
(demonstrated using immunohistochemistry and shown in red) is seen in the outer segments of
cones expressing GFP (A and B).
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Peanut agglutinin (PNA) lectin selectively binds to the protein sheath and
interphotoreceptor matrix surrounding cone photoreceptors, and not rod
photoreceptors.245 It was therefore used to identify the total cone population,
regardless of opsin subtype expressed in the sections of Rho-/-Opn.gfp retina
(Figure 3-2). In keeping with findings from other mouse strains the cones were
found to be evenly distributed across the retinal surface.13;14 The eGFP
expression however, followed a superior-inferior gradient with greatest
expression in the superior retina and posterior pole (Figure 3-2). This pattern
approximates previously described patterns of M-opsin expression in the mouse
eye, and is as expected given that the eGFP expression is driven by the human
long-wavelength-sensitive opsin promoter.12;246 These sections clarified
therefore that the eGFP is expressed in a sub-proportion of the total cone
population.
To elucidate this further, additional sections were counter-stained with an
antibody to the S-opsin protein (Figure 3-3). In the mouse eye S-opsin is
primarily expressed in the ventral retina, with only scattered expression in the
dorsal retina.12;246 This pattern of expression is evident in Figure 3-3.
Thus although cone photoreceptors are evenly distributed along the superior-
inferior axis of the Rho-/-Opn.gfp mouse eye, cones expressing eGFP are found
at greatest density in the superior retina and posterior pole. This distribution is
approximately proportional to the gradient of M opsin expression, and inversely
related to the gradient of s-opsin expression. Therefore the eGFP is principally a
marker of M opsin expressing cones, and not of cones expressing high levels of
s-opsin.
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Legend to Figure 3-2 (following page). The 6 week old Rho-/-Opn.gfp eye has been
sectioned along the superior-inferior axis at the posterior pole of the eye. Peanut
agglutinin lectin (red) was used to show the cone sheaths of all cones regardless of cone
subtype. A composite image is shown (middle right) along with 6 surrounding
enlargements from the different regions. GFP expressing cones are seen throughout the
retina, but are most numerous at the posterior pole of the eye, and in the superior retina.
The insert (*) is a high power magnification from the image to its right, showing the
morphology of GFP expressing cones. Cone cell bodies are aligned at the outermost
edge of the ONL. PNA (red) is seen to surround and overlie the outer segment of GFP
expressing cones, which is seen as yellow on the image.
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Figure 3-1 GFP and PNA in the Rho-/-Opn.gfp mouse at 6 weeks of age. (Legend on
previous page).
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Figure 3-3 Composite image along the superior-inferior axis of the eye of a 6 week old
Rho-/-Opn.gfp mouse. Antibody staining to s-opsin is shown in red. GFP expression is
seen to be most dense in the superior retina and posterior pole. S-opsin expression was
seen to be more dense in the inferior retina (lower-most inset) than in the superior retina
(upper-most inset).
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3.4 In-vivo imaging of cone photoreceptors
Having ascertained the specificity of eGFP expression in histological sections the
aim was to establish an in vivo monitoring method for these cone photoreceptors.
This was achieved using the Scanning Laser Ophthalmoscope (SLO), and
specifically the autofluorescence mode in which light of 500nm or above is
detected following stimulation of the retina at 488nm (the peak absorbance for
GFP) (Figure 3-4).
Figure 3-4 Autofluorescence image of the retina of a Rho-/-Opn.gfp mouse at low(A),
intermediate (B) and high (C) magnification. Images were taken from an
anaesthetised mouse a Heidelberg confocal scanning laser ophthalmoscope. GFP
expressing cells, in this case cone photoreceptors, can be seen as distinct entities.
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In order to count the number of GFP-expressing cones in a defined area of the
retina, and maintain consistency between examinations, the retina was first
imaged with the infra-red mode of the scanning laser ophthalmoscope. As seen
in Figure 3-5, this allows for the optic disc and retinal blood vessels to be used
for orientation of the images and to accurately centre images on the optic disc.
Autofluorescence images were then taken at the same location.
Cone photoreceptor counts were performed using Photoshop (Adobe) and Image
Pro-Plus (Media Cybernetics) software. An overlay was applied to cover the
central 75% of the field of view, and centred on the optic disc. Discrete
hyperfluorescent spots were counted within this defined area. Only the central
75% of the field of view was counted so that counts were not compromised by
small variations in positioning and centring of the original image, or by edge
artefacts (as at the edge of the SLO image there can be some blurring which
making fluorescent spots less distinct).
Legend to Figure 3-5 (following page). In vivo retinal imaging of a Rho-/-Opn.gfp
mouse. Infra-red imaging (uppermost) was used to visualise the optic disc and retinal
blood vessels that were used for orientation. GFP fluorescence was visualised with a
488nm laser and 500nm barrier filter (middle image). Discrete hyperfluorescent spots
were counted in the central 75% of the visual field (indicated by overlay, lower
image). The red spots have been added in Photoshop to overlie discrete spots of
hyperfluorescence; these are then counted using image processing software (Image
Pro-Plus).
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Figure 3-5 In vivo imaging of cone photoreceptors. (Legend on previous page)
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Figure 3-6 Lectin staining was used to show
in detail the retinal vasculature and branching
pattern in flatmounted retinas
To confirm that the distinct fluorescent spots seen with the SLO were indeed
individual GFP expressing cones (rather than clusters for example), experiments
were performed to compare in vivo images with subsequent histological images
from the same eyes.
Both fundi of both 4 rho-/-Opn.gfp mice, of 10 weeks of age, were imaged prior
to the animals being sacrificed on the same day. The retinas were dissected out
and prepared as flat mounts with care to
avoid distortion of the tissues or damage
to the imaged area surrounding the optic
disc. Lectin staining (Figure 3-6) was
used to show the retinal vasculature on the
flat mounts and thus allow images from
the flat mounts to be correctly sized and
orientated prior to being overlaid on the
SLO images where the branching pattern
of the vasculature can also be seen.
These correlations of the flat mounted
retinas and the SLO images showed that
the area of imaged retina, with the SLO focussed on the hyper fluorescent spots,
was 4.3mm2 (sd 0.95mm2), giving a value of 2.4mm2 (sd 0.53mm2) for the area
of each image in which fluorescent cones are counted.
Overlying corresponding areas of the vascular tree in retinal flat mount and SLO
images demonstrates that the hyper fluorescent spots seen on the SLO are
individual cones (Figure 3-7). The SLO images obtained can therefore be used
to monitor in vivo the survival of individual cones over time, as well as give
quantitative data on the survival of the cone photoreceptor population within a
defined area of the posterior pole.
Four sample points were identified where there was distinctive vasculature
evident on the retinal flat mounts that had also been seen in vivo. These were
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Figure 3-7 Histopathological correlation of the SLO image. Retinal flatmouts were
stained with lectin (red) to demonstrate the retinal vasculature, and in the lower image the
underlying GFP-expressing cones (green) are also shown. The vessel bifurcation, with an
intersecting vessel over the upper branch (, can be seen in the histological sections as well
as the in vivo SLO images. Enlargements of the histological and SLO images (lower row) in
this area demonstrate that distinct patterns of hyperfluorescent spots seen in vivo [eg straight
line (and curved line (correspond exactly to individual gfp expressing cones in the flat
mounted retina.
used to compare in vivo counts with histological counts of GFP expressing cells
in corresponding fields of view. At these sample points, all within the posterior
pole of the eye, the in vivo count was 67% (sd 12.3) of the histological count.
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3.5 Characterisation of the cone degeneration in the
Rho-/-Opn.gfp mouse
To better understand the time course of the cone degeneration secondary to a
rod-specific mutation Rho-/-Opn.gfp mice were studied at repeated time points
with functional assessments (ERG), and in vivo counts of GFP positive cones.
At selected time points mice were sacrificed for histological correlation of the
findings. To control for the effects of GFP expression on degenerating cones
Rho-/-Opn.gfp mice were compared to uncrossed rhodopsin knockout mice that
lacked GFP expression.
3.5.1 Loss of cone function
Scotopic ERGs in the Rho-/-Opn.gfp mouse confirmed the absence of rod
function (example trace in supplementary data chapter). To determine the time
course of cone degeneration in the Rho-/-Opn.gfp mouse cone-specific ERG
assessments were performed at repeated timepoints, and the b-wave amplitude
compared over time. The degeneration in cone function in a cohort of Rho-/-
Opn.gfp mice is shown in Figure 3-8. Cone function was approximately stable
until day 52 of age, after which there was a steep decline. Whilst b-wave
amplitudes could be consistently identified, a-waves were less distinct and more
variable. b-wave data only is presented in this thesis. The last data point shown
is for day 73, at which time mean b-wave amplitude to a 10cd.s/m2 flash was
30.1 V (sd 19.3). By day 77 function in most animals was at the detection limit
of the apparatus, as indicated by lack of a distinct b-waves in comparison to
background noise on the recording baseline.
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Cone ERG in the Rho-/-Opn.gfp mouse
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Figure 3-8 Degeneration in ERG cone function in the Rho-/-Opn.gfp mouse. Mice were
examined after light adaptation and in photopic conditions at repeated timepoints. Mean
b-wave amplitude ( sd) to a single flash intensity is shown (n=11).
To examine the effect of GFP expression on cone function a Rho-/-Opn.gfp+/-
male was crossed with a Rho-/- female (i.e. a rhodopsin knockout female without
GFP expression). Cone function was assessed in littermates which were then
imaged to determine which expressed GFP. As shown in Figure 3-9 cone
function in GFP expressing mice was diminished as compared to non-GFP
littermates. The number of littermates was small, and so results from multiple
litters were also compared. These also showed GFP expression to be associated
with reduced cone function. This could be directly due to high levels of GFP
protein within the cell compromising function, light absorption by the GFP
protein reducing opsin stimulation or from an unrelated gene or consequence of
transgene integration being inherited in association with the GFP transgene. This
has not been investigated further, but Rex et al. likewise found cone function in
the Opn.gfp mouse to be reduced as compared to age-matched wild types from
the same genetic background.247 It is also of note that the ERG amplitudes in the
cohorts of animals shown in Figure 3-9 are lower than those examined separately
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in Figure 3-8. This could be due to variation between litters or changes in the
ERG apparatus which occurred between separate experiments. To limit such
variation ERG maintenance changes (such as replacement of corneal electrodes
and the heat pad) were avoided during longitudinal time courses. They however
could still account for differences between separate experiments.
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Figure 3-9 The effect of GFP expression on cone function. Cone function was
compared in litter mates with and without GFP expression (top and middle graphs). In
the top graph b-wave amplitudes are shown for all flash intensities at day 48. The time
course of degeneration is shown with b-wave amplitudes to a single flash intensity at 3
timepoints. In the lower graph data from multiple litters is compared.
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3.5.2 Cone photoreceptor survival
To examine the time course of cone photoreceptor loss Rho-/-Opn.gfp mice were
imaged with the SLO at weekly intervals commencing from the start of
functional loss (week 7 of age). These initial investigations showed that GFP
expression continued at approximately stable levels until week 11, before
degenerating over the subsequent 6 weeks. To quantify this, GFP-expressing
cones were counted at weekly intervals in a cohort of Rho-/-Opn.gfp mice and in
a comparison group of age-matched Opn.gfp mice (which lacked the rhodopsin
knockout genotype/phenotype). The SLO counts from both eyes of each animal
are presented in Figure 3-10. Corresponding example images from each mouse
model, at weeks 11 and 17, are shown in Figure 3-11.
In the Rho-/-Opn.gfp mouse there was a steep and progressive decline in cone
numbers at the posterior pole of the eye. At week 11 the mean central cone
count was 1048 (sd 313) as compared to 36 (sd 47) at week 17. There was also a
more limited decline in cone counts in the Opn.gfp mouse. Mean counts at week
11 and 17 were 942 (sd 178) and 631 (sd 189) respectively. Two way ANOVA
analysis with Bonferroni post-tests confirmed the Opn.gfp and Rho-/-Opn.gfp
counts to be significantly different from one another (p<0.01). At week 17 cones
in the Opn.gfp mouse remained approximately equally distributed across the field
of view, where as in the Rho-/-Opn.gfp mouse residual cones were primarily in
the superior retina (Figure 3-11). The steep loss in cone numbers in the Rho-/-
Opn.gfp mouse occurred approximately 4 weeks after the degeneration in cone
function. Cone photoreceptors were therefore losing function weeks before
loosing GFP expression. The decline in cone numbers in the Opn.gfp control is
discussed in 3.6.
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In vivo cone counts over time
11 12 13 14 15 16 17
0
500
1000
1500
Opn.gfp (n=12 eyes)
Rho-/-Opn.gfp (n=14 eyes)
Age (weeks)
C
en
tr
al
co
ne
co
un
t
Figure 3-10 Cone counts over time. Rho-/-Opn.gfp and Opn.gfp mice were imaged on a weekly
basis between 11 and 17 weeks of age, and the number of discrete cones quantified. The cone
counts reveal a fast degeneration in the Rho-/-Opn.gfp mice, and a statistically significant
slower decrease in GFP signal from the Opn.gfp mice.
Figure 3-11 Example cone degeneration images from Rho-/-Opn.gfp and Opn.gfp mice.
There was a marked cone degeneration in the Rho-/-Opn.gfp mouse, and at 17 weeks
the density of residual cones was maximal in the superior retina. In the Opn.gfp mouse
there was a more limited change in cone density.
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3.5.3 Non-functional cones
To investigate why cones in the Rho-/-Opn.gfp mouse lose function weeks before
cell death eyes were examined histologically at weeks 6 and 13 of age. At the
former timepoint function is approximately maximal, whilst at the latter cone
function was no longer detectable. Immunohistochemistry was performed to
examine expression of proteins integral to the phototransduction pathway, and
visualise outer segments.
The G-protein transducin is directly activated by photo-excited visual pigment,
and in rods the rate of its activation is a critical determinant of the cellular light
sensitivity. Translocation of transducin out of the outer segment and in to the
inner segment allows rods to operate in light conditions that would otherwise
lead to saturation of the response.248 In contrast in cones levels of transducin
activation are controlled by other means, and transducin is consistently
compartmentalized in the outer segment.249-251 This is evident in the wild type
controls in Figure 3-12. In the Rho-/-Opn.gfp mouse limited transducin
expression, also within the outer segment, is evident at 6 weeks of age when cone
function is approximately maximal (Figure 3-8). In sections from 13 week old
Rho-/-Opn.gfp mice, in which the rod-cone degeneration has progressed, the
ONL is only approximately 2 nuclei thick. Residual GFP expression is evident
demonstrating that surviving cones remain but that the normal morphology has
been lost. Of note though, there is no evidence of persistent transducin
expression in these residual cones, which will helps explain the absence of cone
function at this timepoint.
The phototransduction protein arrestin is also translocated between inner and
outer segments in rods, but in the opposite direction to transducin. Thus in the
dark adapted state rod arrestin is found in the inner segments, but on exposure to
light there is a translocation to the outer segment.249 In cones the distribution of
the arrestin protein is less compartmentalised, and in the light-adapted mouse the
protein is found in both the inner and outer segment, cellular processes and in the
synaptic end plate.249 The sections in Figure 3-13 are from light adapted mice,
and demonstrate this pattern of expression. In the wild type mouse cone arrestin
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expression is seen at high levels throughout cone photoreceptors. In the 6 week
old Rho-/-Opn.gfp mouse the expression is reduced as compared to the wild type,
but is still evident throughout the cell body of selected cone photoreceptors. By
13 weeks however, this expression too is much reduced, which is again in
keeping with the absence of function in Rho-/-Opn.gfp mice of this age. The
reduced transducin and arrestin expression could be due to down-regulation of
their respective promoters or due to post transcriptional regulation of mRNA
processing or protein translation.
It is also evident from Figure 3-12 and Figure 3-13 that the morphology of the
cone photoreceptors is altered during the degeneration. In the images from 6
week old Rho-/-Opn.gfp mice cones are evident with long long straight processes
extending across the outer nuclear layer. However by week 13 this normal
morphology is lost. The change in morphology is further illustrated in Figure
3-14 in which GFP expressing cones are shown at weeks 6, 14 and 17. At the
later time points the ONL is thinner and the cones can be seen to be shortened
and apparently angulated. Whilst the shortening is likely to be real the
angulation could also be a sectioning artefact secondary to shearing of the
degenerate retina during cryosectioning.
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Figure 3-12 Cone transducin expression in the Rho-/-Opn.gfp and wild type mouse.
Cone transducin is expressed in cone outer segments of the wild type and 6 week old
Rho-/-Opn.gfp mouse. Levels in the latter are diminished relative to the wild type. By
13 weeks of age residual GFP expression driven by the OPN promoter is still evident but
there is little evidence of continued transducin expression. To control for specificity of
the secondary antibody, sections from a 6 week old Opn.gfp mouse without primary
antibody were stained in the same antibody run. Cryo-sectioins are from the mid-
superior retina.
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Figure 3-13 Cone arrestin expression in the Rho-/-Opn.gfp and wild type mouse. In the
6 week old Rho-/-Opn.gfp mouse cone arrestin is expressed in cone outer segments, cell
bodies and synaptic regions. An identical distribution is seen in the wild type mouse,
but with greater levels. At 13 weeks of age GFP expression driven by the OPN
promoter is still evident but there is no evidence of continued cone arrestin expression.
To control for specificity of the secondary antibody sections from a 6 week old Opn.gfp
mouse without primary antibody, were stained in the same antibody run. Cryo-sections
were obtained from the mid-superior retinal where opn.gfp expressioin was maximal.
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3.6 The Opn.gfp mouse
The decrease in central cone counts in the Opn.gfp mouse, as seen in Figure 3-10,
is suggestive of a slow cone degeneration in this mouse model which lacks the
rhodopsin knockout mutation. This commercially available mouse line has been
used by at least two different research groups previously. Rex et al. found these
mice to have reduced cone function on ERG, as compared to wild types, at 6-8
weeks of age but commented there was no histological evidence of a
degeneration at this timepoint (as evidenced by normal layer thickness, cone
density and PNA staining).247 Beck et al. using the same mouse line, but referred
to as ‘RG-GFP, reported normal ERG function at 8 weeks, but that by 10 months
of age the GFP signal and photopic function had diminished.252 Further
investigations of the Opn.gfp mouse, from which the experimental Rho-/-Opn.gfp
Figure 3-14 Changes in morphology of the gfp expressing cones over time in the Rho-/-
Opn.gfp mouse. Cryosections are shown from 6 week old, 14 week old and 17 week old
mice, and have been counterstained with DAPI only in order to show nuclei. eGFP
expressing cones are seen to display typical cone photoreceptor morphology in the 6 week
old mouse, but this is lost in older mice coincident with loss of the ONL.
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mice were derived, were therefore performed in order to investigate the aetiology
of photoreceptor degeneration.
At day 48 of age, cone function in the Opn.gfp mouse was found to be equal to
that in wild type mice and in rhodopsin knockout mice prior to the onset of cone
degeneration (Figure 3-15). Cone function was similar in one year old wild type
mice (n=3, Figure 11-17). However in two one year old Opn.gfp mice cone
function was absent, despite preservation of rod function (Figure 3-16). Rod
function (as measured by b-wave amplitude to a 0.01 cd.s/m2 flash under scoptic
conditions) was equal in the 1 year old Opn.gfp mice to that in age-matched wild
type mice [mean b-wave amplitude 180 V (sd 20) (n=2) and 150 V (sd 45)
(n=3) respectively, p(difference)=0.20 (t-test)]. There was evidence therefore of
a slow cone photoreceptor specific degeneration in the Opn.gfp mouse, that was
not secondary to rod degeneration.
Cryosections of the year old Opn.gfp retinas (n=4) were analysed with
immunohistochemistry for M/L and S opsin expression. There was no evidence
of these cone-specific proteins or GFP expression in the year old Opn.gfp mice.
In sections of an 8 month old Opn.gfp mouse S and M/L opsin were expressed
but they and GFP were only sparsely distributed in the retina (Figure 3-17)
The histological findings are in keeping with the functional data, and indicate
there is a slow cone degeneration in the Opn.gfp mouse. Duisit et al. have
previously reported RPE cell toxicity after the expression of high levels of
eGFP.253 In this study rat RPE cells were transduced following the sub retinal
injection of lentiviral constructs. High levels of eGFP expression were seen for
approximately one month, after which expression diminished and there was
histological evidence of RPE loss in the transduced area. The use of the same
vector types with an alternative form of GFP (derived from the sea pansy Renilla
reniformis) lead to stable GFP expression within the RPE for at least six months
without signs of toxicity. The toxicity in the first set of experiments was
therefore attributed to eGFP. However in contrast Rex et al. did not find
evidence of toxicity, at least in the short-term, with quantified and high levels of
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expression within either RPE or photoreceptor cells;247 in these experiments
eGFP cDNA was integrated into the genome (transgenic mice) or predominantly
episomal following viral vector mediated transduction; they found no evidence of
altered morphology or altered function with thorough investigations that included
single cell recordings as well as whole field ERGs. Their animals were however
only evaluated up to P30, and so a slow degeneration was not excluded.
In the experiments here Rho-/-Opn.gfp littermates expressing eGFP in cones had
reduced cone function compared to GFP-negative littermates. eGFP expression
could therefore have negative effects that impair cone survival. However
expression was still strong at week 17, and still evident in the 8 month old
Opn.gfp mouse. Thus despite strong transgenic expression any toxicity is not as
potent in the cone photoreceptors as that described by Duisit et al. following
lentiviral infection of RPE cells. Furthermore in the experiments here there was
no evidence of any cone function or opsin expression in year old Opn.gfp mice.
Thus non-GFP expressing cones had also been lost. It is likely therefore that the
Opn.gfp mouse has a slow cone degeneration that is not directly related to eGFP
protein.
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Figure 3-15 Comparison of cone function in the Opn.gfp, wild type and rhodopsin
knockout (KO) mouse. Mean ERG b-wave amplitude (sd) at day 48 is plotted on
the y-axis and flash intensity on the x-axis. There is no difference in cone function
betweent the three different types of mice at this timepoint.
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Figure 3-16 ERGs in two Opn.gfp mice at one year of age. Scotopic ERGs were
performed with flash intensities of 0.001, 0.01, 0.1, 1.0, 3.0, 6.0, 10.0 cd.s/m2. Photopic
ERGs were performed with flash intensities of 0.1, 1.0, 3.0, 5.0, 10.0 and 20.0 cd.s/m2.
Averaged traces are shown.
Figure 3-17 Cryosections from an 8 month old Opn.gfp mouse. Sections from
superior (1) and inferior (2) retina are presented showing GFP expressing cones (a),
opsin immunoreactivity (b) and combined images with DAPI staining (c). GFP
expressing cones were seen but at reduced density when compared to sections from
10 week old Opn.gfp mice. Immunohistochemistry for ML and S opsins confirmed
that both cone subtypes were still present in this aged retina.
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3.7 Discussion
3.7.1 Cone photoreceptor degeneration
The experiments here show cone function in the Rho-/-Opn.gfp mouse to be
approximately stable until P52 and then rapidly decline over the following 4
weeks. These results are in keeping with published literature as to the effect of
the rhodopsin knockout genotype on cone photoreceptors. In the original
description of the rhodopsin knockout phenotype by Toda et al. the cone ERG
was likewise found to be normal until approximately week 7 before degenerating,
in their series, over the following 5 weeks.242
In the experiments here in vivo imaging of the cone photoreceptors illustrated
that eGFP expression, driven by a cone opsin promoter, was persistent despite
near complete loss of rod photoreceptors. Cone photoreceptors, particularly in
the superior retina, continued to survive and produce eGFP for weeks after all
detectable cone function was lost and the ONL was just one cell thick. This is of
interest in relation to theories of rod-cone degeneration and in view of potential
treatment approaches for advanced RP.
It is suggested that if a rod-derived survival or toxic factor were central to cone
photoreceptor loss one would expect a short time lag between the major phases
of cell death. Instead in the Rho-/-Opn.gfp mouse cone photoreceptors persists
for up to approximately 6 weeks in the posterior pole of the eye after rod
photoreceptor degeneration is largely complete. This is a common feature across
a variety of rod-cone degeneration models. Punzo et al. quantified cone
photoreceptor loss in four models of rod-cone degeneration, using quantitative
PCR of S-opsin mRNA levels and histological assessments of M/L opsin and
PNA expression.75 In all cases cone loss only progressed after the major phase
of rod photoreceptor loss. If rod-derived trophic or toxic factors are the primary
determinants of cone photoreceptor fate one would therefore expect there to be a
threshold level with cones dying only after this has been reached. Alternatively
there could be a considerably delayed biological effect. It is of note that in both
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humans and mice the cone photoreceptor loss lags behind that of rods, despite the
different spatial distributions. This indicates that the presence of a cone-only
fovea is not central to the reasons for a delayed loss of cone photoreceptors.
Persistent cone photoreceptors have also been found in patients with advanced
RP, and little if any residual vision. Researchers have therefore been developing
approaches to restore function in these residual photoreceptors. Recently
Busskamp et al. reported restoration of light sensitivity in surviving but non-
functional cones through the expression of an alternative light-sensitive protein,
the bacterial protein halorhodopsin.254 This was performed in fast (rd) and slow
(Cnga3-/- Rho-/- double knockout) murine models of retinal degeneration using
AAV. Protein expression was also induced ex vivo in photoreceptors of human
retinal explants. To be of broad application, this approach is dependent on the
prescence of residual non-functional cones in significant numbers of patients
with advanced RP. In their paper Busskamp et al. demonstrated such residual
cones in the macula of a patient with advanced sporadic RP, and they have
previously been well reported in the rd murine model of retinal degeneration as
well.213;255-258 It remains to be demonstrated however how general a finding this
is. Conceivably certain mutations could be much more likely to result in
surviving non-functional cones than others. It is therefore of note that even in
the rhodopsin knockout mouse, with an absence of one of the most highly
expressed proteins in the outer retina and a fast retinal degeneration, cone
photoreceptors survive for weeks after loss of function.
The data presented here also demonstrates that although cones were surviving for
many weeks after loss of function, they had highly abnormal morphology and the
expression of selected functional proteins (cone transducin and arrestin) was
reduced. This will present a challenge for other treatment approaches, including
neuroprotection, that aim to maintain cone photoreceptors in their normal
functional state and sustain function using the natural cone photoreceptor
apparatus. The shortening of cone photoreceptor outer segments during the
course of retinal degeneration has been reported previously in animal models.75
It has also been seen in the retina of a patient with relatively early RP and good
visual acuity (20/60 4 months prior to death), in which only very small or no
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cone outer segments were visible.259 Potential treatments are likely to need to
halt, or possibly reverse, cone outer segment shortening and this is a potential
outcome measure for the evaluation of treatments and monitoring of disease
progression. However these images from the Rho-/-Opn.gfp mouse also show
how the cell body and inner segment are also seen to collapse and become folded
during the degeneration. This is possible to see in the Rho-/-Opn.gfp mouse as
eGFP is distributed widely in the cell body and inner segment. In contrast more
traditional methods of following cone degeneration with PNA stains for the
surrounding protein sheath or antibody stains for outer segment opsin proteins do
not show such detail. The likely cause for the cone cell body and inner segment
collapse is loss of the surrounding rod photoreceptors that ordinarily constitute
the bulk of the outer retina in rodent retina. It may be impossible to restore
physiological cone function in the absence of a near normal ONL and the
mechanical support it ordinarily provides. The study by Busskamp et al.
however indicates that non-physiological phototransduction, using an alternative
light-sensitive protein, is achievable.
If physical collapse and a loss of surrounding structural support is indeed a
reason for loss of cone function that could explain why rod-cone degenerations in
humans cause loss of peripheral cone function first with relative sparing of the
fovea until advanced stages of the disease; in humans peripheral cones are
surrounded by a high density of rods, and so loss of the rod photoreceptors will
cause thinning of the ONL as seen in the Rho-/-Opn.gfp- mouse. However in the
human fovea the lack of rod photoreceptors means that the cones are more reliant
on one another and Mueller cells for structural support.
3.7.2 Ventral-dorsal gradient
Histological characterisations of the spatial patterns of cone photoreceptor loss
can be hampered by substantial variability between animals.255;258 The in vivo
counts presented here, examining only the posterior pole, likewise showed
greater variability in the Rho-/-Opn.gfp degenerating retina than the OPN
controls (Figure 3-10). However a distinctive feature in the degenerating retina
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was a superior-inferior gradient in GFP distribution, most marked at the latter
stages of the degeneration (Figure 3-11). In part this will have been due to GFP
expressing cones being found at greatest density in the superior retina pre-
degeneration (Figure 3-2) however the distinction between superior and inferior
retina is more distinct at the end of the degeneration than at the start (Figure
3-11). Superior-inferior, or dorsal-ventral, distributions of surviving M/L cones
have been described previously in the rd mouse, the rhodopsin knockout mouse,
the PDE- knockout mouse (which lacks the -subunit of PDE) and the P23H rat
model of rod-cone degeneration.75;255;257 However this pattern of M/L cone
photoreceptor loss is not specific to rod-cone degenerations. The cone
photoreceptor function loss 1 (CPFL1) mouse (which carries a mutation in cone
specific phosphodiesterase 6 (Pde6c)) 252 and guanylate cyclase-1 knockout
mouse, 260 which both have mutations expressed in cone photoreceptors, have
similar patterns of cone loss. A dorsal-ventral gradient of residual cones has also
been described in the RPE65-/-mouse in which there is a rod-cone degeneration
secondary to a mutation expressed in RPE cells,261 and in the Rdh8-/-Abca4-/-
mice in which there is disrupted all-trans-retinal clearance in both rod and cone
outer segments, and subsequent RPE and photoreceptor degeneration.30 The
apparent increased susceptibility of cones in the inferior or ventral retina may
therefore not be related to the underlying genetic mutation, or an inherent
characteristic; instead it may reflect a common external or environmental
influence, such as increased light exposure in the inferior retina which has been
found to accelerate selected degenerations.30;262-267
An inferior-superior gradient of disease progression has also been reported in
selected patients and families with RP.268-270 It is hypothesised that mutations
causing increased cell activation may be more predisposed to the effects of light
than others. The significance of this for treating patients is that targeting of the
superior retina may be more likely to improve vision because of a relative
preservation of cell architecture. It also means that experiments to evaluate
potential treatments need to compare corresponding regions in treated and
untreated eyes. Light exposure is a potential confounding variable. Therefore in
the following experiments using the Rho-/-Opn.gfp model, mice were kept in
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standardised lighting conditions (14 hours light per 24 hours at 200-300 lux
directly under the ceiling lights, and approximately 40 lux within the cage). Eyes
with corneal opacities or cataracts were excluded from analysis. Furthermore,
interventions having a localised effect, such as subretinal injections, were
performed in both superior and inferior hemispheres.
3.7.3 A valuable model to evaluate cone-related outcome
measures
The experiments here have shown that the Rho-/-Opn.gfp mouse allows repeated
assessments of cone function, cone numbers and cone morphology in
degenerating retina. The in vivo findings were corroborated with histological
examinations to confirm that it is individual cone photoreceptors that can be
visualised and counted in vivo. Sample points from the posterior pole of the eye
identified that 67% of GFP expressing cones detected on retinal flat mounts had
been seen in vivo. A previous study imaging GFP expressing ganglion cells in
the rat retina with a similar scanning laser ophthalmoscope found that 60% of the
GFP expressing ganglion cells had been detected in vivo.271 The in vivo counts
are a representative sample of the M/L opsin-expressing cones at the posterior
pole of the eye and can be used to compare rates of degeneration between eyes.
Traditionally studies of cone degeneration have used immunohistochemistry to
identify cone specific proteins or the surrounding interphotoreceptor matrix in
order to identify and image the cones. These techniques principally identify the
cone outer segments. In the Rho-/-Opn.gfp mouse the eGFP is expressed in a
larger proportion of the cell (see Figure 3-1) meaning that changes in cell
morphology can be seen in greater detail, and cones can still be effectively
visualised when outer segments, and the proteins predominantly expressed within
them, have been lost (Figure 3-12 and Figure 3-13).
The degeneration in cone function was found to have a similar time course to that
in rhodopsin knockout mice that have not been crossed onto the OPN line.
However, evaluations of the Opn.gfp mouse also identified a slow cone
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degeneration, that was not secondary to rod degeneration. The Rho-/-Opn.gfp
mouse, derived from a cross of Opn.gfp and rhodopsin knockout mice, may
therefore have stimuli for a cone degeneration in addition to the rhodopsin
knockout mutation. However, the results show that cone loss secondary to the
rhodopsin mutation is fast leading to loss of function within approximately 11
weeks and loss of cone cell bodies over approximately 17 weeks in the posterior
pole of the eye. In contrast the cone loss in the Opn.gfp mouse was very slow,
over approximately 12 months, with limited impact in the young adult mouse
(Figure 3-10). Cone loss in the Rho-/-Opn.gfp mouse, which is largely complete
within 4-5 months, is therefore likely to be predominantly if not exclusively
secondary to rod degeneration.
The ability to study cone numbers and function in vivo in the Rho-/-Opn.gfp
mouse allows repeated assessments in individual animals; this can be expected to
be a valuable tool in evaluating whether the magnitude of any treatment effect on
cone photoreceptors changes in time. The Rho-/-Opn.gfp mouse therefore allows
interventions to be assessed with clinically important outcome measures that
have historically been difficult to assess in rodent models.
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Chapter 4 GDNF as a potential therapy for
retinitis pigmentosa.
4.1 Introduction
Neurotrophic factors, released by glial cells, ordinarily act on neuronal cells to
sustain growth, differentiation and survival.272 As an absence of such factors has
been linked with increased rates of apoptosis, it has long been hypothesised that
augmenting levels could have neuroprotective effects in conditions of increased
apoptosis.143
One such protein, glial cell-line-derived neurotrophic factor (GDNF) was first
identified as a stimulant of dopaminergic neurons in vitro.273 It has subsequently
been identified as protecting a wide variety of cell types from apoptosis under
diverse experimental conditions.274-277 The greatest interest in GDNF has
stemmed from its protective effects in in vivo models of Parkinson disease,278-280
and clinical trials have followed.161 It is also however, synthesized in the
retina281 and has been found to promote photoreceptor survival and morphology
both in vitro282;283 and in vivo in models of retinitis pigmentosa.80;154;158;160
The GDNF protein, in its non-glycosylated state, has a molecular mass of
approximately 15kD.273 It is highly conserved between species and is a member
of a group of 4 structurally related neurotrophic factors known as the GDNF
family of ligands (GFLs), all of which belong to the transforming growth factor β 
super family. The other 3 GFLs are neurturin (NTN), persephin (PSPN) and
artemin (ARTN). GDNF, and the other GFLs, act by binding to a ‘GDNF family
 receptor’ of which there are 4 subtypes (GFR1-4).277;284;285 It is GFR-1
which has the greatest affinity for GDNF.277;286 Bound receptors in turn activate
the membrane bound tyrosine kinase ‘Ret’ (rearranged during transfection)287
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leading to activation of intracellular signalling pathways. In particular GDNF
mediated Ret activation has been shown to lead to interactions with signalling
molecules of the src-family of protein-tyrosine kinases through phosphoinositide-
3 kinase (PI-3K) dependent pathways.288 Phosphatidylinositol 3-kinase/Akt
(PKB) and mitogen-activated protein kinase (MAPK) pathways are also
implicated. 276;277;289 The GFR receptors may alternatively bind to another
trans-membrane protein p140NCAM (an isoform of the neural cell adhesion
molecule NCAM)290;291 but the physiological relevance of this binding for
downstream intracellular signalling remains uncertain.292
The secondary pathways activated by GDNF are able to inhibit cell death
through the intracellular expression of anti-apoptotic proteins belonging to the
inhibitor of apoptosis (IAP) family.293 In particular, inhibition of the X-linked
inhibitor of apoptosis (XIAP) and neuronal apoptosis inhibitory proteins (NAIP),
using anti-sense mRNA, is found to prevent the neuroprotective effects of
GDNF.293
4.1.1 GDNF pathways in the retina
GDNF has been shown to slow rod photoreceptor death in several different
animal models of RP.80;154;156;159;160 There is uncertainty however, over the
molecular pathways through which these effects are mediated.
GDNF receptors are found on photoreceptors, and in vitro it is through these
receptors that GDNF-induced effects can be demonstrated on isolated
photoreceptor preparations.282;283;294-297 However many studies on whole
mammalian retina have found the GDNF receptor components to be most
prevalent in the Mueller glia, with a lower density in the ganglion cell layer and
only a sparse distribution in the photoreceptor layer. 212 298 292 This is not always
the case as for example Harada et al. found immunoreactivity to GFR1 and 2
to be predominantly in the photoreceptor layer of the Wistar rat,299 though in the
presence of light-degeneration expression was strongly up-regulated in the
Mueller glial cells as well.299 300 These findings have contributed to theories
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(reviewed by Bringmann and Reichenbach)17 that the action of GDNF on
photoreceptors is predominantly indirect, acting via the Mueller glia. It is
postulated that GDNF stimulated Mueller glia in turn release secondary
intermediate factors which directly stimulate photoreceptors. In keeping with
this, GDNF supplementation does increase glial fibrillary acidic protein (GFAP)
staining in Mueller glia.80 GFAP is an intermediate filament protein, and up
regulation of its expression is a marker of increased cell activity and up
regulation of gene expression in general. Fibroblast growth factor, which itself
promotes photoreceptor survival in vivo and in vitro,292 143;149;301;302 is one of the
genes up regulated in activated Mueller glia and so is a candidate for the
postulated secondary messenger.
4.1.2 Anti-apoptotic effects in the retina
Optic nerve transection is a commonly used model of neuronal apoptosis in the
adult central nervous system, as following transection approximately 90% of the
retinal ganglion cells (RGCs) undergo apoptosis within 2 weeks.303 Multiple
studies have demonstrated that GDNF reduces apoptosis and enhances survival
of axotomized RGCs.298;304-306 Analogous results are seen with GDNF treatment
of axotomized motor neurons293 and in models of chemically induced oxidative
damage158 which are also acute models of apoptosis.
However, in inherited retinal degenerations photoreceptor apoptosis is less acute,
instead occurring more gradually over a sustained period of time.75;307 The most
convincing evidence of a GDNF-mediated neuroprotective effect in this context
comes from a study in a rat model of RP where the treated eyes had
morphological and functional evidence of rod photoreceptor rescue (increased
ONL thickness and an improvement in scotopic a and b wave amplitudes in the
treated group).160 The animal model used for these experiments was the TgN
S334ter-4 transgenic rat which expresses a mutated rhodopsin gene in which
there is a premature stop codon (at residue 334 of the opsin transgene). The
rhodopsin protein formed lacks 15 amino acids at the carboxy-terminal of the
protein, which is believed to compromise trafficking of the protein to the outer
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segments resulting in photoreceptor cell death by a caspase-3-dependent
mechanism.114;228 The retina of these animals develops normally and then a
degeneration starts at approximately p15 that is slower than that seen in the Rho-
/-Opn.gfp mouse. Although the eyes treated with sub-retinal AAV.CBA.GDNF
had evidence of reduced photoreceptor loss compared to control (i.e.
AAV.CBA.GFP) treated and untreated eyes, there was no direct comparison to
pre-degeneration animals or wild types to help assess the physiological relevance
of the rescue effect. In addition the treatment effect was only demonstrated at
one timepoint (p60). None-the-less the relative preservation of ONL thickness
and rod function does indicate that GDNF can exert a neuroprotective effect on
at least rod photoreceptors, and furthermore can do so in a sub-acute model of
cell death, as well as the acute axotomy models.
GDNF as a therapy
A variety of growth factors and cytokines have been identified as potential
neuroprotective agents. GDNF is notable however in having a favourable safety
profile to date,160;308 including from clinical trials in patients with Parkinson’s
disease. 152-155;309 This is in contrast to CNTF and FGF in particular, for which
side-effects of impaired photoreceptor function154;309;310 and neovascularisation311
have been demonstrated respectively.
The work on GDNF supplementation in inherited retinal degenerations highlights
some of the potential limitations and unknowns of neuro-protective therapies in
general. In particular it is largely unknown how long beneficial effects are
maintained for, and how broadly applicable they are to different diseases and
underlying mutations. Additionally, in the context of rod-cone degenerations, it
is not known if neuroprotective therapies are effective at slowing the secondary
cone photoreceptor loss that has the greatest functional impact in patients.
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Functional potential of GDNF monotherapy
GDNF-mediated preservation of photoreceptor function has been demonstrated
in the rd mouse,80;159 RCS rat 154;156;312 and TgN S334ter-4 rat157;160 models of
retinal degeneration, and in mice treated with chemical inducers of oxidative
damage.158 In these studies GDNF was shown not only to slow photoreceptor
loss, as compared to untreated or control-injected eyes, but also lead to a relative
preservation of photoreceptor function. Thus photoreceptors were maintained in
a functional state.
However, the neuroprotective effect of GDNF is partial, resulting in a slowing
rather than cessation of the retinal degeneration. This is to be expected as the
underlying defect has not been corrected and so there are continued stimuli for
photoreceptor degeneration. Prolonged functional preservation will be
dependent on the prevention of cell death in the cells concerned, and so it is
important to have longitudinal studies that determine the magnitude of the
neuroprotective effects over time. Only longitudinal studies can assess for how
long the neuroprotective effect of GDNF is functionally relevant, but to date
most of the studies have reported outcomes at single timepoints only. Buch et al.
did however evaluate the effect of AAV2/2.CBA.GDNF in the RCS rat at
repeated timepoints and found that the initial functional benefit over untreated
fellow eyes was lost within 2 weeks.154 It remains to be demonstrated whether
higher levels of GDNF expression, or indeed studies in different models of
retinal degeneration, achieve more long-lasting benefits.
In addition, although GDNF and neuroprotective therapies in general, are
considered as potential treatments for a wide variety of IRDs it is important to
emphasise that they, when used alone, can only be expected to achieve functional
benefits in models, or stages of disease, where function still remains. Thus for
example in the rds mouse, in which the lack of peripherin prevents formation of
photoreceptor outer segments,217 GDNF supplementation has no functional effect
unless combined with gene replacement therapy.154 The studies demonstrating
functional benefits of GDNF are in animal models with milder phenotypes and
with treatment at early stages of disease when function still exists.80;156;157;159;160
Chapter 4: recombinant GDNF
149
These functional benefits are unlikely to translate to more advanced RP where
there are residual but non-functional photoreceptors.83;254;255
Neuroprotection without function
To date neuroprotective agents have been primarily evaluated as single-line
therapeutic agents, and in this context functional effects are fundamental to the
value of the treatment. However, many more complex diseases are best treated
with combination therapies, and in this context even an effect that preserved cells
but was not sufficient to maintain function would be valuable.
Dong et al. studied the effects of GDNF supplementation in the context of
oxidative stress induced retinal degeneration.158 Transgenic mice with
doxycycline inducible expression of GDNF were treated with paraquat to
promote oxidative stress and apoptosis within the retina. GDNF expression in
this model lead to only a modest functional benefit as measured by the ERG, but
the histological evidence of neuroprotection was much more striking, with
almost normal appearing outer nuclear layers. Most of the preserved cells may
therefore have been non-functional.
In contrast gene replacement for selected proteins has proved much more
effective at restoring function than preventing cell death,130 and combining the
gene therapy with neuroprotection can improve the outcomes. In the study by
Buch et al. rds mice were treated with rAAV.GDNF both alone and in
combination with gene replacement (rAAV.Prph2).154 Eyes treated with the
combination of GDNF and gene replacement had significantly greater ERG
function at 8 weeks and 3 months following injection than eyes treated with the
replacement vector alone. At least in part this was because of a larger number of
surviving photoreceptors (at 4 months post treatment photoreceptor numbers in
the GDNF and gene replacement group were 74% greater than in the gene
replacement only group). Analagous results were also shown in the RCS rat
treated with lenti-viral vector mediated MERTK expression with and without
rAAV.GDNF. Both ERG function and numbers of surviving photoreceptors
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were greater in the eyes treated with the combination of MERTK and GDNF,
than in eyes treated with MERTK gene replacement alone.
Furthermore, even for patients for whom gene replacement therapy is not an
option, due to the nature of the mutation or stage of disease, it may soon be of
benefit to preserve cone photoreceptors in a non-functional state. In a recent
Science paper Busskamp et al. demonstrated that expression of halorhodopsin in
light-insensitive cones was sufficient to restore not only light-sensitivity but also
sophisticated retinal circuitry functions including ON and OFF responses and
directional sensitivity.254 Halorhodopsin is a light activated chloride pump found
in archaebacteria, and so the reactivated cones were functioning by bypassing the
native phototransduction pathways. This approach is being carried forward into
clinical trials but of note there is no evidence to suggest that this strategy will
prolong the life of the cone photoreceptors. Benefits from the therapy would
therefore be transient in patients with RP. These developments too therefore
demonstrate a need for neuroprotective therapies even, or potentially especially,
if they don’t maintain native means of phototransduction.
Differential effect on rods and cones
The majority of photoreceptor outcome measures in rodent models of retinal
degeneration are rod-dominated, as rods far outnumber the cones and unlike in
higher animals there is no cone-rich area to facilitate assessment of cone-specific
outcomes. Thus, for example, in the study by McGee Sanftner of
AAV.CBA.GDNF in TgN S334ter-4 transgenic rats the outcome measures (ONL
thickness and scotopic ERG function) inform us that GDNF had a
neuroprotective effect on rod photoreceptors, but do not indicate whether there
was any effect on cones.160
Layer and colleagues have however studied the effects of GDNF in chicken
retina, which has a reversed rod-cone ratio to that seen in rodents, such that cones
are far more numerous.294,27 Working in vitro with retinal aggregates derived
from embryonic chicken retinas they too found that GDNF supplementation
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enhanced rod photoreceptor survival and rhodopsin expression, and conversely
that down-regulation of expression (using antisense oligonucleotides) was found
to decrease rhodopsin expression (and the number of rhodopsin staining cells
seen with immunohistochemistry). However, no effect was demonstrated on the
cone photoreceptors. The absence of a demonstrable effect on cone survival
does not however preclude an effect in the degenerating adult retinas of rodents
or humans; Layer et al. were working with embryonic tissue in vitro, and there is
evidence that in this experimental model the development of rods is highly
dependent on micro-environmental changes and spatial proximity of cones,
where as that of cones is less so;313;314 the susceptibility to survival factors may
well be different in vivo. Furthermore, as the cones develop earlier than rods, at
least some will have been at a different embryonic stage to the rods at the time of
the GDNF supplementation or down-regulation, which could influence
sensitivity to GDNF. In addition, the stimuli and mechanisms for cone
photoreceptor loss are likely to have been very different in the in vitro retinal
aggregates to the situation in rod-cone retinal degenerations. In particular the
secondary loss of cones in vivo in rod-cone degenerations is at least in part
through oxidative damage,95 and the delivery of systemic antioxidants has been
shown to slow this in both fast and slow murine modes of retinal
degeneration.315;316 GDNF is protective against oxidative retinal damage induced
in mice with paraquat, iron or hypoxia.158 Although this latter study too used rod
dominated outcome measures (ONL thickness and scotopic ERGs), it is plausible
that if these effects were on cones as well as rods then GDNF would be
protective for the oxidative damage that occurs in cones during rod-cone
degenerations.
Even if in contrast to rods, cones are not directly sensitive to GDNF, it is
conceivable that GDNF expression in rod-cone degenerations could lead to an
indirect effect on cone survival by augmenting rod survival. By enhancing rod
survival in this situation, GDNF would diminish the stimulus for cone
degeneration. Such an indirect action would not have been apparent in the study
by Layer et al. because of the reversed ratio of rods to cones. In the retinal
aggregates used by Layer the cones were far more prevalent and so will have
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been less dependent on surrounding rod photoreceptors for structural and
metabolic support.
It is of both interest and clinical importance to identify whether this difference in
GDNF sensitivity of rods and cones in embryonic chicken retinal aggregates
does correspond to a difference in degenerating adult mammalian retinas.
Whether any effect on cones is direct, or indirect by augmenting rod survival,
could then be tested by inducing cone specific expression of one of the down-
stream effectors of GDNF mediated effects. XIAP would be a suitable candidate
for this as its inhibition can prevent the neuroprotective effects of GDNF,293 and
furthermore it is an intracellular protein and so cell-specific expression could be
achieved.
4.1.3 Aims
It remains to be demonstrated whether GDNF treatment does or does not delay
secondary cone degeneration in models of RP. A treatment effect on cones is
potentially more feasible than one in rods as, in rod-cone degenerations, the
cones themselves express no genetic mutation and are initially healthy prior to
degenerating secondary to the rod photoreceptor loss. However the models used
previously have not facilitated an assessment of cone-specific outcome measures,
and one of the principal aims is to address this. This is a clinically relevant
question to address as even the most effective means of preserving rod
photoreceptors will be of limited clinical relevance in the absence of a
concomitant effect on cone photoreceptor function, and hence colour and high
acuity central vision.
Assessing cone function in the Rho-/-Opn.gfp mouse, following treatment with
GDNF, will allow an assessment of whether there is an effect on the secondary
cone degeneration. Furthermore, if there is an effect, it will be possible to
monitor the magnitude of the effect over time, potentially addressing further
unknowns as to the duration of GDNFs effects on apoptotic photoreceptors.
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4.2 GDNF receptor expression
Before embarking on GDNF treatments the first experiments were to designed to
test whether the GDNF receptors were still expressed in the degenerating retina
during the time period of cone degeneration. Previously Jomary et al. reported
that GFR2 mRNA expression levels were lower in the rd mouse retina than in
wild types, as detected with in situ hybridisation.212 Furthermore, whilst it
looked as though there may be expression within photoreceptors in the adult wild
type retinas, this was not evident in the rd mouse. Down-regulation of the
sensitive receptors during the cause of the degeneration could limit the potential
efficacy of GDNF as a potential therapy. However in situ hybridisation is no
longer the most reliable means of quantifying and comparing levels of expression.
Furthermore, whilst down-regulation of expression may be expected to cause
decreasing expression of GFR2 signal with time in the rd mouse, this is not
what was found. Instead, the authors found the GFR2 signal to be less
widespread in the rd retinal images, than in the age-matched wild type retinas at
early timepoints. However, during the degeneration (p17 and p20) and in adult
rd retinas (p60) in which photoreceptors are lost increasing expression was seen
within the inner retina. The same research group went on to examine GFR2
expression levels in a rat-model of light-induced retinal degeneration, and found
essentially the opposite of the findings in the rd mouse; in the rat model of light-
degeneration GFR2 expression increased during the course of the degeneration,
and this was particularly evident in the photoreceptors.295 These conclusions
were well supported with western blot analysis and immunocytochemistry. No
variation in GFR1 expression levels was seen.
Whether GFL receptors are present in inherited retinal degenerations is of
relevance for the therapeutic potential of neurotrophic factors such as GDNF.
The relevance of where they are expressed is less clear as the mechanism of
action may be indirect via Mueller cells, and furthermore the GFR receptors may
be secreted and, once bound to GDNF, be able to stimulate other neuronal cell
types expressing RET.282;317 The first line of experiments was therefore to
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identify if GFR1 and GFR2 are present or not in the degenerating retina of the
rhodopsin knockout cone-GFP mouse.
4.2.1 Primer design and testing
Primers were designed to bind to murine GFR1 or GFR2 mRNA. To test
these primers whole eyes from an 8 week old wild type and 11 week old Rho-/-
Opn.gfp mice were enucleated, and mRNA isolated and quantified. cDNA was
then generated for primer testing.
Amplicons of the expected size were detected with cDNA from both mouse lines
confirming presence of the GFR mRNA in both samples. Control PCR reactions
for -actin were run alongside to test for successful cDNA generation and PCR
reactions.
Figure 4-1 Validation of primers for murine GDNF receptors. PCR reactions were
performed with GFR1 and GFR2 primers, and cDNA from adult wild type (wt) and
11 week old Rho-/-Opn.gfp eyes.  Β-actin primers were used as positive controls.
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4.2.2 GFR1 and GFR2 expression in the Rho-/-Opn.gfp mouse
over time.
To look for GFR1 and GFR2 mRNA in specifically the retina, and whether it
is maintained in time Rho-/-Opn.gfp eyes were isolated at 10 days of age, 13
weeks of age (approximate age of maximal cone photoreceptor loss) and 17
weeks of age (approximate endpoint of cone degeneration). An adult wild type
eye was also enucleated to be used as a positive control. Retinas were dissected
out in RNA later immediately following enucleation and stored at -800C prior to
mRNA isolation and cDNA preparation. These PCR reactions confirm that the
GFR receptors to which GDNF has the greatest affinity are present throughout
the rod-cone degeneration in the Rho-/-Opn.gfp model of retinitis pigmentosa.
Figure 4-2 Detection of GFR1 and GFR2 mRNA. cDNA from wild type retina and
Rho-/-Opn.gfp retina at repeated timepoints confirmed the presence of GFR1 and
GFR2 mRNA. -actin control PCR reactions were run alongside for each sample to
test for the presence of cDNA , and successful PCR reactions.
4.3 Intra-vitreal delivery of recombinant protein.
A minimally invasive means of delivery of GDNF to the retina is with an intra-
vitreal injection of the recombinant protein. This means of delivery has the
advantages of being relatively technically undemanding to perform, and
comparatively safe as evidenced by the complication rates in clinical trials of
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Ranibizumab.189 In addition the timing and dose of drug delivery is highly
controlled. It is therefore a favoured means of delivering therapeutic agents both
experimentally and in clinical practice.
For a therapeutic agent delivered to the vitreous cavity to act within the retina,
sufficient levels must pass through the structural and cellular barriers of the
vitreal-retinal interface (including the internal limiting membrane) and inner
retina. In comparison to the highly effective anti-VEGF agent ranibizumab,
which has a molecular weight of 48 kDa, GDNF is relatively small with a
molecular mass of 15kDa.273 Furthermore, where as ranibizumab has to reach
the outer retina to exert its therapeutic agent GDNF may only have to reach the
inner retina, if indeed its action on photoreceptors is via the Mueller cells whose
processes transverse the retina. Evidence that GDNF protein delivered to the
vitreous cavity can indeed be effective in photoreceptor neuroprotection comes
from animal model studies of slow-release capsules implanted into the vitreous
cavity.157
4.3.1 Validation of assay
In order to be able to quantify levels of murine GDNF a commercial enzyme-
linked immunosorbent assay (ELISA), previously validated with human and rat
GDNF, was first tested with recombinant murine GDNF. Homology between
murine and human forms of GDNF is 92.2% for the amino acid sequence, and
98.5% for the mature GDNF formed following cellular proteolytic processing
prior to secretion.318
Recombinant murine GDNF was purchased from Peprotech (London, UK) and
reconstituted in autoclaved PBS to produce a working solution of 500g/ml. The
GDNF ELISA kit used, with human GDNF standards, was purchased from R&D
systems. In a 96 well plate a dilution series of the recombinant murine protein
was produced in triplicate along side the recombinant human protein standard (in
duplicate). Concentrations were measured using the ELISA kit and compared to
calculated concentrations to assay the sensitivity of the assay (Figure 4-3). The
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apparent increased sensitivity for the murine GDNF is likely to be an
experimental artefact (possibly relating to the manufacturer’s aliquoting of the
recombinant protein or preparation of the dilution series). The results validate
the ELISA prep used as a valid means of assaying murine GDNF.
Figure 4-3 Comparison of ELISA detection of human and murine recombinant GDNF
protein. Error bars (+/- standard deviation) are shown for the murine GDNF series.
Concentrations of human and murine GDNF were measured to very similar, validating
the use of the assay for either protein.
4.3.2 Pharmokinetics
To establish the half-life of GDNF in the mouse eye wild type mice were injected
with recombinant protein, and the eyes harvested for analysis at six subsequent
timepoints.
For this experiment, 18 wild type mice were injected intravitreally with 500ng of
recombinant murine GDNF in 1l of PBS, at 38 days of age. At each of the 6
timepoints (midday on days 1, 2, 5, 8, 16 and 33) 3 mice were culled and the
eyes snap frozen in liquid nitrogen. At completion of the time series treated eyes
were crushed whilst still frozen and then suspended in 120l of reagent diluent
with 1/100 protease inhibitor. Following vortexing samples were spun at 10 000
rpm for 5 minutes and the supernatant used for ELISA to determine the
concentration of GDNF.
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For the day 1 and day 2 samples supernatants were analysed at 1/100, 1/1000 and
1/10000 dilutions. Day 5, 8, 16 and 33 samples were analysed undiluted and at
1/10, 1/100 and 1/1000 dilutions. Only ELISA results falling within the range of
the standard curve were used for further analysis (OD 0.1 to 1.5) (Figure4-4).
Figure 4-4 Standard curve from ELISA experiment to determine concentration of
GDNF in wild type mouse eyes. Known concentrations of recombinant GDNF were run
alongside samples to be evaluated in order to correlate optical density (OD, y-axis) with
GDNF concentration (x-axis). A 4 parameter sigmoidal best fit line is used with the
ELISA because of plateaus at high and low concentrations. This fits the data with a high
correlation coefficient (r2=0.997).
Mean values of GDNF concentration at the selected timepoints are shown in
Figure 4-5. On a logarithmic scale the decrease between day 1 and day 8 is
approximately linear which is suggestive of GDNF elimination following 1st
order kinetics. This would indicate that drug elimination is proportional to drug
concentration, which is the case for most pharmaceutical agents within the body.
The levels from day 8 onwards were at the detection limit of the assay.
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Figure 4-5 The decrease in GDNF levels following intravitreal injection in the mouse
eye. Mean  sd. Single eyes of 18 wild type mice were injected intravitreally with
500ng of recombinant murine GDNF. At days 1, 2, 5, 8, 16 and 33 three mice were
culled to establish intra-ocular GDNF levels.
To calculate the half life of GDNF in the mouse eye it was assumed that the drug
does indeed follow first order decay, and an exponential best fit line was applied
to the results of the first 4 timepoints (Figure 4-6). The curve fits with a
correlation coefficient of 0.84 and has a half-life of 0.68 days (95% confidence
intervals 0.40 to 2.44). The half-life of GDNF in the murine vitreous cavity is
therefore calculated to be 16 hours. This is shorter than the half-life of 37 hours
that has been reported in pig eyes319, which may relate to the substantial
differences in vitreous volume or the relationship of metabolic rate to animal size.
The adult mouse eye has a relatively small vitreous cavity, which is estimated to
be ~7l. In contrast the volume of the vitreous cavity in the pig eye is closer to
that in a human, 4000l. In adult eyes the vitreous body is avascular, and so
drug elimination will occur primarily at the outer surface by diffusion. A smaller
surface area to volume ratio, as is the case in the porcine eyea will therefore be
a The equations for the surface area and volume of a sphere are S=4r2 and V=(4r3)/3
respectively. With volume being proportional to radius to the power of 3, but surface area being
proportional to radius to the power of 2, the surface area to volume ratio will decrease with an
increase in radius (r).
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associated with a lower rate of drug elimination. In addition Kleiber’s Law
refers to the finding that metabolic rate of organisms is proportional to body
mass to the power of ¾.320 The higher metabolic rate in the mouse than the pig
could also explain the difference in half life, if the higher metabolic rate
corresponds to a steeper concentration gradient.
Figure 4-6 Application of an exponential best fit line to the GDNF level results from day
1 to 8. R2=0.84. (Mean  sd).
Conversion to absolute values
For all the GDNF ELISA experiments each harvested eye was diluted in 120l of
reagent diluent. Harvested eyes were approximately 3mm in diameter, giving an
ocular volume of 14l, in keeping with published estimates. The ELISA
measured values therefore reflect an approximate 10-fold dilution of absolute
concentrations within the eye.
4.3.3 Evaluation of single bolus
LaVail previously evaluated a large number of neurotrophic factors by
performing intra-vitreal injections, at a single timepoint, into 1 eye of mice with
various retinal degenerations.301 GDNF was not one of the neurotrophic factors
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evaluated. The value of these experiments was that for CNTF, and to a lesser
extent BDNF, a single injection was sufficient to produce a protective effect in
some of the mouse models. The CNTF mediated neuroprotective effects were
seen in the rd, nervous and Q344ter models of retinal degeneration. Similar
experiments have demonstrated neuroprotective effects for FGF-2 in the RCS rat
and, the TgnS344ter-4 rat, and in albino rats with light-induced photoreceptor
degeneration. 143;149;150;321
Of note, whilst the half-life of GDNF in the mouse vitreous eye is relatively short
at 16 hours, that is not to say the biological effect is not considerably longer.
Within the nigrostriatal dopaminergic system of parkinsonian rats a single
injection of GDNF exerts a biological effect lasting over 8 weeks. 322 It is
important to identify whether GDNF has a prolonged biological effect in retinal
degenerations as repeat intravitreal injections are feasible clinically, as seen with
the treatment of AMD with antivegf agents.
Dose
The effect of a single intra-vitreal injection of 500ng of GDNF was evaluated in
11 Rho-/-Opn.gfp mice. Whilst the exact effective dose (ED50) of GDNF for
outer retinal degeneration is unknown, Frasson et al. demonstrated a
neuroprotective effect in the rd mouse with 330ng of GDNF, in an injection
volume of 1l, when delivered directly into the sub-retinal space. This is a
similar dose as used for other growth factors with intra-vitreal injections in
mice.143;301 It is a considerably higher concentration of GDNF than has been
found to be effective in neural tissues273, but is supported by the short-term in
vitro studies of rat rod photoreceptor morphology by Carwile et al., where 1ng/l
of GDNF, but not 0.1ng/l was found to enhance rod outer segment survival.283
330-500ng/l is also a considerably higher dose than that found to be effective in
preventing retinal ganglion cell apoptosis in rat models of glaucoma when one
takes into account the vitreous volume. In a dosing study in rats by Klocker et al.
500 ng intra-vitreally was found to have an optimal effect, and 2g had no
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additional benefit.305 The vitreous volume in the adult rat is approximately
56l323, and so the approximately 10 times greater than the vitreous volume in
the mouse eye.
An intravitreal dose of 500ng is therefore likely to be suprathreshold for GDNF
receptors in the inner retina, and in the same order as used previously for sub-
retinal injections in mice. Furthermore a concentration of 500ng in 1l (an
appropriate volume for the intra-vitreal injections in mice) has been reported as
showing no signs of toxicity in cell culture.319 The following experiments were
therefore performed with a GDNF dose of 500ng in 1l injected intra-vitreally.
Intra-vitreal Injections
Injections were administered at day 38 of age so as to treat before the ONL was
lost by over 50%, and before cone function had already started to deteriorate. A
single eye of each of the 11 animals was treated, with the side randomised to
control for any bias in subsequent ERG analysis. To control for the effects of
sub-retinal injection a further 4 mice were treated at the same timepoints with
unilateral injections of 1l of PBS. All injections were performed under direct
visualisation with an operating microscope; with the needle tip held in close
proximity to the optic nerve head an assistant depressed the plunger with a slow
motion so as to ensure delivery to the inner retina, whilst minimising the
potential for direct mechanical trauma from the infusion.
Results
Cone function in GDNF, PBS and untreated eyes was evaluated with ERG
assessments under photopic conditions. Assessments were performed at days 45,
52, 60 and 73 for pre-, early-, mid- and late-degeneration time-points
respectively.
The assessment at day 45 was performed to look for functional consequences
following the intra-vitreal injection procedure 7 days previously. As this
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timepoint is pre-degeneration, a neuroprotective effect is unlikely to be
detectable but lasting iatrogenic damage will be. Neither intra-intravitreal
injections of PBS or rGDNF had an effect on baseline cone function, as
compared to fellow untreated eyes (paired t-test, p=0.87 and p=0.38 respectively).
To detect an effect on cone function degeneration rGDNF, PBS and untreated
eyes were assessed at 3 timepoints spanning the degeneration, and analysed with
analysis of variance (ANOVA) and post test Bonferroni tests. Time point, but
not treatment group, was a significant determinant of cone function. There was
no evidence that a single bolus of rGDNF at day 38 improved cone function at
subsequent timepoints, or led to a delay in the cone degeneration. The rate and
time course of cone function degeneration was not altered, as shown in Figure 4-
7. Comparison of treated and untreated eyes in individual mice revealed that in
only 1 of the 11 treated with GDNF was function greater in the treated eye than
in the untreated eye at all timepoints. In 2 of the 11 cone function was greatest in
the untreated eye at all timepoints, and for the rest the eye with greatest function
varied over time. There was therefore no evidence of a sub-group of responders
that should be analysed separately to non-responders.
Figure 4-7 The effect of single intravitreal rGDNF or PBS injections in the Rho-/-
Opn.gfp mouse. All eyes were treated with 500ng of intravitreal GDNF at day 38 of age.
Mean b-wave amplitude ( 1 sd) to a photophic flash of 10 cds.m-2 is shown at each
timepoint. The interconnecting line is shown for the untreated eyes to show the normal
course of degeneration.
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Discussion
Injections in to the mouse vitreous cavity are potentially complicated by the
small vitreous cavity and relatively large intraocular lens. Compromised retinal
function could result from direct damage to ocular tissues, or from consequent
variations in intraocular pressure in particular. Conversely however, studies of
intra-ocular injections in the rat have also demonstrated that the procedure itself
can induce neuroprotection.143;321 This is most pronounced with sub-retinal
injections in the RCS rat, probably due a combination of clearance of sub-retinal
toxins and the release of endogenous growth factors in response to the injury.
However in their initial study of FGF in the RCS rat, Faktotovich et al. found
histological evidence of photoreceptor rescue in eyes which had undergone a
single intra-vitreal injection of PBS.143 Their intra-vitreal injections were
performed through the retina where as in these experiments the aim was to inject
through the pars plana and thus avoid direct injury to the retina. None the less it
was important to evaluate whether the procedure itself compromised cone
function in this animal model, or resulted in a subsequent neuroprotective effect.
This was achieved by pre-degeneration (p45) assessments and following PBS-
treated controls during the course of the degeneration. These evaluations were
consistent in showing no procedure-related effects on cone function.
GDNF has a prolonged biological effect on dopaminergic neurons,322 but an
analogous effect on cone photoreceptor function was not demonstrated in these
experimental conditions. This was despite using a supra-threshold dose, and a
timepoint chosen to aid the chances of detecting any effect. At p38 cone
numbers are still approximately maximal, and most rod photoreceptors are still
present so there was the potential for both a direct action on cone photoreceptors,
and an indirect effect by augmenting rod photoreceptor survival. No effect was
evident however.
A negative result following such experiments with a single intra-vitreal injection
is open to a far greater number of interpretations that a positive result. In
particular methodological factors such as the timing of injection, or dose used
may lead to a potential therapeutic effect being undetected. Furthermore the
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response to intra-ocular survival factors has been found to vary considerably with
the animal model in which it is tested.301;324
LaVail noted that the variability of results was far greater with intravitreal
injections into mouse as opposed to rat eyes, and suggested that the small size of
the mouse eye presents particular challenges to achieving consistent delivery of
proteins with intravitreal injections.301 The authors therefore expressed
reservations regarding negative interpretations from such studies evaluated in the
small mouse eye only. In order to try and minimise variability of delivery in the
experiments presented here, intravitreal injections were performed under direct
visualisation with the needle tip maintained directly above, and in close
proximity, to the optic disc. This is in contrast to the technique used in humans
where the needle is kept in the centre of the vitreous cavity, and direct
visualisation is not necessary.325 The pharmokinetics evaluation on page 169
validated this technique of intra-ocular protein delivery and did not support
LaVail’s concerns of inconsistent protein delivery in the mouse eye.
4.3.4 Evaluation of repeated bolus
Given the short half-life of GDNF within the murine vitreous, further
experiments were performed to reduce the risk of a positive treatment effect in
this model being missed due solely to timing of injection.
Rho-/-Opn.gfp mice (n=7) were treated with 500ng of GDNF, delivered by intra-
vitreal injection to a single eye, at days 36, 42, 50, 57 and 64. Fellow eyes were
treated with 1l of PBS to act as a control for the effect repeated injections might
have on function, and media clarity for subsequent SLO imaging. Functional
analysis was performed at days 45, 60 and 73 to leave adequate intervals between
anaesthetics, and SLO imaging was performed at day 77.
Results
1 of the 7 mice failed to recover fully from the first anaesthetic a further 2
developed corneal scars during the course of the experiment preventing inclusion
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in the day 73 and day 77 assessments. Functional assessments are presented
across the full range of flash intensities examined and reveal no difference
between the GDNF and PBS treated eyes (Figure 4-8). There was no evidence of
either a protective or toxic effect from the repeated GDNF injections on cone
function.
In order to confirm that cone survival was similar in GDNF-treated animals
compared to controls, SLO imaging was also performed at day 77. This was the
9th anaesthetic and procedure for the remaining cohort of animals, and by this
time the ocular media were sufficiently clear for good quality SLO imaging in
only 3 of the initial cohort of 7 animals. Mean central cone counts were 838
212 and 580 189 for the GDNF and PBS treated eyes respectively.
Comparison of GDNF and PBS treated eyes in individual animals, to limit the
effect of inter-animal variation, revealed no statistically significant difference
between the two groups (p=0.22, paired t test, n=3).
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Figure 4-8 The effect of repeated GDNF bolus injections on cone function. Mean b-
wave amplitudes to a range of photopic stimuli are shown, with standard deviations
indicated by error bars. At each of the timepoints there is no significant difference in
cone function between the GDNF treated and PBS treated eyes. The rate of functional
cone degeneration over time is the same in both groups of eyes.
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Figure 4-9 Central cone density for GDNF and PBS treated eyes of 3 animals at
p77. Pairs of eyes from individual mice are shown in rows. Right eyes (labelled
OD) were treated with GDNF. Left eyes (labelled OS) were treated with PBS. SLO
images are shown. There was no overall difference between GDNF and PBS
treated eyes.
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4.3.5 Conclusions
GDNF has been reported as a potential neuroprotective agent for inherited retinal
degenerations. Histological and functional efficacy has been demonstrated in
selected animal models of retinitis pigmentosa, and of the photoreceptor-toxic
and angiogenic side-effects that have been found with other growth factors when
administered within the eye have not been found with GDNF. 150;152-155
The experiments here, identifying GFR1 and 2 expression in the degenerating
Rho-/-Opn.gfp retina, are supportive of further work to evaluate GDNF as a
potential therapeutic agent. The pharmokinetics of a single dose of GDNF to the
mouse vitreous cavity was investigated, and the half-life determined.
The combination of a single bolus, and then repeated bolus, injection regime was
used to look for a treatment effect at multiple timepoints. Previously McGee
Sanftner et al. have demonstrated rod photoreceptor neuroprotection in
transgenic rats with a rhodopsin mutation.160 It was therefore of interest to
examine the effects of GDNF supplementation both at early timepoints which
were favourable for rod neuroprotection, as well as at later timepoints when the
rods have largely degenerated and any treatment effect would have been likely to
be independent of rods. Recombinant protein injections were used for these
experiments as a means of delivering precisely known doses at exact timepoints.
The experiments demonstrated that with these intravitreal boluses of GDNF
protein there was no effect on cone photoreceptor function in this animal model
of rod-cone degeneration. There was also no evidence or repeated GDNF
boluses having an effect on the numbers of surviving non-functional cone
photoreceptors in the latter stages of the degeneration.
If substantiated these results would preclude a valuable role for GDNF, at least as
a sole therapeutic agent, in the clinical setting. It could be that the pro-
degeneration stimuli in this model are too strong for the neuroprotective effects
of GDNF found in other models of RP. Alternatively, it remains possible that
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GDNF does not have a neuroprotective effect on cone photoreceptors. However,
experimental limitations could also lead to a neuroprotective effect remaining
undetected with these experiments. In particular, with this mode of GDNF
delivery the intra-ocular levels will have been highly fluctuant, as shown by the
pharmokinetics data. The most convincing evidence for a neuroprotective effect
from GDNF in other models has been with sustained expression of the protein,
using gene therapy for example. It could therefore be that a neuroprotective
effect of GDNF is dependent on consistently high intra-ocular levels of the
protein. Furthermore, the timing of GDNF administration in these experiments
was targeted to preserve the cone photoreceptors directly. It could instead be that
GDNF has an indirect effect on cones, and that by preserving rod survival even
transiently to preserve oxygen consumption or trophic factor release, it indirectly
preserves cone function and survival. To detect such an effect GDNF should be
administered early on during the rod phase of the rod-cone degeneration. In
addition, the power of these experiments to detect a therapeutic effect was
compromised by exclusions during the course of the repeated bolus experiments.
Corneal and lens clarity in the mouse eye is readily compromised with repeated
anaesthetics and procedures which entail a risk of corneal desiccation or
abrasions. In the repeated bolus experiments the protocol included 9 anaesthetics
and procedures, and the outcome measures were highly dependent on corneal
clarity. Over 50% of the experimental animals were excluded by the completion
of the experiment, such that numbers of cone photoreceptors at p77 were
assessed in only 3 animals.
The findings therefore provide no evidence of a neuroprotective effect of GDNF
on cone photoreceptors in this RP model. This could however be due to the need
for sustained GDNF expression and it might be that weekly injections were
simply not regular enough to maintain sustained levels of intraocular protein. To
determine whether these findings reflect the true potential of GDNF further
experiments were performed using gene therapy to achieve sustained and long-
lasting elevation of intra-ocular GDNF levels.
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Chapter 5 Inner-retinal GDNF gene
therapy
5.1 Introduction
Following the isolation and sequencing of GDNF,273 the principle challenge to
studying its efficacy as a neuroprotective agent in vivo has been how to deliver
the protein to the neuronal tissue of interest at sustained and high levels without
repeated invasive procedures. Systemic delivery has proved ineffective given the
inability of therapeutic amounts to penetrate the blood–brain barrier. In an early
trial of GDNF for Parkinson’s disease a cannula was implanted intra-cranially
with the tip within the right front ventricle, and a distal access port lying under
the scalp skin into which repeated injections could be administered.326 There
was however no improvement in parkinsonism in this trial, and there were
significant side effects related to the implanted cannula and central actions of
GDNF. Furthermore, examination of the brain of a trial subject who died of
unrelated causes provided no evidence of significant diffusion of the
intracerebroventricular GDNF to the relevant brain regions, the putamen and
substantia nigra .327
Implantable devices from which GDNF is secreted have also been developed for
use within the eyes of animal models.159 These however retain the disadvantage
of releasing the GDNF distal to its site of action and relying on diffusion down a
concentration gradient. Injections of GDNF-secreting mouse embryonic stem
cells into the vitreous cavity of rat eyes were reported to result in significant
elevations of plasma GDNF.157 The explanation for this finding is unclear as the
plasma levels were higher than the vitreous levels in treated animals. None the
less the finding at least raises the concern that high intra-vitreous levels could
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result in systemic side-effects, particularly in the context of retinal dystrophies
and disruption to the normal blood-retinal barrier.328
Gene therapy, using viral vectors, has the advantage of being an effective and
safe means of inducing sustained expression of proteins close to their site of
action.197 Intra-retinal transgene expression and functional effects have been
observed for at least 3 years after a single administration of viral vector.198;329
These are likely to persist considerably longer given that the transduced cells are
typically non-dividing.197;198
For retinal gene therapy the viral vector, containing the transgene sequence, is
delivered into the eye by means of a single intra-vitreal or sub-retinal injection,
with the former being the less invasive option. Recombinant adeno-associated
virus serotype 2 (rAAV2/2), injected intra-vitreally, leads to effective
transduction of predominantly ganglion cells in the inner retina.330;331 It is
therefore well suited to the delivery of GDNF which is a diffusible extracellular
protein , for which the majority of the receptors are ordinarily found in the inner
retina.
5.2 Gene Therapy to express GDNF in the inner retina
5.2.1 The cmv.gdnf plasmid and in vitro testing
The cytomegalovirus (CMV) promoter sequence is derived from the major
immediate-early promoter of the human cytomegalovirus. It is one of the first
viral promoters to be activated following viral infection, and has proved to be an
effective promoter in cell types that are naturally infected by the CMV virus in a
human host, which includes photoreceptors, RPE and ganglion cells within the
retina.331;332 It is a constitutive promoter, that is largely unregulated allowing for
continual transcription of its downstream gene (although in certain circumstances
activity may be down-regulated by methylation).333 It was therefore chosen as
the promoter to drive Gdnf production in the following experiments.
The murine Gdnf coding sequence was cloned into the pd10 plasmid downstream
of the CMV promoter (shown schematically in Figure 5-1 with the full plasmid
Chapter 5: Inner-retinal GDNF gene therapy
173
map in the supplementary data chapter). Following an initial ATG start codon
the sequence encodes a highly conserved secretion signal enabling extracellular
secretion of the mature GDNF protein by transduced cells.318.
The pd10 plasmid into which Gdnf was cloned contains the 2 inverted terminal
repeat (ITR) regions (of 145 nucleotides each) that are required for viral vector
formation (specifically for encapsidation of the nucleic acid genome).334 At the
3’ end there is also the SV40 polyadenylation (SV40pA) sequence. The
polyadenylation signal, in this case derived from the simian 40 virus, allows for
efficient transcription termination, and polyadenylation of the mRNA formed (an
essential processing event for most eukaryotic mRNAs). Multiple restriction
enzyme sites within the plasmid facilitate the inclusion of transgene and
promoter DNA. The sequence of the CMV.Gdnf pd10 plasmid generated was
confirmed with restriction enzyme digests and sequencing of the region
containing the CMV and Gdnf sequences.
ITR CMVPromoter
Gdnf
sequence ITRSV40pA
Figure 5-1 The pd10 plasmid following ligation with the CMV promoter and murine
Gdnf transgene. The pd10 plasmid includes a polyadenylation site derived from simian
virus 40 (SV40pA) and two inverted terminal repeats (ITR).
To test whether the plasmid could successfully induce Gdnf production in
transfected cells 3 wells of 293T cells (75 000 cells/well) were transfected with
CMV.GFP (as a negative control) and 3 wells were transfected with the
CMV.GDNF plasmid. Supernatant was collected after 48 hours and tested for
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evidence of Gdnf protein using an enzyme-linked immunosorbent assay (ELISA).
Gdnf protein was detected in the supernatant from CMV.GDNF transfected cells
at a concentration of 41  1.97 pg/ml where as in the supernatant from
CMV.GFP transfected cells and untransfected cells the recorded concentrations
were 0.05  0.01 pg/ml and 0.01  0.00 pg/ml respectively (Figure 5-2). The
plasmid was therefore confirmed to be a successful means of inducing cellular
Gdnf production.
5.2.2 AAV 2/2 production and in vitro testing
Recombinant AAV serotype 2 carrying the CMV.GDNF construct was produced
using published methods and purified using a heparin column.131;230 The viral
vector titre was determined with a dot-blot and found to be 1.3 x1013 genome
particles/ml, as shown in Figure 5-3.
Vector efficacy was tested in vitro prior to in vivo use. This was performed by
infecting 3 wells of 293-T cells with and without co-infection with adenovirus
which increases the speed and efficiency of infection by AAV2/2. After 3 days
the concentration of Gdnf in the supernatant was determined. The results shown
in Figure 5-2 confirm Gdnf production in AAV2/2 infected cells.
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Figure 5-2 In vitro testing of the CMV.GDNF plasmid and rAAV2/2. Supernatant from
293 T cells transfected CMV.GFP or CMV.GDNF plasmids, or infected with rAAV2/2
CMV.GDNF was collected, and the Gdnf concentration determined by ELISA. Viral
infection was performed with and without concomitant adenovirus infection to improve
infection efficiency (superinfection). Supernatant from untreated cells was analysed
alongside. Concentrations were determined with ELISA.
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Figure 5-3 Measurement of AAV2/2 CMV.GDNF titre by dot-blot analysis. Blue
circles and text indicate sample points for the densometric analysis, indicating a titre of
1.3 x1012 vg/ml.
5.2.3 In vivo quantification of Gdnf after intra-vitreal rAAV2/2
At day 11 of age, 4 Rho-/-Opn.gfp mice were treated with a single intravitreal
injection of AAV2/2 CMV.GDNF to the right eye (1l) and the left eye was
untreated. These 4 mice were used for functional assessments (ERG analysis at 3
timepoints) and then culled at day 73 of age. Gdnf concentrations in both eyes
from each animal were assayed by ELISA, and the results are shown in Figure 5-
4. Levels of protein are shown per eye, which were calculated from measured
levels assuming that the volume of each eye was approximately 14l. Mean
Gdnf concentration in treated eyes was 5 times as high as in untreated fellow
eyes.
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Figure 5-4 GDNF protein assays (ELISA) in AAV2/2 CMV.GDNF treated and
untreated fellow eyes of 4 Rho-/-Opn.gfp mice. Each eye was analysed in duplicate.
There was a 5 fold difference between treated and untreated fellow eyes.
5.3 In vivo examination of the effect of inner retinal
GDNF production on cone photoreceptor loss.
The aim of the following experiments was to determine whether increased inner
retinal Gdnf expression in the Rho-/-Opn.gfp mouse has an effect on the
degeneration of cone function. rAAV2/2 CMV.GDNF treated eyes were
compared with untreated fellow eyes. However, it is also important to control
for potential effects of the intravitreal injection procedure, and the effect of viral-
vector mediated transduction on inner retinal cells.
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The importance of such controls is well illustrated by related experiments in
other rodent models of retinal degeneration. In the RCS rat injections of saline
alone in to the sub-retinal space result in beneficial, albeit transitory, effects on
photoreceptor survival.143;335;336 This is likely to be due to the combination of the
injection reducing the local concentration of accumulated toxins and an injury
effect stimulating endogenous growth factor release. Working in the mouse, Cao
et al. likewise found that a trans-scleral 1mm stab incision into the outer retina
led to upregulation of bFGF and CNTF expression, which persisted for 16 days
following the injury.337 To isolate the specific effects of Gdnf, experiments were
first performed with a related viral construct expressing an alternative reporter
gene.
5.3.1 The effect of intra-vitreal injection and inner retinal cell
transduction on cone photoreceptor mediated retinal function.
AAV2/2 was prepared using an existing ‘CBA.RFP’ plasmid (for map see
appendix). The chicken -actin promoter (variously abbreviated to CBA or CAG)
consists of the chicken -actin promoter cloned downstream of the CMV
enhancer. Like the CMV promoter is it a strong constitutive promoter, and is
therefore an appropriate promoter to use to control for the effect of inner retinal
cell transduction. A plasmid with the red fluorescent protein (RFP) reporter gene
was chosen to facilitate confirmation of expression in the rhodopsin knockout-
gfp mouse, where there is already strong gfp expression in the outer retina.
6 mice were treated with AAV2/2 CBA.RFP (1l intra-vitreal at p11) to a single
eye, with the fellow eye untreated as a control. Virus was approximately titre-
matched to the concentration of AAV2/2 CMV.GDNF used elsewhere (to within
0.5 of a log unit). Functional ERG assessments were performed at days 52, 60,
66 and 73 of age (Figure 5-5).
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Analysis of variance (ANOVA) with Bonferroni post-hoc tests revealed no
difference between cone function in the rAAV2/2 CBA.RFP treated eyes, and
fellow untreated eyes. Following the day 73 assessments eyes were prepared for
histological analysis which confirmed transduction and RFP expression in inner
retinal cells of the treated eyes (Figure 5-6).
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Figure 5-5 The effect of AAV2/2 CBA.RFP on cone function in the rhodopsin knockout
cone-GFP mouse. ERG b-wave amplitudes, to a range of flash intensities, are shown in
treated and fellow untreated eyes, for 3 timepoints during the degeneration. By day 73
the cone functional degeneration was complete in both eyes of this litter.
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Figure 5-6 RFP expression in AV2/2 CBA.RFP treated eyes of the rhodopsin knockout
cone-GFP mouse. Image sets A and B are from separate mice, sacrified at day 73 of age.
At this timepoint the retinal degeneration is well established such that ONL thickness is
reduced and cone photoreceptors expressing GFP are dysmorphic. As shown in both
image sets, the RFP is predominantly expressed in the ganglion cells. Less frequently
cellular RFP expression is also seen within the INL. For each animal panels 1-3 show
RFP, GFP and DAPI separately, and then panel 4 is a combined image.
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5.3.2 Inner retinal GDNF expression and cone photoreceptor
degeneration
To evaluate the effect of intra-vitreal rAAV2/2 cmv.gdnf, eyes were injected
with GDNF or PBS at p10-p14, and compared to untreated fellow eyes. The
volume of all injections was 1l. Pooled b-wave amplitudes to a single flash
intensity (10 cd.s/m2) in GDNF-, PBS- and un-treated eyes are shown in Figure
5-7. Analysis of variance with post-hoc bonferroni tests revealed cone function
was dependent on time, but was not different in the GDNF-, PBS- and untreated
groups. The course of functional degeneration was not altered in the GDNF
treated eyes.
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Figure 5-7 Cone function over time in treated and untreated eyes of the rhodopsin
knockout cone-GFP mouse. Means +/- sd are shown for GDNF (n=20), PBS (n=12) and
untreated (n=14) eyes.
To establish whether inner retinal Gdnf expression resulted in a relative
preservation of cone cell bodies SLO imaging was used to quantify cones in
GDNF-, PBS- and untreated eyes at weeks 11 and 17 of age (Figure 5-8).
As for the functional analysis analysis of variance (ANOVA) with post-hoc
bonferroni tests revealed that cone numbers were dependent on the week of
analysis (p<0.0001) but not the intervention group (p=0.75).
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Figure 5-8 In vivo cone photoreceptor quantification in the rhodopsin knockout cone-
GFP mouse. Mean counts (sd) at weeks 11 and 17 are shown for GDNF (n=4), PBS
(n=3) and untreated (n=3) eyes. Example SLO images are shown in the lower panel.
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5.4 Discussion
These results show, with larger numbers of mice, that inner retinal expression of
Gdnf had no effect on cone functional deterioration in the rhodopsin knockout
cone-GFP mouse. This was demonstrated at 4 timepoints spanning the full
timecourse of cone degeneration, and there was no evidence of either a transient
or long-lasting effect. Analysis of cone numbers in the posterior pole of the eye,
also at timepoints spanning the period of maximal cone photoreceptor loss,
likewise demonstrated no treatment effect with inner-retinal Gdnf expression.
Previously an improvement in cone function has been reported following GDNF
supplementation in the rd mouse.159 In this study biodegradable microspheres
that release approximately 10ng of GDNF per day were injected into the vitreous
cavity of mice at PN11 of age. An improvement in averaged b-wave amplitude
to 10 cds/m2 stimuli under photopic conditions was reported at PN23. This time
point is at the completion of the majority of rod photoreceptor death, but prior to
the point of maximal cone photoreceptor loss.75;213 The b-wave amplitude in the
GDNF loaded spheres was found to be approximately 30% higher than that in
eyes treated with blank spheres, though background levels of noise in the
example traces shown are also high. It was also found that function in the eyes
treated with blank microspheres was approximately 40% higher than that in
untreated eyes. The substantial ‘sham’ effect is likely to be due to the observed
inflammatory response, and endogenous growth factor release, following the
treatment intervention.337 The effect of GDNF on top of the sham effect was
limited, and only demonstrated at a single timepoint. Furthermore, there was no
corresponding cone-specific histological outcome measure to corroborate
functional findings.
Repeated functional and histological assessments in the rhodopsin knockout
cone-GFP mouse allow for a more robust assessment of cone neuroprotection. In
this model, the functional and histological outcome measures were consistent in
showing no cone neuroprotection mediated by GDNF expression in the inner
retina, under the experimental conditions used.
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The levels of GDNF protein expressed in these experiments in the rhodopsin
knockout cone-GFP mouse were comparable to those achieved with the slow-
release intra-vitreal microspheres used by Andieu-Soler in the rd mouse.159 They
are however likely to be lower than the levels of GDNF which were used to
demonstrate rod photoreceptor neuroprotection in the TgN S334ter-4 rat model
of retinal degeneration.160 In these latter experiments photoreceptors and RPE
cells were transduced following sub-retinal injection of an rAAV2/2.CBA.GDNF
vector. Although absolute levels of the human GDNF transgene were not
determined, it has been demonstrated previously that sub-retinal delivery of an
rAAV2/2 vector leads to higher levels of transgene expression than is seen
following intra-vitreal delivery of the same vector.331 Further experiments were
therefore performed to evaluate whether cone neuroprotection is achieved with
GDNF expression at higher levels and in the outer retina.
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Chapter 6 Outer-retinal GDNF gene
therapy
6.1 Introduction
To study the effects of sustained and high levels of GDNF expression in the outer
retina rAAV serotype 8 (rAAV2/8) was delivered to the sub-retinal space
through trans-scleral sub-retinal injections.
The rAAV2/8 vector has a wide range of tissue tropisms, and exceptionally high
rates of gene transfer.338-341 In addition, the onset of transgene expression is
particularly fast. Following sub-retinal injection of the vector into the mouse eye,
Natkunarajah et al. demonstrated RPE cell transduction after just 24 hours and
photoreceptor transduction by day 5.194 By 7 weeks stable levels of transgene
expression had been achieved that were higher than maximal levels achieved
with either rAAV2/2 or rAAV2/5. rAAV2/2 and 2/5 were found to have higher
tropism for RPE cells than for photoreceptors. In contrast, the rAAV2/8
transduced both cell types approximately equally. Sub-retinal injections of
rAAV2/8.CMV.GDNF were therefore used to achieve much higher levels of
transgene expression in the outer retina than would be achieved following intra-
vitreal or subretinal delivery of the rAAV2/2.CMV.GDNF used in the previous
chapter.194;330;331
The disadvantage however with sub-retinal injections of viral vector is that there
is inevitably iatrogenic damage to the retina. This was evident for example in the
recent study showing successful treatment of Aipl1 h/h mice, where at the initial
timepoint following sub-retinal injection ERG function was significantly worse
in the treated eyes than in the untreated eyes.133 This pattern reversed in time as
the effects of photoreceptor rescue overcame the initial effects of trauma. Any
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potential treatment must have benefits that not only outweigh negative effects
induced by its delivery, but also result in an improvement over the natural history.
In the following experiments sub-retinal rAAV2/8.CMV.GDNF is therefore
compared with untreated fellow eyes, and control vector and PBS are used to
control for the effects of sub-retinal injections in this murine model.
6.2 AAV2/8 mediated delivery of GDNF to the outer
retina
6.2.1 Viral vector production and testing
rAAV2/8 was prepared using the pd10 CMV.GDNF plasmid tested previously in
vitro and in the in vivo AAV2/2 experiments. Batch #1 was purified using the
standard ion exchange technique discussed in the methods section, and a dot-blot
examination determined the vector titre to be 5x1013 vg/ml (see supplementary
data).
GDNF expression in eyes treated with the vector was confirmed with ELISA.
Total protein and GDNF concentrations were measured in the treated and
untreated eyes of 6 Rho-/-Opn.gfp mice. Treated eyes were injected at p14 of
age with superior and inferior injections of 1.5l of viral vector. Eyes were
analysed in the late stages of degeneration (weeks 15-17 of age). GDNF levels
were expressed relative to total protein to facilitate comparison between eyes,
and between different studies.
As shown in Figure 6-1, for 5 of the 6 animals GDNF concentration in treated
eyes was 2 log units higher than in untreated fellow eyes. In one animal (2654=4)
there was no detectable GDNF in the treated eye despite total protein being
approximately normal (data in supplementary data chapter). The absence of any
detectable GDNF in this sample, in contrast to the untreated fellow eye, is
indicative of an experimental error in the ELISA for this sample. Results from
this eye have therefore been excluded from further analysis. Results from
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animals culled at week 15 and week 17 of age are not significantly different to
one another and have been pooled together for further analysis.
The mean GDNF concentration in uninjected eyes was 5.3  5.2 pg/g protein.
The GDNF concentration in eyes transfected with rAAV2/8 CMV.GDNF was
1236.4  546.9 pg/g protein. This was over 232-fold higher than levels in
untreated fellow eyes, and the difference is significantly different (unpaired t test,
p=0.0003). At weeks 15 and 17 rod photoreceptor degeneration is largely
complete and cone numbers are reduced. GDNF expression at these timepoints
will therefore have been from RPE cells and residual cones, and is likely to have
been considerably higher prior to rod photoreceptor degeneration. Nonetheless
the 232-fold difference between treated and untreated fellow eyes in these
AAV2/8 CMV.GDNF experiments can be compared to the results obtained
following AAV2/2 CMV.GDNF where there was a 5 fold difference between
treated and untreated eyes (Figure 5-4).
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Figure 6-1 ELISA identifying [GDNF] after rAAV2/8 CMV.GDNF injection. Single
eyes of Rho-/-Opn.gfp mice were injected at p14 and eyes were enucleated at late stages
of retinal degeneration. The results from two different treatment cohorts (using different
vectors, doses and timepoints) are shown. Treated eyes are compared with untreated
fellow eyes. Each eye was tested in triplicate at two different dilutions. The upper
graph shows [GDNF] in treated and untreated eyes of 6 different animals. Means are
shown in the lowermost graph. Error bars represent the standard deviation .
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6.2.2 The effect of rAAV2/8.CMV.GDNF (batch#1) on cone
degeneration.
Four Rho-/-Opn.gfp mice were treated with superior and inferior injections of
rAAV2/8.CMV.GDNF (batch#1) at P14. Evaluation of cone function at P52 and
P60 demonstrated a marked reduction in function in the treated eyes. Pooled
data, and inter-eye differences for individual animals, are shown in Figure 6-2.
The mean reduction in cone function to a 10 cd.s/m2 flash was 64% of the
untreated value at day 52, increasing to 78% at day 60. In each of the 4 animals
cone function was substantially diminished in the treated eyes, as compared to
untreated fellow eyes.
rAAV2/8.CMV.GDNF treated eyes, and fellow untreated eyes, were enucleated
at day 60. Eyes from two animals were used for confirmation of GDNF
expression, whilst the remaining two pairs of eyes were used for histological
analysis. ELISA confirmed high concentrations of GDNF protein (>30 ng/ml) in
duplicate samples of both treated eyes, whilst levels in untreated fellow eyes
were 5.4ng/ml (sd=0.6ng/ml). Cryosections revealed ONL thinning in treated
eyes, as compared to the untreated fellow eyes (Figure 6-3). ONL thinning was
apparent across the entire retinal cross-section, and not confined to the point at
which the injection needle had entered the sub-retinal space. In addition in the
treated eyes the gfp-labelled cones were dysmorphic with evidence of mis-
localisation of the cone photoreceptor bodies within the ONL. There were also
sub-retinal deposits of GFP protein, which may be due to degenerating cones
being phagocytosed by inflammatory or RPE cells in the subretinal space. In
contrast, in the untreated eye at day 60 the normal cone photoreceptor
morphology is still evident and the ONL is thicker. These changes indicate that
retinal degeneration was more advanced in the treated eyes, which is in keeping
with the ERG data. To help elucidate the cause of this negative and presumed
toxic response further experiments were performed with sub-retinal injection of
control vector and PBS, in addition to a titration series of the vector used and an
evaluation of vector purity.
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Figure 6-2 Assessment of cone function following treatment with
rAAV2/8.CMV.GDNF (batch#1). ERG assessments were performed at day 52 and day
60 of age. b-wave amplitudes to a series of flash intensities in photopic conditions are
presented. In the upper row mean values in the treated and fellow untreated eyes are
shown for the 2 time-points, and for each flash intensity examined. In the lower row the
difference between treated and untreated eyes is shown for individual mice (labelled
SA1-4) at day 52 and day 60.
Chapter 6: Outer-retinal GDNF gene therapy
193
Figure 6-3 Retinal morphology in the eyes of Rho-/-Opn.gfp treated with
AAV2/8.CMV.GDNF (batch#1) compared to untreated fellow eyes. Eyes were
harvested at day 60. The GFP labelled cones are dysmorphic in the treated eyes as
compared to in the untreated fellow eyes. In addition the ONL is reduced in thickness in
the treated eyes as compared to a corresponding section from the untreated fellow eye.
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6.2.3 Sub-retinal injection in degenerating retina
Sub-retinal injections in patients undergoing gene therapy are generally
performed following a vitrectomy and via a fine (41gauge) trans-retinal needle,
the tip of which is passed from the vitreous cavity through the retinal layers and
into the sub-retinal space. With gentle fluid pressure the retina separates from
neighbouring RPE cells. The procedure used here in mice, described in detail in
the methods section, instead uses the trans-scleral approach to access the sub-
retinal space. A 34 gauge needle is passed tangentially through the tough sclera,
and once the needle tip is seen to be penetrating the RPE it is advanced further
with gentle injection of fluid to form a bullous retinal detachment. In patients
treated with RPE65 gene therapy the sub-retinal fluid is seen to be absorbed
rapidly in the first 2-3 days following surgery.199 The detachments induced here
in mice affect a larger portion of the retina, but the retina reattaches relatively
readily and more quickly in mice which has been one of the major challenges for
researchers using murine models of retinal detachment.342 Observed differences
in speed with which the retina reattaches in human and mouse eyes may relate to
differences in the relative size of the vitreous body. The vitreous in humans is
important in the pathophysiology of retinal detachments and makes up a large
portion of the ocular volume; in mouse eyes the solid crystalline lens occupies a
much larger portion of the eye, and the vitreous cavity is a relatively small.
In these GDNF experiments large retinal detachments are formed in young mice
with an inherited retinal degeneration. Cone photoreceptor outcome measures
are then assessed, which is of note in view of studies indicating that cone
photoreceptors are particularly vulnerable to the effects of retinal detachment.343-
346 Experiments were therefore performed to control for the effect of sub-retinal
injections of vector into this mouse model.
An rAAV2/8 control vector was prepared using the same protocols and in the
same laboratory as the GDNF vector, but using a similarly-sized pd10 null
plasmid which lacked a start codon (Figure 6-4). The titre of the control vector
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was 4.2x1012 vg/ml. A western blot performed on transfected cells and animals
treated with the control vector confirmed no transgene expression (data in
supplementary data chapter).
CMV Gdnf ITRITR 5.4Kb
CMV Null-HA ITRITR 6.3Kb
Figure 6-4 GDNF and null plasmids. Both plasmids contained a CMV promoter. The
null plasmid lacks an ATG start codon and was non-protein producing. This was
confirmed by western blots to look for expression of a haemagluttinin (HA) tag fused
with the null sequence (see supplementary data).
The advantage of using this control vector rather than just PBS is that it, like the
Gdnf vector, will transfect the photoreceptors and RPE cells, be transported to
the nucleus, and will initiate mRNA transcription. There will however be no
transgene translation in control vector transfected cells. The control vector was
produced and purified using the same standardised protocols as the GNDF vector,
and so they will both have broadly the same chemical properties. To examine
whether injections of viral vectors have an impact over and above the mechanical
effects of forming a retinal detachment, control vector injections were compared
to PBS injections.
In order to determine the effects of sub-retinal rAAV2/8 injections 6 Rho-/-
Opn.gfp mice were injected with control vector to one eye; fellow eyes were used
as untreated controls for comparison. A further 4 animals received bilateral
injections with control vector to one eye and PBS to the other. All injections
were performed at p14 of age, and involved superior and inferior injections with
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a volume of 1.5l. Statistical analysis was performed using two-way analysis of
variance (ANOVA) and post-hoc Bonferroni tests.
Cone function was significantly reduced in the control vector treated eyes, as
compared to fellow untreated eyes at day 52 (p<0.05) (Figure 6-5). This was
evident at all flash intensities tested, except for with the 1cd.s/m2 flash to which
the responses were small in either eye. At days 60 and 73 inter-eye differences
were not significant. The reduction in function to a 10cd.s/m2 flash at day 52
was 33.8% of the untreated value (sd=9.8%).
The finding that the 33.8% reduction in cone function was not sustained at the
day 60 and day 73 examinations indicates that the degeneration was not
accelerated in the treated eyes, but rather there is likely to have been some
recovery such that responses in treated and untreated eyes were no longer
significantly different at later timepoints. The caveat however is that these mice
have a relatively fast degeneration and the reduction in response amplitude with
time makes it progressively less likely that inter-eye differences will be detected.
Likewise, in the mice treated with control vector in one eye and PBS in the other,
there was an inter-eye difference evident at day 52 only. The reduction in
function with control vector at this timepoint was 31.5% (sd 21.1%). This could
be due to chemical constituents of the vector preparation compromising retinal
function, or a consequence of vector transduction in stressed and degenerating
cone photoreceptors.
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Figure 6-5 A comparison of cone function in control vector or PBS treated and
untreated eyes. In the graphs to the left pooled data is presented for b-wave amplitudes
in response to a 10cd.s/m2 flash stimulus. Statistical analysis was performed using 2
way ANOVA and Bonferroni post-hoc tests. Significance (p<0.05) is highlighted an
asterix (*). In the graphs to the right the mean and standard deviation of inter-eye
differences are presented across the range of stimuli used, at the day 52 timepoint.
These graphs show that although the pooled data is presented for 1 stimulus intensity
only, similar differences were found for the 4 brightest flash intensities tested. At the 4
brightest flash intensities examined cone function was worse in control vector treated
eyes than in either untreated or PBS treated fellow eyes.
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6.2.4 Sub-retinal injection in wild-type retina
To test whether these substantial detrimental effects of the control vector were
specific to the Rho-/-Opn.gfp mouse and degenerating cones, subretinal
injections were also performed in wild type mice. Wild type mice were assigned
to one of three treatment groups in order to compare PBS injections in one eye to
the untreated fellow eye, control vector injections in one eye to the untreated
fellow eye, or PBS injections in one eye to control vector injections in the fellow
eye. In each group injections were performed in wild type mice at p14 of age,
and consisted of superior and inferior injections of 1.5l each. Functional ERG
assessments were performed at day 52 of age.
As indicated by the photopic traces in Figure 6-6 cone function was similarly
diminished in the PBS and control vector treated eyes in comparison with
contralateral untreated eyes. The reduction in cone function with PBS and
control vector injections to a 10cd.s/m2 flash was 28.1% (sd 9.9) and 23.3 % (sd
4.6) respectively. Comparison of the percentage reductions revealed that the
effect of control vector injections was the same for cones in wild type retina as in
degenerating retina (p(difference)=0.37, n=6 degenerating; n=5 wildtypes). The
effect of control vector over and above that of PBS in degenerating retina, was
not seen in wild type mice. In wild type mice there was no difference between
control vector and contralateral PBS treated eyes.
Stimuli of low flash intensity in scoptopic conditions elicit a rod-specific
response, but at higher flash intensities the response is mediated by both rods and
cones. In the dark adapted rhodopsin knockout mouse the flash intensity
threshold to induce cone function (as defined by a 5V b-wave) is 0.085
cd.sec/m2.242 If one assumes the cone threshold is the same in the wild type as in
the rhodopsin knockout then the first 4 flash intensities in the scoptopic series in
Figure 6-6 (0.0005, 0.003, 0.007 and 0.03 cd.s/m2) are rod specific. At the 0.007
and 0.03 cd.s/m2 intensities the mean b-wave amplitude is lower in the PBS or
control vector treated eyes than in untreated fellow eyes. There is no significant
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difference in rod function between PBS and control vector treated eyes of the
same animal.
The greatest reduction in rod function following control vector injections was at
0.007 cd.s/m2, and in this cohort of 5 animals was a reduction of 31.7% (sd 28.4)
of b-wave amplitude in the untreated eye. There is no evidence of sub-retinal
injections having a significantly different effect on rods or cones in these results.
These experiments therefore determined that sub-retinal injections cause a
decrease in rod and cone function at 5 weeks following injection. No difference
in magnitude of effect was found between rod or cone photoreceptors, or
between injections of control vector or PBS in wild type eyes. In the Rho-/-
Opn.gfp eyes there was evidence of the control vector having a greater
detrimental effect than PBS alone in 4 animals. This has not been repeated or
investigated further. However, in both wild types and rhodopsin knockout cone-
GFP eyes sub-retinal injections resulted in approximately a 30% reduction in
cone function, as compared to fellow untreated eyes at 5 weeks post injection.
This provides a baseline for comparison with other vector preparations, and
suggests that the cones in the degenerating rhodopsin knockout cone-GFP retina
are not significantly more sensitive to the effects of retinal detachment, than
those in age-matched wild type mice.
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Figure 6-6 The effect of sub-retinal injections on rod and cone function in the wild type
mouse. Mice were treated with PBS to 1 eye only, control vector to 1 eye only or
control vector to 1 eye and PBS to the other. Mean inter-eye differences in b-wave
amplitudes to scoptopic and photopic ERG protocols are shown in each graph. 95%
confidence intervals are shown by the error bars. Significance (p<0.05) is indicated with
an asterix (*) and was tested for using ANOVA analysis with the Bonferroni correction
for multiple analyses. Individual responses for the 4 animals in the control vector-PBS
groups are shown in the inset graphs, with coloured symbols for each animal.
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6.2.5 Titration series of rAAV2/8.CMV.GDNF (batch#1)
Sub-retinal injections of a dilution series of the rAAV2/8 CMV.GDNF (batch#1)
were performed in Rho-/-Opn.gfp mice. These experiments were carried out in
order to determine whether the toxic effect was dependent on the concentration
of the vector administered into the sub-retinal space, and to enable comparison
with the control vector in the same animal model.
Viral dilutions were performed in ultrapure PBS-MK, which is the same solution
as is used to elute purified rAAV2/8 in the standard production protocols. The
volume of sub-retinal injections was identical in all groups (superior and inferior
injections of 1.5l of viral vector). All injections were performed at p14 of age,
and for comparisons between groups cone function was assessed to a 10 cds/m2
flash at p52.
At each viral vector concentration used treatment had a negative effect on cone
function (Figure 6-7). The toxic effect was diminished with dilution of the
vector. Injections of 1x1012 and 5x1012 viral vector lead to a smaller toxic effect
on cone function than injections of the undiluted 5x1013 preparation (p=0.019
and p=0.021 respectively, unpaired t-test). Differences between the 1x1012 and
5x1012 preparations were not significant.
The 5x1012 CMV.GDNF (batch#1) and control viral vector preparations were
effectively titre matched given the sensitivity of the dot-blot assay used.
Comparison of the effect of these two preparations on cone function revealed no
difference (p=0.37, unpaired t-test) (Figure 6-8)
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Figure 6-7 Dilution series of rAAV2/8 CMV.GDNF (batch#1). The difference in b-
wave amplitudes, to a photopic 10 cd.s/m2 flash stimulus, between the treated and
untreated eyes of individual animals was calculated, and expressed as a percentage of
the untreated value; positive values indicate a positive treatment effect, whilst
conversely a negative difference indicates that function was greater in the untreated eye.
Means for each treatment group are shown, with the error bar showing standard
deviation.
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Figure 6-8 Comparison of the effects of titre matched rAAV.CMV.GDNF and control
vector preparations on cone function. Percentage differences in cone function (b-wave
amplitude to a 10 cd.s/m2 flash at P52) between treated and untreated eyes of individual
mice are shown for CMV.GDNF-batch#1 (n=10), CMV.GDNF-batch#3 (n=4) and
control vector treated (n=5) mice. Means for each treatment group are shown with
horizontal lines, and the error bars indicated the standard deviations.
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6.2.6 Modified Vector Purification Protocol: Phase Separation
The finding that vector titre correlated with the magnitude of the functional
deficit following sub-retinal injection could be explained by a dilutable
constituent of the vector preparation having a toxic effect. The rAAV2/8
production method used for the rAAV.CMV.GDNF (batch#1) and control vector
has been used previously to successfully rescue rod photoreceptors in the Aipl1
hypomorphic and knockout mice using gene replacement therapy.133 Any toxic
effects in those preparations was rapidly outweighed by beneficial effects of the
gene replacement constructs used, and so potentially the fact that toxicity was
evident with the CMV.GDNF vector may reflect the absence of a strong
therapeutic effect in the Rho-/-Opn.gfp mouse. Alternatively, iatrogenic damage
to cone photoreceptors may be much more demanding to overcome. Ongoing
work by Dr. Carvalho and Professor Ali has however demonstrated cone
photoreceptor rescue in the CNGB3 mouse model of retinal degeneration
(personal communication) using the same rAAV2/8 preparation protocols and
agents; this has been achieved with a gene replacement construct. Some treated
animals have been found to gain a substantial improvement in cone function but
of note in others the effect was not seen and there was evidence of significant
damage following the sub-retinal injections.
With the anion exchange column method of vector purification used here for
rAAV2/8 purification there is the potential for contaminant proteins in the 293T
cell lysate to have a similar affinity to the ion exchange column, and so to be co-
eluted along with the rAAV; this potential source of toxicity has been reported
previously with heparin-based affinity chromatography columns.347 A further
vector purification step was therefore introduced in an attempt to separate vector
from co-eluted components of the cell culture medium.
Chahal et al. used a two-phase extraction technique to demonstrate that purified
rAAV2/2 could be selectively partitioned into the aqueous phase when added to a
mixture of the high molecular weight polymer polyethylene glycol (PEG-4000)
with ammonium sulphate.348 Analogous techniques have been used previously to
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separate other types of viral vector (including adenoviral and retroviral vectors)
from cellular and protein contaminants. With time the mixture separates into 2
phases with a lowermost aqueous phase, and an uppermost polymer based phase.
Chahal et al. demonstrated that 100% of added AAV could be recovered from the
aqueous phase, whilst many cell or medium components appeared to be
partitioned to the hydrophobic supernatant. Their production and purification
protocol for AAV2 produced in insect cells resulted in high purity vector (as
examined with SDS-PAGE and silver stains). However, this technique had not
been used previously in combination with the AAV2/8 purification protocols,
and for rAAV produced using co-infection of 293T cell cultures.
To investigate whether addition of a two-phase extraction step improved
rAAV2/8 purity in combination with existing 2/8 purification protocols133, a
40 plate preparation of 293T cells was transfected with the CMV.GDNF plasmid.
Harvested cells were sub-divided into 2 equally sized aliquots. One aliquot was
purified using the standard protocol (batch#2), and the other was prepared in
parallel incorporating the two-phase separation step (batch#3) (Figure 6-9).
The latter step involved cell lysate being added to a mixture of ammonium
sulphate and 20%PEG, after repeated centrifugation and passage through a 0.22
M filter. The mixture was left to partition into aqueous and hydrophobic phases
before the vector-containing aqueous phase was used for further purification.
The hydrophobic phase was discarded.
The titre of both vector preparations was examined on the same dot-blot to
facilitate comparison. Both preparations were of high titre. Vector purified with
the two phase separation had a genomic titre of 1.5x1013 vg/ml. The identical
aliquot of harvested cells purified using the standard protocol produced vector
with a titre of 1.1x1013 vg/ml. This equates to a titre difference of approximately
30%. A difference of this relatively small magnitude is unlikely to be of
functional significance.
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Figure 6-9 Two-phase separation. 5 mls of a 1M ammonium sulphate and 20%
PEG4000 mix have been used to form a hydrophobic upper phase, and a hydrophilic
lower phase in each of the 2 falcon tubes shown. In tube A 5mls of DMEM medium has
been added to this mix to aid illustration of the 2 phases. An equal volume of lysate
from transfected 293T cells, from which cell debris had been removed by repeated
centrifugation and passage through fine filters, was added to tube B. The upper phase,
supernatant, is hydrophobic and contains proteins and cellular contaminants. The vector
is partitioned in the lower aqueous phase.
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Figure 6-10 Genomic titres of the CMV.GDNF vector made with and without two phase
separation. Vector purified with and without the two phase separation is of a similar
high genomic titre (1.5x1013 and 1.1x1013 respectively).
To examine the protein content of each vector the constituent proteins were
separated with sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE), and then visualised with a fluorescent protein stain (Spyro Ruby
protein stain, Invitrogen). 1 and 3 l samples of each vector (batch #2 and #3 of
CMV.GDNF) were titre-matched and run in parallel. The results are shown in
(Figure 6-11). As expected the 3l sample of each vector has identical but
stronger protein bands than the corresponding 1l sample. In each lane there are
3 protein bands that are considerably stronger than any of the others. These are
seen at 87, 72 and 62 KD in all the samples and correspond to the 3 protein bands
of the AAV-2 capsid, VP1, VP2 and VP3 respectively.230;349 Furthermore the
relative densities of the VP1, VP2 and VP3 bands are in keeping with the
expected ratio of 1:1:10.
In the vector sample purified without phase separation there are multiple
additional protein bands, that are either not evident at all, or only to a lesser
extent, in the sample purified with phase separation. Those smaller than the
VP1-3 bands may be due to degraded capsid proteins. In the standard
purification sample there is also evidence of protein of greater than 90 KD; this is
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a contaminant that is not normally seen in the preparation of rAAV2 based
vectors; it is not in keeping with any of the capsid proteins. The VP1-3 bands are
themselves also stronger in the vector sample purified without phase separation,
despite the titre-matching. This could be due to incomplete or damaged capsids
or loose hydrophobic proteins being removed in the partitioning procedure.
Figure 6-11 SDS-PAGE separation and protein staining of vector samples. Identical
aliquots of rAAV2/8.CMV.GDNF were purified with and without an additional phase
separation step. 1 and 3l titre-matched samples of each vector are analysed here,
alongside a sample of the buffer in which the vectors were eluted, PBS-MK. A
commercial protein ladder was also run in conjunction to allow sizing of the protein
bands. The AAV-2 capsid proteins VP1, VP2 and VP3 are seen in each of the vector
samples, but not in the PBS-MK. These bands are stronger in the 3l than in the
corresponding 1l samples for each vector preparation. Additional protein bands (*) are
particularly evident in the vector sample prepared without phase separation. Some of
the same contaminant bands are also evident in the phase separation sample, but to a
lesser extent.
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Electron microscopy (EM) was performed using the negative stain uranyl acetate
to enhance contrast. This stain binds to the edge of protein matter but is
excluded from the space occupied by it. Low protein content areas appear dark
on the EM image due to the presence of stain which scatters incident electrons.
In contrast electrons pass relatively unimpeded through areas of high protein
content resulting in bright areas on the image formed.
The electron micrographs of both samples show non-enveloped icosahedral
particles with a diameter of approximately 20-25 nm (Figure 6-12). This is as
expected for a vector derived from Parvoviridae family virions.232;350 In both
samples a mixture of clear and dark centred particles are seen, which correspond
to full and empty capsids respectively. These are shown in the enlargement
within Figure 6-12 and counted in Figure 6-13. Between 83 and 86% of vector
capsids in these two samples were devoid of genome and hence non-functional.
These figures are as expected for experimentally produced viral vectors.351
Comparison of the electron micrographs from the two vector samples reveals less
background staining in the phase separation sample and a relative increase in the
contrast between vector particles and the background medium rendering the
particles more defined. These are markers of a lower protein content in the
vector carrier solution.
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Figure 6-12 Transmission electron micrographs of rAAV2/8 purified with and without
two-phase separation. Titre-matched samples of each vector were negatively stained
with 4% uranyl acetate solution prior to imaging. Digital enlargements (1.7X) are
shown alongside the main images to show morphological detail. In both samples a
mixture of full and empty vector particles are seen (as indicated by white and black
arrows respectively). Vector particles containing genome DNA have a homogenous
grey centre, whilst empty particles have a black centre. The black patches in both
images, which overlie some of the vector particles, are artefacts.
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Figure 6-13 Genome packaging in vectors sample purified with and without phase
separation. 2l samples of each vector preparation were prepared for EM. The sample
prepared with phase separation had a higher titre (1.5x1013vg/ml) that the standard
purification sample (1.1x1013vg/ml). The greater number of vector particles in the phase
separation sample is therefore as expected. Single images from each sample were
counted. Full (blue) and empty (red) capsids were marked on the EM images and
counted using Image Pro-Plus software.
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6.2.7 The effect of AAV2/8 CMV.GDNF on cone degeneration
4 Rho-/-Opn.gfp mice were treated with rAAV2/8.CMV.GDNF (batch #3 –
purified with two-phase separation) to 1 eye only. Fellow eyes were left
untreated for comparison. Mice were treated at p14 of age with vector diluted in
PBS-MK to 5x1012vg/ml. Superior and inferior injections of 1.5l of vector
were delivered by sub-retinal injections as described previously.
Treated animals were evaluated with ERG assessments at p52, p60 and p73.
Cone function was diminished in treated eyes by 31, 48 and 63% of the untreated
value at days 52, 60 and 73 respectively. The effect of ultra-pure CMV.GDNF
(batch#3) preparation on cone function at P52 was no different from that seen
with CMV.GDNF (batch#1) or with the control vector (p=0.33 and p=0.84
respectively, unpaired t-test) (Figure 6-8).
Figure 6-14 Cone function in rAAV2/8 CMV.GDNF treated and untreated eyes (n=4).
Mean b-wave +amplitudes to a 10 cds.m-2 flash are presented at 3 timepoints (p52, p60
and p73) +/- standard deviation as shown by the error bars.
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A repeat cohort of Rho-/-Opn.gfp mice (n=6) were treated with
rAAV2/8.CMV.GDNF and central cone counts performed at weeks 12 and 17.
Analysis of these counts and the raw images are shown in Figure 6-15 and Figure
6-16 respectively. Single eyes were treated and fellow eyes were used as
untreated controls. Two-way ANOVA with Bonferroni post tests confirmed that
counts were lower in the treated eyes (p=0.0285). The cone degeneration was
therefore more advanced in eyes treated with rAAV.CMV.GDNF which is in
keeping with the functional assessments.
Figure 6-15 Central cone counts in GDNF and untreated eyes. Rho-/-Opn.gfp mice
(n=6) were treated to one eye only with rAAV2/8.CMV.GDNF (batch#3). Fellow eyes
served as untreated controls. Cone counts at weeks 12 and 17 revealed that cone
degeneration was more advanced in treated eyes (p=0.03).
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Figure 6-16 In vivo imaging of cone photoreceptors in GDNF treated and untreated eyes
of degeneating retina. Rho-/-Opn.gfp mice (n=6) were treated to one eye only and
fellow eyes served as untreated controls. All images have been equally brightened and
enhanced to aid printing.
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6.3 Discussion
In these experiments rAAV2/8 has been used to induce expression of GDNF in
the outer retina. There was no difference in cone function between CMV.GDNF
treated and null vector treated eyes, and in all animals cone function in treated
eyes was diminished as compared to that in untreated fellow eyes. There was no
evidence of a neuroprotective effect from GDNF.
Previous experiments with rAAV2/2 revealed no histological or functional
evidence of toxicity after 1 year of inner-retinal GDNF expression in Sprague-
Dawley rats.308 Similarly in a separate study no functional evidence of toxicity
was found in wild type mice 8 weeks following sub-retinal injection of
rAAV2/2.CBA.GDNF.154 However, sub-retinal rAAV2/8 leads to substantially
higher levels of transgene expression than is achieved with rAAV2/2.194 In the
experiment by Wu et al. with intravitreal rAAV2/2 in Sprague-Dawley rats, the
background levels of GDNF in untreated eyes was 8.0  5.4 pg/g protein. This
is very similar to the level found in untreated mouse eyes in these experiments,
5.3  5.2 pg/g protein. However, in the experiments by Wu et al. treatment
with rAAV2/2 lead to a five fold increase, where as here with rAAV2/8
CMV.GDNF there was a 232 fold increase evident in the end stages of the retinal
degeneration. The CMV.GDNF plasmid, delivered into the subretinal space
packaged in rAAV2/8, will have initially lead to approximately equal levels of
GDNF expression in RPE cells, rod photoreceptors and cone photoreceptors.194
GDNF levels in the treated eyes are therefore likely to have been even higher
prior to rod photoreceptor and cone photoreceptor degeneration. It was therefore
of interest to identify why cone function was impaired in the treated eyes in these
experiments, and include experiments to identify whether high levels of GDNF
could themselves be the cause of the toxicity.
There was no difference in cone function between eyes treated with titre matched
preparations of rAAV2/8.CMV.GDNF (batches #1 and #3) and control vector
containing a null plasmid. Sub-retinal injection of each of these three
preparations lead to a similar effect on cone function at 5 weeks post injection.
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There was therefore no evidence that GDNF expression, from vector at this titre,
augmented the negative effects of a sub-retinal injection. However,
isovolumetric sub-retinal injections of higher titre CMV.GDNF (5x1013 vg/ml,
batch #1) vector did increase the magnitude of the negative effect on cone
function. This could be explained either by a constituent of the vector
preparation having a toxic effect, or by there being increased GDNF expression
induced by high-titre vector injections and at this level GDNF itself exerted a
toxic effect. It has however not been established that CMV.GDNF batch#1
injected at 5x1013 vg/ml does indeed induce significantly higher levels of GDNF
expression than is seen with isovolumetric injections of 5x1012 vg/ml. Although
the repeated injections of 500ng of recombinant protein in chapter 4 produced no
functional toxicity, this are not directly comparable with the rAAV2/8
experiments as gene-therapy mediated expression leads to much more sustained
levels of transgene expression, and the gene therapy was performed at far earlier
timepoints (p14 as opposed to the first injection of recombinant protein at p36).
The detrimental effect of subretinal rAAV2/8 at 5x1012 on cone function was not
due to GDNF expression. It was also not significantly reduced by a dilution of
the vector to 1x1012 vg/ml, or by altered purification methods to reduce protein
contaminants. This would be in keeping with the detrimental effects of viral
vector at this titre being dominated by mechanical effects of the retinal
detachment induced, as opposed to a dose-related toxic effect due to a viral
vector constituent. This conclusion is supported by the experiments comparing
control vector (at 5x1012 vg/ml) and PBS in wildtype mice, where there was no
difference in detrimental effect. The related comparison of control vector and
PBS in rhodopsin knockout cone-GFP mice was however at odds with this
conclusion as a greater effect was seen with control vector than with PBS. The
latter result was obtained with just 4 mice and would need to be repeated in much
larger numbers were it necessary to investigate this negative effect further.
The damage to photoreceptors that follows a retinal detachment is likely to result
primarily from physical disruption of normal cellular structures and interactions,
and reduced oxygen tensions whilst the retina remains separated from the RPE.
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Ordinarily photoreceptors are embedded in an inter-photoreceptor matrix (IPM)
and closely surrounded by RPE cell microvilli. Cone photoreceptors, in addition,
are surrounded by a specialized area of IPM known as the cone sheath,352 which
is of particular importance in maintaining retinal adhesion through interactions
with both the neural retina and the RPE.353 Separating the retina from the RPE
leads to disruption of these physical interactions, with damage to the morphology
of photoreceptors and RPE monolayer in the area of detachment.344;354;355
Whilst the inner retina is dependent on the retinal blood vessels, the
photoreceptors of the outer retina are reliant on the deep choroidal vasculature.
A retinal detachment therefore causes physical separation of the photoreceptors
from their normal blood supply, affecting diffusion gradients and active transport
through the RPE. In experimental models of retinal detachment oxygen
supplementation has been found to reduce photoreceptor death, suggesting that
oxygen-deficiency is at least one of the causes of detachment-associated
photoreceptor loss.345;356;357 In addition the detachment stimulates a reactive
gliosis which itself impairs neuronal survival, and augments photoreceptor
degeneration. Evidence for this comes from glial fibrillary acidic protein (GFAP)
and vimentin deficient mice in which there are attenuated glial cell responses,
and reduced rates of photoreceptor degeneration following detachment.358 It may
be that the damaging reactive gliosis is itself initiated by the relative oxygen
deficiency, and hence secondary to it.
With a long-standing retinal detachment there is substantial photoreceptor loss in
the area of detachment, and this is through apoptosis.359-361 However, even with
early and successful reattachment surgery in previously healthy eyes (and hence
grossly normal retinal and RPE cells), the restoration in vision following surgery
is usually incomplete.344;362 Yang et al., working in a mouse model of retinal
detachment, found that the peak of photoreceptor death was within the first 3
days of the detachment.342 This is in keeping with other studies in humans and
ground squirrels (which have a cone rich retina) showing apoptosis as early as 8
hours following detachment, and diminishing rapidly after one week.343;363 Cone
photoreceptor outer segments are also extensively disrupted following just 1 day
of retinal detachment.344
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Re-attachment of the retina does however stop further apoptosis and is followed
by reversal of IPM disruption and a gradual improvement in photoreceptor
morphology.344 Sakai found photoreceptor length and ERG function to continue
to improve for up to 96 days following a 1 day experimental detachment; 344 this
is in keeping with clinical studies reporting slow improvements over the long
term.364;365 At the 96 day timepoint in Sakai’s study cone outer segment length
was approximately 70% of normal.
Studies of experimental detachments in both cat and squirrel models have found
retinal detachment to have a greater impact on cone photoreceptors than on rods,
both in terms of morphology and cell death.344-346 Yang et al., working in the
mouse model of detachment which differs in being more rod-dominated, did not
detect a difference in levels of apoptosis but did find a greater loss of opsin
expression in the cones than in the rods.342 Other studies too have found early
down-regulation of opsin and calbindin proteins in cone photoreceptors, but not
rods, following experimental retinal detachments.343;366 Based on the numbers of
mitochondria found in these cell types it is estimated that cones have a faster
metabolic rate than rods,367 and potentially the down-regulation of protein
expression in cones could be a survival mechanism to conserve energy in the
hypoxic conditions induced by a detachment.366
The absence of a neuro-protective effect of GDNF on cone photoreceptors in the
Rho-/-Opn.gfp mouse is a novel finding. In selected rodent models GDNF
supplementation has been demonstrated to preserve rod-dominated outcome
measures in the short-term.80;159;160 The absence of a significant neuroprotective
effect on cone photoreceptors would preclude these positive experimental
findings translating into substantial benefits for patients with rod-cone
dystrophies.
219
Chapter 7 Inhibition of apoptosis
7.1 Introduction
7.1.1 Apoptosis pathways and the caspase enzymes
Controlled cell death, and specifically apoptosis, is a highly conserved feature of
multi-cellular organisms and is prominent during both development and adult life.
The apoptosis pathway is also central to many pathologies. For example, in
inherited retinal degenerations the increased loss of neuronal cells is through the
apoptosis pathway.44;102;113 Conversely reduced rates of apoptosis are found
within malignant tumours, where specific inhibitors of apoptosis are associated
with malignant transformation and resistance to chemotherapy agents, which
themselves act through promotion of apoptosis.368;369
Central to the process of apoptosis are the caspases, a family of cysteine protease
enzymes. These enzymes are constitutively expressed as very low-activity pro-
enymes. Activation of the apoptosis pathway leads to ‘initiator’ caspases (eg -6,
-8, and -9) cleaving and hence activating one another in a hierarchical order, thus
generating a self-amplifying initiation cascade. Downstream caspases, known as
‘effector’ or ‘executioner’ caspases (eg -2, -3 and -7) will then, once activated,
effect the molecular steps of cell death and organised destruction of cellular
structures.
Activation of the caspase cascade occurs through either extrinsic or intrinsic
pathways (Figure 1). The extrinsic pathway originates from activation of a cell
surface receptor (eg Fas) whereas the intrinsic pathway is triggered by
cytoplasmic stimuli, such as cytochrome c release from mitochondira. The pro-
apoptotic potential of these caspase pathways is balanced by the anti-apoptotic
effect of the Bcl-2 and inhibitor of apoptosis regulatory proteins.
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Figure 7-1 The Intrinsic and Extrinsic pathways of Apoptosis. The caspase enzymes
are involved in the initiation of the apoptosis pathway, as well as effecting the steps of
organised destruction of the cell. There are 2 principle pathways of activation. The
‘extrinsic’ pathway is activated by binding of extra-cellular signals (typically emitted
by immune effector cells including cytolytic T lymphocytes (CTLs) or natural killer
(NK) cells) to membrane bound death receptors (members of the tumor necrosis
factor membrane-receptor (TNF-R) family). Ligand binding to the receptors leads to
formation of death-inducing signalling complexes (DISC) or exocytosis of granules
containing perforin and granzymes, and subsequent caspase-8 activation. The
‘mitochondrial’ (also known as ‘intrinsic’) pathway is initiated by the release of
mitochondrial pro-apoptotic factors such as cytochrome c in response to intracellular
stress responses; this in turn activates caspase-9. The activated initiator caspases (-8
and -9) in turn lead to activation of effector (also know as ‘executioner’) caspases
such as caspase 3. The X-linked inhibitor of apoptosis (XIAP) protein is however a
potent inhibitor of the apoptosis pathway through its binding to both initiator and
effector caspases; therefore to allow apoptosis to proceed the release of additional
pro-apoptotic factors is required from the mitochondria (eg DIABLO or OMI) to
displace XIAP from the required caspases.
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7.1.2 Bcl-2 regulatory proteins.
Members of the Bcl-2 protein family have an inhibitory effect on the apoptosis-
activation pathway by impeding release of cytochrome c from the inter-
membrane space of mitochondria.370;371 In vitro supplementation of bcl-2 has a
neuroprotective effect on neurons dying through apoptotic mechanisms,372;373 but
in-vivo the effect on photoreceptors has been limited and transient.115;116;118 In
the study by Bennett et al. recombinant adenoviral mediated expression of bcl-2
was reported to result in histological evidence of photoreceptor neuroprotection
for approximately 6 weeks in the rd mouse.116 This viral vector is not an
effective means of transducing photoreceptors however, and so the limited
histological effects may not have been directly due to transgene expression in
specifically photoreceptors. Studies of transgenic mice with genomically
delivered bcl-2 and an inherited photoreceptor degeneration have demonstrated
either no effect374 or limited and short-lived effects.115;118 Furthermore, Chen et
al. found that expression of high levels of bcl-2 expression resulted in loss of
wild-type photoreceptors. This occurred in a dose-dependent manner but further
underlines the case that bcl-2 is not a favourable therapeutic target.115 The
mechanism of cell loss with increased levels of bcl-2 is not established.
7.1.3 Inhibitor of apoptosis (IAP) proteins and their regulation
In contrast to the bcl-2 proteins, the inhibitor of apoptosis proteins (IAPs) bind
directly to specific initiator and effector caspases. This contributes to their being
the most powerful intrinsic inhibitors of cell death when over-expressed. The X-
linked inhibitor of apoptosis (XIAP) binds to both initiator and effector caspases
375-377 and is the most potent of the IAPs. 378,379 (Figure 7-1).
Structurally the IAPs are defined by the presence of an amino-acid-zinc-finger
motif, known as the baculoviral IAP repeat (BIR). The number of BIRs in each
IAP varies between 1 and 3, but they are highly conserved regions and mediate
the protein interaction with caspase enzymes (Figure 7-2).380
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IAPs, and specifically XIAP, are highly expressed in a variety of cancers, and
there is evidence that they are central to the means by which cancer cells acquire
resistance to apoptosis.379;381;382 Reducing IAP expression or activity has
therefore been a focus for anti-malignancy treatments. Antisense
oligonucleotides to knockdown XIAP mRNA were found to exert potent
antitumor activity in preclinical solid tumour models,383 and this approach has
now entered the clinical domain. A phase I/II trials found a XIAP antisense
oligonucleotide, in combination with chemotherapy, to be highly effective in
cases of refractory acute myeloid leukaemia,384 and further clinical trials are
ongoing (www.clinicaltrials.gov).
Conversely increasing expression of IAPs could be a potent means of inhibiting
or slowing apoptotic cell death in neurodegenerative disorders, and notably RP
where there is a secondary mutation-independent loss of cone photoreceptors.
This hypothesis is supported by a number of studies in which over-expression of
XIAP has been demonstrated to reduce cell death in response to cyto-toxic
stimuli including ischemia, 385;386 neurotoxin,387 and in motorneurons following
axotomy and in the SOD1 transgenic mouse mouse of amyotrophic lateral
sclerosis.293,488 Transgenic over-expression of XIAP in mice has also been
associated with reduced age-related cochlea hair cell loss within the ear, as
compared to wild type littermates.388
However, unsurprisingly it is also apparent that the role of IAPs is more complex
than a simple correlation between levels of IAPs and rates of apoptosis.379 These
proteins are highly regulated, and exist in equilibrium with endogenous
regulators. Their binding to caspase enzymes, through the BIR domains, is
reversible, and hence a dynamic process subject to regulation.
Means of IAP regulation can be considered in terms of ‘autologous’ features of
the proteins themselves, and then external influences whereby the action of IAPs
are modulated by other proteins.
With regard to the ‘autologous’ control, selected IAPs contain a carboxy-
terminal RING (really interesting new gene) zinc finger which allows for auto-
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ubiquitination, the process by which proteins can be labelled for proteasomal
degradation.389 Through this domain certain IAPs including XIAP inhibit
apoptosis under normal conditions but in response to more severe apoptotic
stimuli they promote their own degradation.389;390 Their inhibition of specific
caspases is therefore a measured and variable response to cellular stresses.
The IAP antagonistic proteins that block anti-apoptotic activity of IAPs include
the ‘direct IAP binding protein with low pI’ (DIABLO),391 392;393 which was
previously known as ‘second mitochondria-derived activator of caspase
(Smac)’.394 This protein is itself activated in mitochondria and the released form
can then bind directly to IAPs to inhibit their caspase-inhibitory binding. Others
include Omi/HtrA2 and GSPT1/eRF3, all of which share the presence of an IAP-
binding motif (IBM) at the amino terminus of the mature protein to directly
interfere with IAP binding to caspase enzymes.395-397
More recently the protein XAF1 (XIAP-associated factor 1) has been identified
as a negative regulator of the caspase-inhibiting activity of XIAP and
interestingly it is found to be down-regulated in many proliferating tumours.
398;399 Thus, whilst looking at IAP levels alone is too simplistic a means of
anticipating rates of cellular apoptosis, the ratio between XAF1 and XIAP has
been found to correlate with rates of apoptotic cell death in at least two types of
tumour.400;401
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Figure 7-2: The structural and regulatory domains of XIAP. The xiap protein
contains 3 baculoviral IAP repeats (BIR). BIR 2 & 3 each contain a conserved
surface groove, which mediates direct binding to specific caspase enzymes.
However, mitochondrial IAP-binding motif (IBM)-containing proteins bind at these
same sites and so inhibit the caspase related activity of XIAP. XIAP also contains a
ubiquitin-binding (UBA) domain and a RING-finger domain conferring ubiquitin
protein ligase (E3) activity which mediates auto-ubiquitination in times of severe
apoptotic stress.
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7.1.4 Physiological roles of XIAP
The anti-apoptotic effects of IAPs and XIAP, when found at increased levels in
tumours or when expressed artificially, have obvious clinical implications and
have been the focus for much of the early work relating to these proteins.
However these proteins are also involved in copper homeostasis, intracellular
signalling, cell division and cellular morphogenesis (reviewed by Srinivasula
and Ashwell).369 The “inhibitor of apoptosis” description may even be
considered as misleading with regards to the physiological roles of these proteins,
as under normal conditions (in contrast to when over-expressed) they provide
only limited resistance to apoptosis.369;402 In part this may be due to the RING-
domain that for many of the IAPs catalyses degradation in response to
proapoptotic stimuli under normal conditions.389;403 An alternative nomenclature
that names the proteins after their distinctive structural motif, the BIR, rather
than implying function has therefore been proposed, though is not so widely
used.404
In humans, congenital absence of XIAP expression causes an X-linked
lymphoproliferative disorder.405 Lymphocytes from affected patients show
enhanced rates of apoptosis in response to stimulation with the TNF-associated
apoptosis-inducing ligand receptor, the death receptor CD95 (also termed Fas or
Apo-1) and the T-cell antigen receptor (TCR)-CD3 complex. XIAP-deficient
patients also have low numbers of natural killer T-lymphocytes, which could be
explained by reduced survival or reduced differentiation of this cell type. In
mice lack of XIAP, or any of the common RING-containing IAPs, still permits
grossly normal development and survival.369;406Absence of XIAP does lead to
delayed lobuloalveolar development in the mammary gland, 407 but it is
somewhat surprising that the phenotype is not more severe given the number of
functions with which the IAPs are implicated. It is also evident that there are
differences in the apparent physiological roles of XIAP between mice and
humans. The limited phenotypes may be explained by compensatory up-
regulation of agonists and/or down-regulation of antagonists and redundancy in
the pathways in which XIAP is involved.
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7.1.5 Over-expression of XIAP
Whilst the exact role of XIAP at physiological levels is complex, and apparently
non-essential for most cell types, the question remains as to whether
manipulation of levels is of potential therapeutic benefit. In particular it is of
clear clinical importance to identify if increased expression, to supra-
physiological levels, is effective at slowing cell death and achieving sustained
neuroprotection. Likewise down-regulation in tumours may be a means of
slowing tumour growth, or increasing susceptibility to adjunctive chemo- or
radiotherapy. Seeger et al. generated cell lines stably expressing XIAP at
approximately two to five times the normal physiological levels, which is
approximately comparable to levels found in tumour cells. At this level of
expression XIAP levels alone were not predictive of cellular fate when exposed
to chemotherapy agents, but instead the outcome was also dependent on levels of
its physiological inhibitor DIABLO.408 In these experiments the absence of a
single inhibitory protein rendered XIAP over-expressing cells severely resistant
to cytostatic agents. This is in keeping with clinical studies showing that XIAP
levels alone are not predictive of clinical outcome, and that levels of its inhibitors
are also of relevance.400;401;409
7.1.6 XIAP mediated resistance to photoreceptor apoptosis
As with GDNF, the initial studies demonstrating a neuroprotective effect for
XIAP within the retina were with acute models of apoptosis.410-412 Petrin et al.
treated rats with a DNA methylating agent, N-methyl-N-nitrosourea (MNU),
which causes a peak of photoreceptor apoptosis at 24 hours following intra-
peritoneal (IP) injection. XIAP expression was induced in photoreceptors using
a rAAV2 vector injected in to the sub-retinal space, and a photoreceptor specific
promoter (MOP500). rAAV2 vector was injected 6 weeks prior to the MNU
administration to allow time for high levels of expression to develop. At 48
hours, 72 hours and 1 week following the IP injection of MNU there was
evidence of histological protection in four of the six XIAP treated eyes. This
was judged by comparison to untreated and rAAV2.GFP treated eyes. In two of
the four XIAP treated eyes with morphological protection there was still
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evidence of ERG function at 1 week post IP injection, where as in untreated and
GFP treated eyes there was none. Each animal was treated with only a single
sub-retinal injection of vector and so the area of optimally treated retina was
limited, as was evident from the histological analysis where the greatest
protective effect was seen close to the injection site. The ERG outcome
measures may have been improved with double sub-retinal injections to
maximally treat a larger area of retina.
The loss of photoreceptors in RP is also through apoptosis, although this is in the
context of chronic cellular stress rather than an acute chemical insult as with
MNU. Potentially a chronic and persistent source of cellular stress could be
harder to treat than an acute and transient insult. Leonard et al. evaluated gene
therapy mediated expression of XIAP in the P23H and S334ter transgenic rat
models of RP, in which rhodopsin mutations lead to a rod cone degeneration
which was followed over approximately 7 months.119 rAAV2/5 was used with
the chicken -actin promoter to achieve expression in photoreceptors, and sub-
retinal injections were performed at P14-17. At 28 weeks following injection
there was histological evidence of neuroprotection in the treated eyes of both rat
models. The ONL was thicker in XIAP treated eyes than in untreated and GFP-
treated controls. However, in the S334ter rat there was no functional benefit
from XIAP treatment, and the ERGs were no different to those in GFP treated
eyes. There was a tendency for b-wave amplitude in GFP treated eyes to be
worse than that in untreated fellow eyes. This was not tested for significance but
is likely to relate to the effects of sub-retinal injection. Likewise, in the P23H rat
mean a- and b-wave amplitude was lower in GFP treated eyes than in untreated
fellow eyes at all timepoints, although again this was not tested for significance.
ANOVA analysis with Bonferroni-Dunn correction revealed a significant
difference between the XIAP and GFP treated groups. However it was only at
the latter stages of the degeneration that XIAP treated eyes were better than
untreated fellow eyes, and by this stage the levels of function are substantially
reduced relative to pre-degeneration. The statistical analysis presented by the
authors only confirmed that XIAP treated eyes were different from GFP treated
controls, and not untreated fellow eyes. Subretinal injections induce retinal
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damage, and photoreceptor death which is also through apoptosis.359-361 It thus
appears that in these models, and following a subretinal injection, the ability of
XIAP expression to prevent apoptosis and maintain photoreceptors in a
functional state is limited. The authors caution that the magnitude of the
functional effects in their study could be an underestimate because of single
injections only treating approximately 20% of the retina. Furthermore the sub-
retinal injection procedure used (which was trans-corneal) may have caused
confounding variables including corneal opacities that were not controlled for.
Similar results were found with XIAP overexpression in the rd10 model of
retinal degeneration.413 This murine model has a relatively slow retinal
degeneration caused by a loss-of-function mutation in the β-subunit of rod cGMP 
phosphodiesterase gene (Pde6b). rAAV2/5 mediated photoreceptor expression
of XIAP in these animals likewise resulted in transient histological evidence of
neuroprotection, but no evidence of a functional benefit.
7.2 Aims
To test whether XIAP over-expression leads to cone neuroprotection in the Rho-
/-Opn.gfp mouse XIAP was first expressed in both rods and cones using gene
therapy and the CMV promoter. With this approach cone neuroprotection could
be mediated indirectly by augmenting rod survival and slowing rod-cone
degeneration, or directly through an effect within degenerating cones. To
separate these potential mechanisms of action in the event of a therapeutic effect
a cone-specific promoter was also prepared and tested.
In the evaluation of XIAP in the P23H and S224ter transgenic rats the authors
noted limiting factors that could have led to functional effects being
underestimated.119 In the experiments here double sub-retinal injections were
performed with high titre virus; this approach can lead to transduction of high
percentages of photoreceptors across the entire retinal surface. In ongoing work
fluorescence-activated cell sorting of rAAV2/8.CMV.GFP treated eyes (double
sub-retinal injections at P10 of age) resulted in over 80% of photoreceptors
expressing GFP (personal communication Dr Livia Carvalho). In addition in the
following experiments sub-retinal injections were performed through the trans-
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scleral route, instead of via the trans-corneal approach that was used previously
to evaluate XIAP expression in photoreceptors.119 Animals were also examined
for corneal opacities prior to ERG and SLO procedures, and so corneal opacities
are less likely to have affected the experimental results.
7.3 The cone arrestin promoter
The human arrestin 4 promoter was investigated as a cone-specific promoter.
The arrestin proteins block the activity of G protein-coupled receptors that have
been phosphorylated by G protein receptor kinases. Within photoreceptors they
participate in a gateway controlling G protein-mediated signalling and hence
leading to deactivation of the phototransduction cascade. Absence of arrestin
proteins in deficient mice leads to prolonged activation of the signalling
pathways rendering photoreceptors more susceptible to saturation.414;415
There are 4 arrestin subtypes; arrestin-1 is expressed in high levels in
both rods and cones. Arrestins 2 and 3 are the ‘non-visual’ forms, and
the more recently discovered arrestin 4 is found in cones and a subset
of pinealocytes.415;416 Arrestin 4 (ARR4), also known as ‘cone arrestin’, is found
in mouse cones driven by either the S or M opsins (Nikonov et al., 2008). Due to
the specificity of its expression within the retina the promoter for this protein was
chosen for further investigation. The human ARR4 promoter was cloned by Dr
Livia Carvalho, and subcloned into the pd10 plasmid with a downstream hrGFP
reporter gene.
To establish specificity and transduction efficiency of the promoter rAAV 2/8
virus was prepared with the hARR4.hrGFP plasmid. The virus was titred by dot-
blot analysis at 1x1012 virus particles/ml. 2l of this virus was injected into the
sub-retinal space in each eye of 4 rhodopsin knockout mice. The mice were 3
weeks of age at the time of injection, and were imaged with the scanning laser
ophthalmoscope 3 weeks later (Figure 7-3). The retina shown had been treated
with a single sub-retinal injection in the superior retina. This image shows that
with sub-retinal injections it is possible to treat cells in the posterior pole of the
eye that can then be imaged with the SLO in vivo.
Chapter7: Inhibition of apoptosis
230
Following imaging the mice were sacrificed and dissected eyes were fixed in
4% PFA for 1 hour. 10m thick sections were prepared following
cryopreservation in OCT, and stained with primary antibodies to cone
transducin, S opsin or ML opsin. The GFP expressing transduced cells were
found to almost exclusively co-localise with the cone-specific markers, as shown
in Figure 7-4. Occasional expression was evident in rod photoreceptors
indicating expression was not 100% cone specific, but this was rare. Of note the
hrGFP expression was confined to cone outer segments, which is in contrast to
eGFP expression in the Rho-/-Opn.gfp mice.
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Figure 7-3 Collage of SLO images from ARR4-GFP injected eye. A rhodopsin
knockout mouse was injected with l of rAAV2/8 containing the ARR4-gfp cassette,
as a subretinal injection. These SLO images were taken from the left eye 3 weeks
following injection showing transduced cells expressing GFP. The single injection was
performed under the superior retina.
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Figure 7-4 Immunohistochemistry of retina treated with rAAV2/8.ARR4.hrGFP. GFP
expression is seen to co-localise with cone transducin (GNAT2, 1a-c), s-opsin (2a-c) and
M/L opsin expression (3a-c). In 3c GFP expression is seen within a single rod nucleus.
hrGFP expression within cones was seen in the outer segments. The images shown are
not from the same eye as shown in Figure 7-3.
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7.4 Testing of CMV.XIAP in vitro
PCR reactions were used to generate XIAP cDNA with appropriate restriction
enzyme sites (Apa I and BsrG I) to allow cloning into a pd10 plasmid. The
CMV promoter was used in order to drive high levels of transgene expression in
both rod and cone photoreceptors.331 The sequence of the entire CMV, XIAP
and intervening linkage region was checked following cloning.
7.4.1 Species-specific primers
The XIAP sequence is highly conserved between species. However there are
subtle differences in the coding sequence of human and murine XIAP that can be
used to distinguish between the two. Primers, shown in
Table 7-1, were designed to exploit the limited differences between murine and
human XIAP. The binding efficacy and specificity of these primer pairs was
tested by running PCR reactions, for each primer pair, with cDNA prepared from
adult wild type mouse retina and linearised plasmid DNA containing the human
XIAP sequence. Linearisation of the plasmid was performed to aid primer
binding, and was achieved by incubation of the circular DNA with the Spe1
restriction enzyme for 2 hours. The PCR reactions were run at a range of
temperatures between 55 and 62C, and the products were examined on a 2%
agarose gel (Figure 7-5).
Sequence (5’-3’) Amplicon Size (bp)
Mouse Xiap
Left
GAATTCAGATCCCCAGAACG
120Mouse Xiap
Right
GCTGGCTTCAAACCCAGATA
Human XIAP
Left
ACTGGTGAAGGAGATACCGTGCG
445Human XIAP
Right
CAACAAAAGCACTGCACTTGGTCAC
Table 7-1 Species specific XIAP PCR primers
The murine and human primer sets were found to be specific for the mouse and
human XIAP sequences respectively. The absence of a PCR product with
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murine primers and murine DNA at 57.5C is likely to be an experimental
artefact.
7.4.2 In vitro testing of plasmid expression
The CMV.XIAP plasmid was assessed in vitro for its ability to produce XIAP
mRNA. BHK cells are were used in the first instance, because of the relative
reliability with which they can be transfected.
Figure 7-5 Determination of primer efficacy and specificity. 40 cycle PCR reactions
were run with each of human and mouse primers and human and mouse XIAP
sequences, at a range of temperatures. To test for murine Xiap DNA mRNA from wild
type retinas was isolated and cDNA generated. These samples are labelled “wt
cDNA”. To test for human XIAP cDNA linearised pd10 plasmid contain human XIAP
cDNA was used, and is labelled “plasmid cDNA”. Murine -actin primers were run
alongside to act as a positive control (using the murine cDNA) and as a negative
control (using the sequenced plasmid DNA which is known not to contain the -actin
sequence).
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BHK cell transfection
BHK cells were seeded in a 24 well plate to give 75 000 cells per well. 8 wells
were transfected with the CMV.XIAP plasmid, 8 with a CMV.GFP plasmid and
the remaining 8 wells were left untransfected. Transfections were performed
using a lipofectin protocol; after 48 hours the success of transfection was
confirmed by examining for GFP expression, and the CMV.XIAP transfected
and un-transfected cells were collected for mRNA isolation.
mRNA samples from the collected cells were treated with DNAse to remove any
residual plasmid DNA. To determine whether this process was complete, and
hence that any XIAP detected with the hXIAP primers was from the transfected
cells and not a false positive from residual plasmid DNA, the cDNA preparation
steps were performed in duplicate with one sample being treated with water
rather than reverse transcriptase (termed “no-RT controls”).
PCR reactions with the hXIAP primers (Figure 7-6) were positive with samples
from both the transfected and un-transfected BHK cells, but not in the no-RT
controls, indicating that the xiap naturally produced by this hamster cell line is
itself detected by the human xiap primers. The possibility of contamination was
also considered and so an additional plate of un-transfected bhk cells was
prepared, and analysed, again confirming the PCR product from untransfected
cells. These results indicate that at the sites of primer binding hamster XIAP has
high congruity with human XIAP, and differs from mouse Xiap. Further testing
for specifically plasmid expression was therefore performed in murine cell lines
as the murine Xiap sequence is known, and cross-reaction of murine Xiap with
these hXIAP primers should be avoided.
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Figure 7-6 Testing for hXIAP in transfected BHK cells. PCR reaction products have been
run on a 2% agarose gel. PCR reactions were run with hXIAP primers, shown previously
to detect specifically human XIAP cDNA with the formation of a 445bp product. Samples
were used from BHK cells transfected with CMV.XIAP and untransfected cells. Each
sample was run in duplicate, with and without reverse transcriptase (RT). If the treated
samples contained residual plasmid cDNA a positive band would have been seen with the
“NO RT” samples. Positive bands were seen with both the transfected and untransfected
BHK samples.
Mouse Fibroblast transfection.
Lipofectin and PEI transfections using a CMV.GFP were first attempted in the
NSL mouse fibroblast line, but without success. The NIH-3T3 cell line was
therefore used instead, which is a line of mouse fibroblast cells, originally
derived from the NIH Swiss mouse. Lipofectin and PEI transfections were
performed in parallel.
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Two 24 well plates were seeded with 80 000 NIH-3T3 cells per well. 8 wells of
one plate were transfected with a 50:50 mix of CMV.XIAP and CMV.GFP
plasmids using lipofectin. 8 wells of the other plate were similarly transfected
using a PEI protocol. The other wells in each plate were left untransfected to
serve as controls.
72 hours following transfection the cells were examined for GFP expression.
This was evident in PEI transfected cells (Figure 7-7: PEI transfected 3T3 cells
expressing GFP (shown in black and white), but not in the lipofectin infected
cells.
mRNA from the PEI transfected cells, and associated un-transfected controls,
was isolated. To enhance mRNA yield the cells from groups of 4 wells were
pooled prior to mRNA isolation. The 2 resultant samples of mRNA from
transfected cells, and 2 samples from untransfected cells, were used for cDNA
geneneration using the reverse transcriptase protocol (with and without the
reverse transcriptase enzyme). Samples were then used for PCR reactions using
the hXIAP primers.
As shown in Figure 7-8 human XIAP expression was detected in both samples
from the CMV.XIAP transfected cells, but not in the un-transfected cells nor no-
RT controls. These experiments confirm that the CMV.XIAP plasmid produced
XIAP mRNA in murine cells.
Figure 7-7: PEI transfected 3T3 cells expressing GFP (shown in black and white).
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Figure 7-8: PCR detection of XIAP expression. PCR reactions using 100 ng of linearised
CMV.XIAP DNA were run as positive controls in lanes 1 and 7; these show the expected
PCR product of 445bp. The XIAP PCR product is not seen in lanes 2&3 or 8&9 from
untransfected NIH-3T3 cells. However, in lanes 4 and 10 from cells transfected with
CMV.XIAP the 455bp PCR product is seen confirming expression. Lanes 6 and 11 serve
as negative “no-RT” controls, confirming that the XIAP product seen in lanes 4 and 10
results from cellular expression of the plasmid, and not from residual plasmid DNA in the
collected samples.
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Figure 7-9 Confirmation of hXIAP transgene expression. cDNA was generated
from the CMV.XIAP virus treated, and untreated, eyes of a Rho-/-Opn.gfp mouse.
This cDNA was run in a PCR reaction with -actin and human XIAP (transgene)
specific primers. A PCR reaction with the linearised CMV.XIAP plasmid was run
alongside as a positive control. The human XIAP amplicon (445 bp) is seen in the
treated eye, and positive control, only. Murine -actin amplicons were seen for both
the treated and untreated eyes, confirming successful cDNA generation.
7.5 Confirmation of transgene expression in vivo.
rAAV2/8 CMV.XIAP was prepared with a genomic titre of 1x1013 vg/ml. In
order to confirm virus function in vivo, one of a litter of treated mice was culled
to look for transgene-specific mRNA expression in the treated eye. The mouse
in question had been treated with inferior and superior injections of 1.5l of
CMV.XIAP virus (1x1013 vg/ml) to the right eye, at 19 days of age; the left eye
was untreated. Four weeks following injection mRNA was isolated from the
retinas of each eye, and cDNA generated. Transgene expression was confirmed
using primers to distinguish between endogenous and human (transgene) XIAP
mRNA.
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7.6 XIAP expression and degeneration of cone function
To examine the effect of XIAP expression on cone photoreceptor degeneration 5
Rho-/-Opn.gfp mice were treated with rAAV2/8.CMV.XIAP and evaluated with
photopic ERGs at days 52, 60 and 73 of age (pre-, mid- and terminal stages of
the cone functional degeneration). Mice were treated with double sub-retinal
injections of the viral vector, each of 1.5l, at day 11 of age. ERG function
results are presented in Figure 7-10. At each flash intensity, and at each
timepoint, mean cone function was lower in the treated eyes than in untreated
fellow eyes. At days 52 and days 60 cone function, in response to a 10 cd.s/m2
flash, was worse in the treated eye than untreated eye in every one of the animals.
The effect of subretinal rAAV2/8.CMV.XIAP on cone function was compared
with that of control vector. There were minor differences in the timing of
injection and vector titre to take into account with this comparison.
rAAV2/8.CMV.XIAP was injected at P11 and at a titre of 1x1013, giving 3x1010
genome particles per eye. Control rAAV2/8 was injected at P14 instead, and at a
titre of 4.2x1012, giving 1.3x1010 particles per eye. The percentage reduction in
cone function for each animal, and at each timepoint, was calculated for the b-
wave amplitude in response to a 10 cd.s/m2 flash [(untreated eye-treated
eye)/untreated eye)x100]. Despite the greater number of vector particles injected
with the CMV.XIAP preparation the effect on cone function was the same as that
seen with the control vector (Figure 7-11). T-tests revealed no difference
between the reduction in response seen with CMV.XIAP with that seen with
control vector (p=0.68, 0.13 and 0.39 for day 52, 60 and 73 respectively). There
was therefore no evidence that CMV.XIAP had a detrimental effect over and
above that from a sub-retinal injection of control vector.
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Figure 7-10 The effect of rAAV2/8 on cone function in the Rho-/-Opn.gfp mouse.
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Figure 7-11 For each animal the difference in cone function between treated and
untreated fellow eyes was calculated and expressed as a percentage of function in the
untreated eye. Cone function was examined using a photopic flash ERG sequence in
light-adapted animals; b-wave amplitudes to flash stimuli of an intensity of 10 cd.s/m2
were used for analysis. Means of the % change are plotted for each treatment cohort and
compared using the t-test.
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7.7 XAF1 expression
XAF1 is one of the principal inhibitors of XIAP. If increased XIAP expression
leads to a secondary up-regulation of XAF1 the anti-apoptotic effect of XIAP
could be negated. In vivo the ratio of XIAP and XAF1 expression is a more
informative predictor of outcome than levels of XIAP expression alone.400;401
Therefore in three animals, all of which had shown no treatment effect with
rAAV2/8.CMV.XIAP eyes were enucleated for determination of XAF1
expression levels.
Animals were culled at week 17 following functional (ERG) and anatomical
(SLO) assessments, and so were in the late stages of retinal degeneration.
mRNA was isolated, and cDNA generated, from the treated and untreated eyes in
each animal. XAF1 expression was quantified using quantitative real-time PCR,
and determined relative to -actin expression. A range of cDNA, probe and
primer concentrations were first evaluated to optimise the reaction conditions.
Optimised reaction curves along with the primers and conditions used, are shown
in the supplementary data chapter. Each sample was analysed in triplicate at two
dilutions.
-actin (gene name ACTB) is a cytoskeletal protein expressed at approximately
stable levels in all cells. Levels of expression are likely to have been equal in
treated and untreated eyes, and so in each eye the number of copies of XAF1
cDNA were first normalised to number of copies of -actin cDNA to allow
comparison between samples. In 2 of the 3 animals XAF1 expression was
greater in the treated eye than in the untreated eye (Figure 7-12). There was
however no experimental reason to exclude the animal (#1) with no difference
between treated and untreated eyes; the sub-retinal injections had been
satisfactory in this animal, and ERG and SLO data was in keeping with the rest
of the cohort. Analysis including all 3 animals revealed no overall difference in
XAF1 expression between treated and untreated eyes (p=0.18, paired t-test).
Increasing the numbers of eyes examined would increase the probability of
detecting a small difference between treated and untreated eyes. However, even
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in animals #2 and #3 the levels in the treated eye were only between 3 and 5 fold
those in the respective untreated fellow eyes. In the previous chapter it was
identified that rAAV2/8 mediated expression of GDNF, using the same promoter,
lead to a 232 fold increase in expression. The relative increase in XIAP
expression achieved with rAAV2/8 will also depend on the endogenous
expression levels, but is likely to have been orders of magnitude greater than a 3-
5 fold difference. A 3 to 5 fold change in XAF1 expression is therefore unlikely
to be of biological significance and so no further animals were injected.
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Figure 7-12 XAF1 expression levels in CMV.XIAP treated and untreated eyes of the
Rho-/-Opn.gfp mouse. In the uppermost graph XAF1 expression levels are compared
between eyes of individual animals. Levels are expressed as a percentage of those in the
untreated eye of animal #1. Mean levels, in treated and untreated eyes, are shown in the
lowermost graph. A paired t-test including the data from all 3 animals revealed no
significant difference between treated and untreated eyes.
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7.8 Discussion
7.8.1 rAAV2/8.CMV.XIAP in the Rho-/-Opn.gfp mouse
The aim of these experiments was to slow cone photoreceptor loss in the Rho-/-
Opn.gfp mouse through the expression of XIAP. A plasmid containing XIAP
cDNA was validated in vitro, and used in vivo with the same promoter and vector
that had previously expressed GDNF at over 200 times the levels found in fellow
untreated eyes. One of the treated mice was culled for mRNA analysis and this
confirmed expression of the human transgene in the mouse eye.
There was however no evidence of cone neuroprotection in mice treated with the
rAAV2/8.CMV.XIAP vector. Cone function in treated eyes was no different to
that in control vector injected eyes. In CMV.XIAP and control vector injected
eyes cone function was worse than in untreated fellow eyes due to effects of the
sub-retinal injection.
Despite the evidence for transgene mRNA in a treated eye attempts to quantify
protein levels in 4 other treated mice have been unsuccessful. Related in vivo
experiments with XIAP constructs have used a haemagglutinin (HA) tag fused to
the XIAP protein in order to detect and quantify transgene expression.119;412
Despite the possible impact on XIAP protein function this was done specifically
because of difficulties with available antibodies to the XIAP protein when used
with in vivo samples (personal communication, Dr Wai Gin Fong). There was no
reporter gene or HA tag with the construct evaluated here. The in vitro data
confirming a functional plasmid, and the in vivo result confirming human XIAP
mRNA show the plasmid and vector to be functional. It remains possible
however that the expression of the transgene mRNA did not lead to adequate
expression of transgene protein. This could have been due to inhibition of
translation for example.
Alternatively it is possible that the human XIAP protein is not effective in mouse.
Human XIAP has previously been evaluated in rats.119;410;412;417 Rat and mouse
XIAP coding sequences both have 89% homology to the human XIAP coding
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sequence, and have 90% homology to one another, as determined from the
National Institute of Health databases, and comparison of the sequences
(www.ncbi.nlm.nih.gov). A difference in human XIAP efficacy between rats
and mice is therefore relatively unlikely.
Leonard et al. demonstrated evidence of rod photoreceptor preservation in
rAAV-XIAP treated eyes in two rat models of retinal degeneration.119 In both
the P23H and S344ter models XIAP treated eyes had a relative preservation of
ONL morphology and thickness; this indicates a difference in the numbers of rod
photoreceptor nuclei but gives no indication as to the number of cone
photoreceptors in view of the relative abundances of these two types of
photoreceptor. In the P23H rat rAAV-XIAP was associated with improved ERG
in late stages of degeneration. The effect was small but significant. However by
the time the effect was seen the majority of pre-degeneration ERG function had
already been lost. The data shown is for responses to a relatively dim flash (0.63
cd.s/m2) without prior light adaptation to bleach rod responses. The functional
data in this study is therefore also predominantly, if not exclusively, a measure of
rod-specific outcomes and provides no evidence of cone neuroprotection.
Likewise Yao et al. demonstrated that increasing XIAP expression in rod
photoreceptors, subsequently transplanted into the rd9 mouse, enhanced their
survival.418 Rod numbers were increased at both early and late timepoints in the
XIAP treated group as compared to cells transplanted without XIAP treatment.
The absolute numbers of XIAP treated cells still declined in time though. There
are likely to have been multiple stimuli for cell death during this time course, and
differing molecular mechanisms involved. These are not characterised but the
results do provide further support that XIAP overexpression has the potential to
partially reduce rates of rod photoreceptor death. The experiments here in the
Rho-/-Opn.gfp mouse in contrast used exclusively cone specific outcome
measures. A positive treatment result with the CMV.XIAP construct would have
given evidence of cone neuroprotection, and the mechanism could have been
investigated with means of a cone-specific promoter to distinguish between a
direct effect on cones or enhanced cone survival secondary to rod photoreceptor
survival. However, the negative results reported here are open to multiple
interpretations as discussed. It can be more challenging to prove a negative
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treatment effect, and in this situation evidence of protein expression in vivo
would be required. It therefore remains to be demonstrated therefore whether
overexpression of XIAP does or does not mediate cone photoreceptor
neuroprotection in the context of a rod-cone degeneration.
The study of XIAP overexpression in the P23H and S344ter rats indicates that
even in rods the effect of XIAP over-expression is limited.119 These are two
relatively slow retinal degenerations. In the S344ter model there was no
functional benefit over untreated eyes. In the P23H rat there was only a benefit
at late stages of the degeneration, and this was limited in magnitude. Further
studies in the Rho-/-Opn.gfp mouse, which has a much faster retinal degeneration
and more severe phenotype, may be better placed using mutant XIAP that is
resistant to autoubiquitination and so potentially of greater efficacy.389
7.8.2 The ARR4 promoter
In the absence of a positive treatment effect with the ubiquitous CMV promoter
XIAP expression was not investigated with a cone-specific promoter. The
evaluations of this novel promoter (cloned by Dr Carvalho) and not previously
used therapeutically in vivo, confirmed predominantly cone-specific expression.
In the 6 week old rhodopsin knockout mouse GFP expression driven by the
promoter was seen in cone photoreceptors. None of the injected mice were
evaluated at later timepoints, but the previous investigations in the Rho-/-Opn.gfp
mouse identified that arrestin expression in cones was down-regulated prior to
cell death, and indeed whilst eGFP was still evident when driven by a derivative
of the human long wavelength sensitive cone promoter (OPN1LW-human). It is
not known whether the reduced arrestin protein expression in the non-functional
cones was due to reduced transcription or post-transcriptional regulation of the
protein, but the former in particular could limit effectiveness of the promoter in
treating degenerating cones. Komaromy et al. have confirmed that derivatives of
the OPN1LW-human promoter are effective in non-functional cones of the dog
CNGB3-/- achromatopsia model as well.419 The ARR4 promoter was not used
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further here but it would be of interest to study whether it too leads to transgene
expression in non-functional cones.
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Chapter 8 Rhodopsin gene replacement
8.1 Introduction
Mutations in the rhodopsin gene account for approximately 25% of cases of
autosomal dominant RP,48 and are less commonly causative of autosomal
recessive and sporadic cases as well.49-51 Some of these mutations may be best
treated by expression of wild type rhodopsin to effectively dilute out a negative
effect of the mutant protein. “Block and replace” approaches are also under
investigation experimentally where by all endogenous rhodopsin expression
(mutant and wild type) is suppressed and gene replacement therapy is used to
express replacement rhodopsin. The former approach in particular, like the use
of neuroprotective factors, could be applicable to large numbers of patients
regardless of the exact nature of the underlying mutation. Either strategy is
however reliant on the expression of wild type rhodopsin. This presents
particular challenges because the rhodopsin protein is highly expressed but
overexpression has toxic sequences. If however rhodopsin gene replacement is
effective at slowing secondary cone photoreceptor loss it could be of benefit to
large numbers of adRP patients.
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8.1.1 Strategies for adRP
Dominant phenotypes are caused by loss of function, gain of function or
dominant negative mechanisms, or due to a combination of these.420 Loss of
function mutations are most commonly associated with recessive inheritance, but
are also seen in dominant disease when the expression of one functional allele is
not sufficient to maintain the normal phenotype. In this situation a loss of
function mutation in a single allele results in a pathological phenotype, and this is
known as haploinsufficiency. Haploinsufficiency is not a common cause of RP,
but has been described in association the PRPF31 gene which encodes an mRNA
splicing factor.421;422 Gain of function mechanisms have been associated with the
P23H mutation seen in approximately 12% of AdRP patients.26 The mutant
protein is misfolded and aggregates into intracellular inclusions with a
detrimental effect on cell function.226 Dominant negative mechanisms, where by
the expression of mutated gene compromises the role of the normal allele, are
also implicated with the P23H mutation however, as wild type proteins were
found to be co-sequestered within the inclusions. Dominant negative
mechanisms are sometimes considered as a form of gain of function mutations.
Selected dominant mutations may be treated by increasing expression levels of
the wild type protein. Mao and colleagues expressed wild type rhodopsin in the
P23H transgenic mouse using rAAV2/5.423 Increasing the levels of wild type
rhodopsin was found to slow the retinal degeneration suggesting that the effect of
the dominant mutation could, at least to an extent, be competed out. It will be of
interest to see if similar effects are seen in models with related rhodopsin
mutations, and to determine the effect of varying expression levels.
Overexpression of rhodopsin in wild type mice leads to photoreceptor
degeneration. The rhodopsin expression level to be therapeutic in the presence
of a mutation, but avoid toxicity, could therefore be variable depending on the
strength of the dominant negative mechanisms in play.
An alternative approach being developed is to suppress expression of the mutated
gene, and concurrently express replacement wild type protein. Suppression of
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specific genes may be achieved with antisense nucleotides, ribozyme technology
or RNA interference, of which it is the latter that has shown the greatest promise
for chronic conditions such as inherited retinal degenerations. Antisense
oligonucleotides bind to specific mRNAs, and inhibit expression through
structural changes that block translation or by inducing degradation. They have a
short half-life within the cell however, and so structural modifications are
required to potentiate the silencing effect. Antisense oligodeoxynucleotides,
which incorporate a deoxyribose sugar, have proved effective at targeting VEGF
expression and reducing laser-induced neovascularisation in primate eyes.424
This treatment effect was demonstrated in the short-term at 3 days following
laser. The fast degradation of oligonucleotides and oligodexoynucleotides
renders this approach less suited to the long-term silencing of a mutated gene.
Ribozymes have a structure more resistant to degradation. Sub-types can be
designed to cleave specific mRNA molecules, and thus effectively silence a
particular transcript. Specificity to single point-mutations has been demonstrated
in vitro,425 and limited efficacy has been demonstrated in vivo in the P23H rat
model of dominant RP.134;135;426 Treatment effects have been demonstrated for
up to 3 months following treatment. However the use of double stranded RNA
(dsRNA) molecules and the RNA interference approach, has largely superseded
the previous knockdown results achieved with ribozymes. Through eukaryotic
cellular pathways low numbers of dsRNA molecules are able to achieve almost
total cellular knockdown of a particular mRNA transcript.427 It is likely that this
powerful system evolved as a line of defence against transposons and viral
infections. In mammalian cells short dsRNA molecules, 19-21 bp long, are
incorporated into the RNA induced silencing complex (RISC).428;429 The short-
interfering dsRNA (siRNA) then guides the RISC to the complementary mRNA
which is catalytically cleaved. In vitro and in vivo studies have now
demonstrated that expression of short hairpin RNA (shRNA) molecules, which
are cleaved within the cell to generate siRNA, can be used to silence dominant
rhodopsin mutations. O’Reilly et al. demonstrated approximately 90% silencing
of the rhodopsin gene in retinal explants using shRNAs.138 Rhodopsin cDNA
was also generated that was resistant to the shRNA used. Rhodopsin targeting
shRNA and resistant rhodopsin cDNA, were then expressed using rAAV2/5 in
transgenic mice carrying the P23H allele on a rho+/- background. This resulted
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in morphological preservation of photoreceptors in the treated eyes, as compared
to control eGFP injected eyes. ONL thickness was approximately 33% thicker in
the treated eyes at 2 months of age following injections at P10. It would of
course be interesting to compare function in treated eyes to that in uninjected
controls and evaluate whether this preservation is maintained at later timepoints,
but none the less this study showed proof of principle for the “block and replace
approach” to dominant mutations.
8.1.2 The challenges of rhodopsin gene replacement
Rhodopsin is one of the most prevalent proteins within the retina and constitutes
over 90% of the protein content of rod outer segments.430 Furthermore rod outer
segments are replaced at a rate of approximately 10% per day430;431 and
continued high levels of rhodopsin expression are required to compensate for this
turnover. In addition to being highly expressed, rhodopsin protein is also
essential for normal rod cell development and survival. This is evident from the
rhodopsin knockout models where the rod photoreceptors fail to develop outer
segments or detectable function, and rapidly degenerate.90;242 These factors
render the rhodopsin gene a challenging target for gene replacement therapy. It
is also evident that overexpression of rhodopsin has a toxic effect on rod
photoreceptor survival. This was first demonstrated in transgenic models where
congenital overexpression of rhodopsin resulted in retinal degeneration.
Subsequently Mao and colleagues demonstrated that mature photoreceptors are
also susceptible.423 rAAV5 mediated rhodopsin expression in wild type mice
lead to reduced ERG function in treated eyes, as compared to untreated controls.
There was no comparison made to control vector injected controls or histological
analysis of these eyes, but injection of the same vector into the P23H transgenic
mice had a positive treatment effect. The authors hypothesised that in the wild
type retina the relative excess lead to rhodopsin protein being mis-folded and
aggregating.
Palfi et al. demonstrated rAAV2/5-mediated rhodopsin replacement, to
approximately 40% of physiological levels in rhodopsin-knockout mice.432 This
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was sufficient to generate a rod-derived ERG where there is normally none.
However cone function was significantly compromised, probably relating to the
timing of sub-retinal injections at P0 as similar reductions in cone function were
seen in control vector and PBS-injected eyes. Injections at later timepoints, with
the construct and vector used, were less effective at restoring rod function. There
was therefore no evidence of cone photoreceptor neuroprotection following
rhodopsin gene replacement in this study.
8.1.3 Aims
The aim of the following experiments was to restore rhodopsin expression, in
mice homozygous for rhodopsin gene disruption, to approximately physiological
levels and study the effect on cone photoreceptor degeneration. Sub-retinal
injections were performed at timepoints later than P0 in order to try and limit
iatrogenic damage to the cone photoreceptors.
8.2 rAAV-mediated rhodopsin expression in vivo
rAAV is the most effective vector for the transduction of photoreceptor cells, and
specifically rAAV2/8 has been used to treat a fast rod photoreceptor
degeneration in mice.133 AAV2/8 was therefore prepared using the human
rhodopsin coding sequence (hRHO) driven by the bovine rhodopsin promoter
(bRHO, see supplementary data chapter). This promoter has been used
previously to effectively rescue rod photoreceptor function in the rds murine
model of retinitis pigmentosa.130
Virus was concentrated and purified to a titre of 5x1012 vg/ml (supplementary
data, Figure 11-8) and injected into the subretinal space of rhodopsin knockout
mice at P14 of age. To assess transgene expression in vivo the treated and
untreated fellow eyes were harvested 4 weeks following injection, fixed in
paraformaldehyde and prepared for cryosection. Rhodopsin expression in the
treated eye (and not in the untreated eye) was confirmed with immunostaining
(Figure 8-1). These results also demonstrate that the technique of superior and
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inferior subretinal injections (each of 1.5l of virus) leads to effective
transduction of photoreceptors across the retina.
.
Legend to Figure 8-1 (Following Page)
(A). Superior-inferior section through the optic disc of a treated eye. Superior and
inferior injections of viral vector were performed at P14 and the eye harvested at P47.
Cryosections were incubated with antibody to rhodopsin protein (red) and
counterstained with the DAPI nuclear stain (blue). Rhodopsin protein is evident across
the entire superior inferior section of the eye following the double injections. (B).
Superior-inferior section through the optic disc of the untreated fellow eye from the
same animal as in image A. The fellow eye was prepared and stained with rhodopsin
antibody alongside the treated eye in image A. No rhodopsin staining is evident within
the retina (C). To control for specificity of the antibody secondary, sections from the
treated eye were prepared without applying the primary antibody (to rhodopsin).
Weak staining was seen of retinal blood vessels, but there was no cellular staining in
the ONL.
(D). A high magnification image from the same treated eye shows rhodopsin
expression within cell bodies of the ONL and additional expression between the ONL
and RPE.
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Figure 8-1 Rhodopsin protein in AAV2/8 treated rhodopsin knockout mice. Legend on
previous page.
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In order to study further the distribution of rhodopsin expression and rod photoreceptor
morphology, treated eyes were compared to wild type eyes with immunohistochemistry
for the rhodopsin and rod transducin proteins (Figure 8-2). In both treated and wild type
rod photoreceptors the rhodopsin protein is primarily located in the outer segments.
Protein is also seen within the cell body and inner segments where it is produced and
assembled.431;433 The outer segments of the treated rods are however considerably
reduced in size as compared to those of the wild type mouse. This is of significance as
the outer segment is essential for phototransduction. This finding was confirmed by
staining for the rod transducin protein which is also located in rod outer segments
(Figure 8-2).
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Figure 8-2 Comparison of rhodopsin and transducin expression in treated rhodopsin
knockout and untreated wild type retina. All images are single slice confocal sections
from mice sacrificed at 7 weeks of age. Rhodopsin and transducin expression in the
treated eyes has a similar distribution to that in wild type eyes, but levels are reduced.
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8.3 Assessment of the effect of rhodopsin expression on
rod function.
To assess whether treatment led to restoration of rod function ERGs were
performed at day 40 and 47 of age. In 3 of the 6 rhodopsin knockout mice
treated at day 14 b-waves were detected at low light intensities indicative of rod
function (Figure 8-3). Although of low amplitude (maximum 30V) these were
a consistent feature at both timepoints examined in these 3 animals. Toda et al.
have previously established that the flash intensity threshold to induce cone
function (as defined by a 5V b-wave) in the dark adapted rhodopsin knockout
mouse was 0.085 cd.sec/m2.242 The responses at the first 3 flash intensities tested
(0.003, 0.007 and 0.03 cd.s/m2) are therefore from rod and not cone
photoreceptors. This is confirmed by the control traces from the untreated
littermates in which no response was detected with a flash intensity below 0.5
cd.s/m2.
In all 3 of the successfully treated eyes the dark-adapted 0.5 cd.s/m2 flash
response was greater in the treated than in the untreated eyes. This is despite the
cone function (tested in isolation in the photopic light-adapted protocols) being
lower in the treated eye than in the untreated, consistent with the effects of sub-
retinal injection on cone function. The increased dark-adapted 0.5 cd.s/m2 flash
response in the treated eyes can therefore be attributed to rod function in that eye
in addition to the compromised cone function.
The 30V rod response is however over 8 fold lower than that detected in age-
matched wild types examined with the same ERG protocol (Figure 8-4),
indicating only a partial rescue effect. This is in keeping with the histological
data indicating reduced rhodopsin expression, transducin expression and outer
segment formation in the treated animals as compared to wild types. Reasons for
the absence of rescue to wild type levels, despite high titre virus and widespread
rod transduction, could relate to the timing of injections or the efficiency of
transgene expression with the plasmid used
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Figure 8-3 Rod and cone function in the rhodopsin knockout mouse treated with
rAAV2/8.bRHO.hRHO at P14. The top two rows of traces are from a single mouse
treated with AAV2/8 bRHO.hRHO to the right eye only. The third row of traces is from
a littermate in which neither eye was treated (analysis performed at day 40). Stimulus
intensities are shown on the top row of traces only. As highlighted (*) in the treated
eyes only there is evidence of rod function. There is no rod response in the untreated
fellow eyes or control littermate. Cone function is reduced in the treated eyes as
compared to the untreated fellow eyes.
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Figure 8-4 Rod function in young wild type mice.
(A) 4 wild-type mice (C57/BL6) were dark adapted overnight and scoptopic ERGs
performed at day 40 and day 52 of age. B-wave amplitudes are plotted at each of the 4
stimulus intensities examined.
(B) A representative intensity series from one of the mice at 40 days old is shown.
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8.4 Timing of rhodopsin expression
In the mouse, rhodopsin expression is well established by P3-5 and increases in
levels until after weaning. 434-436 During this time the number of post-mitotic rod
photoreceptors progressively increases, and these mature and develop the outer
segments and synapses essential for retinal function (Figure 8-5).437 Early
expression of rhodopsin in the Rho-/-Opn.gfp mouse is therefore likely to
increase the chance of functional rod photoreceptors developing. However, this
has to be balanced against disadvantages of performing early subretinal
injections. In particular, early sub-retinal injections induce greater levels of cone
damage, 432 and as the eye is smaller the volume of vector that is well tolerated is
smaller too.
Figure 8-5 Timing of neuronal cell development in murine retina. Developing mice
were treated with daily pulses of radioactive thymidine to label cells in S phase at the
time of the pulse. With this technique mature cells will retain high levels of the label.
However, in cells that undergo subsequent division the label is diluted. By analysing
mature retinae for heavily labelled cells the timing of development of those cells can be
determined. This graph from R.W. Young shows the percentage of cells born on a given
day is shown for 7 retinal cell types.437 (H.C.-horizontal cell; G.C.-ganglion cell).
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To investigate the effect of early injections 4-7 mice were injected at each of
days 5, 7 & 8. In view of the small eye at these timepoints a reduced volume of
virus was injected (superior and inferior injections of 1l each). None of these
early injections resulted in detectable rod function, despite histological evidence
of transgene expression (Figure 8-6).
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Figure 8-6 Rhodopsin gene replacement in the neonatal rhodopsin knockout mouse.
Immunohistochemistry confirms expression in the treated eye following injection at P5
(top row). There is no rhodopsin expression in the fellow untreated eye. However, the
extent of expression is reduced as compared to an age-matched wild type eye (middle
left). Antibody specificity was confirmed with a no primary control using wild type
retina (middle right). A high power image from the treated eye shows rhodopsin
expression within the cell body and inner segment of a rod photoreceptor but there is no
outer segment staining. Limited outer segment staining is seen in the low power image.
Scotopic ERG traces from the same animal, examined at P44 are shown confirming
absence of rod function in both eyes, and reduced cone function in the treated eye (as
evidenced by the response to a 0.5cd.s/m2 flash).
Treated Untreated fellow eye
Chapter 8: Rhodopsin gene therapy
265
8.5 Combination with GDNF
The efficacy of gene replacement therapy can be augmented through concomitant
expression of GDNF. This was demonstrated by Buch et al. in the RCS rat and
rds mouse, where the combination of Gdnf expression and gene replacement
improved function and photoreceptor survival as compared to treatment with
either construct alone.154 Eyes receiving gene replacement or growth factor
alone were injected with diluted viral vectors such that the number of vector
particles for each construct was equal in these eyes as in those receiving
combination therapy. In the rds mouse eyes treated with the combination of
AAV.CBA.GDNF and AAV.Rho.Prph2 had 51% greater b-wave amplitudes 2
months following injection than eyes treated with AAV.Rho.Prph2 alone. This
effect was lost by 4 months following injection. The RCS rat has a null mutation
in the RPE-specific gene Mertk. Gene replacement was performed using
Lentivirus. RCS rat eyes receiving AAV.CBA.GDNF in combination with
Lenti.Mertk had 50% greater b-wave amplitudes at 6 weeks post injection than
eyes receiving gene replacement alone. This effect was not maintained beyond 8
weeks post injection. Thus Gdnf had an additive effect, but in the presence of
continued cell death the benefit was transient.
Despite earlier results with GDNF alone, Gdnf was therefore co-expressed with
the rhodopsin replacement construct in the Rho-/-Opn.gfp mouse. Single eyes
(n=4) were treated with a 50% mixture of rAAV2/8.CMV.GDNF and
rAAV2/8.bRHO.hRHO. Vectors were used at maximum titre and eyes were
injected at P14 with superior and inferior injections of 1.5l each. The total
number of rAAV2/8.bRHO.hRHO vector particles injected in these eyes was
therefore 50% lower than in eyes receiving this construct alone in previous
experiments. These eyes were assessed with ERG assessments at weeks 8 and
week 10. Week 8 assessments were performed twice (24 hours apart) and there
was no repeatable evidence of rod function. Cone function was reduced in all 4
treated eyes as compared to untreated fellow eyes. Immunohistochemistry
however showed rhodopsin expression in treated eyes despite the lack of rod
function (Figure 8-7). Further experiments were performed to increase levels of
rhodopsin expression.
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Figure 8-7 Combination treatment with rhodopsin and GDNF in the Rho-/-Opn.gfp
mouse. Rhodopsin was detected with immunohistochemistry (red) in eyes of 10 week
old mice. In the treated eye there is evidence of rhodopsin expression in rod inner
segments, whilst there is none in the untreated eye. Sections from a wild type eye were
prepared along side and show extensive rhodopsin expression in rod cell bodies, inner
and outer segments.
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8.6 Optimisation of expression
Gene expression in vivo is regulated at multiple levels, including at the level of
DNA transcription and mRNA translation. An understanding of the cellular
processes through which genes are expressed, and how levels of expression are
regulated, allows modification of plasmid sequences to maximise transgene
expression. Ultimately this should lead to lower doses of viruses and DNA
particles being required to get a therapeutic effect. Significantly, this in turn can
be expected to diminish the risks of inflammatory reactions or insertional
mutagenesis that have been reported with high titre gene therapy treatments.438
Furthermore maximising transgene expression may facilitate gene therapy
treatments in unfavourable cellular environments, such as in the presence of
competing mutated proteins or cellular stress responses that act to compromise
gene expression; this is of relevance to the treatment of patients with selected
missense mutations.439
In the case of the RPE65 plasmid used to demonstrate treatment of LCA first in
dogs and then in patients, sequence modifications of the plasmid lead to a four
fold increase in protein levels when evaluated in RPE cell culture (personal
communication Dr Prateek Buch). This was achieved through intron insertion,
optimisation of the Kozak consensus sequence, and codon optimisation. These
same approaches were used to optimise the rhodopsin plasmid with the aim of
increasing protein expression levels in vivo.
8.6.1 Intron insertion
The inclusion of an intron in plasmid DNA can be a highly effective means of
increasing transgene expression.440 Introns are sequences of non-protein coding
DNA that through multiple mechanisms can be associated with increased mRNA
levels and increased translational yield from spliced mRNAs (reviewed by Le
Hir et al. and A.B. Rose).441;442 Of note sequences within the intron (enhancers
or alternative promoters) can increase levels of transcription, whilst other
components can act to aid RNA polyadenylation, stability and transport.440;441;443
The process in which intronic sequences are removed from mRNA by the
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spliceosome is also associated with increased rates of protein translation. Nott et
al. found that experimental insertion of a single intron was most effective when
the intron was inserted at the 5’end of a transgene, as opposed to the 3’ end, with
the former leading to a 29 fold increase in in vitro gene expression as compared
to an intron-less construct.440 The effect of intron insertion is however variable,
and dependent on the nature of the intron and the point of its insertion.444
A short (159bp) intron, originally derived from the SV40 viral genome, was
cloned in to the pd10 rhodopsin plasmid (Figure 8-8) and the sequence checked
by enzyme digests and plasmid sequencing. This intron has previously been
found to increase expression of GFP driven by the human rhodopsin kinase
promoter when tested in mice.445 It has also been used in concert with codon
optimisation and Kozak sequence modifications to increase expression of the
RPE65 gene in vitro (Dr Buch, personal communication).
Figure 8-8 The pd10 rhodopsin plasmid optimised for protein expression.
8.6.2 Kozak consensus sequence optimisation
The initiation of mRNA translation by ribosomes is influenced by which bases
are found either side of the start codon. At selected positions along the mRNA
molecule certain bases can favour ribosomal initiation more than others and so
influence levels of protein production.446;447 This variability is likely to have
evolved as a means of regulating levels of protein translation, and hence the
degree to which different genes are expressed. In eukaryotes the -5 to +6 region
(with +1 being the first base of the start codon) has the greatest influence and is
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referred to as the Kozak consensus sequence.446 The nucleotides at the -3 and +4
locations in particular are highly conserved, as shown in Figure 8-9, and
changing the sequence to conform with the naturally conserved sites can be a
means of increasing gene expression.447 Bennicelli et al. used this approach
when treating the Briard dog model of LCA;448 however this was an empirical
approach as the effect of the Kozak sequence modifications they made were not
determined.
The Kozak consensus sequence of the bovine rhodopsin-rhodopsin plasmid (CA
GCC ATG AAC) was compared with data for nucleotide prevalence in
mammalian mRNA (as shown in Figure 8-9), and with in vitro evidence of the
effect of base substitutions in the region of an ATG codon.447 The bovine
rhodopsin-rhodopsin plasmid has an adenine at +4, which is the second most
prevalent nucleotide at that location. A guanine instead could be expected to
increase protein production447 but is not possible whilst still keeping a codon for
asparagine, the first amino acid of the rhodopsin gene. The -5, -2, -1, and +5
nucleotides are all optimal, and the -3, +4 and +6 nucleotides are all of second
preference. In the context of a favourable sequence in general the impact of
single nucleotide substitutions is diminished. As the existing Kozak sequence
was found to be only marginally sub-optimal no substitutions were made.
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Figure 8-9 Graphical representation of relative nucleotide abundances at locations either
side of the AUG translation initiation site in mammalian mRNAs. The overall height of
the nucleotide stack indicates the sequence conservation at that position, whilst the
height of the nucleotide symbol within the stack indicates the relative frequency of each
base at that position. The graphic shows that position -3 is the most conserved site, and
that A and to a lesser extent G are commonly found at that location; C or T are
uncommon at -3. In contrast the +8 site is not a conserved site, and any of the
nucleotides are found at that location with approximately equal prevalence. Adapted
from Wegrzyn et al. 2008.449
.
8.6.3 Codon optimisation
Most amino acids can be coded for by multiple different DNA codons. For
example, alanine is coded for by GCT, GCC, GCA or GCG. There are therefore
typically a very large number of different transgene sequences that can be used to
induce expression of the same protein. Which transgene sequence is used can
significantly alter the levels of expression through influences on the efficiency of
transcription, translation and mRNA stability. In a recent study of lentiviral
vector mediated expression of factor VIII (in a study of treatments for
haemophilia) codon optimisation increased expression up to 44 fold in vivo.450
In part this was due to the elimination of transcriptional silencers and inhibitory
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sequences in the original cDNA, but may also have been due to effects on the
speed of translation and subsequent folding of protein domains. tRNAs
associated with less commonly used codons are themselves less prevalent within
the cell, and this influences the speed and efficiency of protein translation.451;452
Stalling and errors (including terminations, substitutions and frame shifts) in
protein translation are all more common with rare codons, and these in turn can
lead to alternative protein folding pathways being used with consequences for
protein transport and function.453;454
The original rhodopsin transgene sequence was analysed using the
OptimumGeneTM algorithm (Genscript, New Jersey, USA; www.genscript.com).
This identified that it was possible to use more prevalent codons, and use codon
combinations that improve mRNA stability and ribosomal binding, without
altering the amino acid sequence of the protein formed. The nucleotide changes
made to optimise the rhodopsin transgene are shown in the supplementary data
chapter (Figure 11-9), and were performed commercially by Genescript. All
changes were made to optimise expression in humans. Although the plasmid is
to be tested in mice the largest differences in optimal codons are seen between
prokaryotes and eukaryotes. Differences between mammalian species are
relatively small. Of note there were no significant cis-acting regulatory elements
in the sequence amenable to change. However it was possible to improve the use
of more prevalent codons (Figure 11-10, supplementary data), and improve the
distribution of more prevalent codons along the length of the transgene sequence
(Figure 11-11, supplementary data). The GC content, which is inversely
associated with the thermodynamic stability of RNA secondary structure, 455 was
also improved by removing peaks of high GC content in order to prolong the
half-life of the mRNA formed (Figure 11-12).
8.6.4 Evaluation of optimised plasmid
Expression of a transgene driven by the rhodopsin promoter can not readily be
evaluated in standard cell cultures, and so these optimisation steps were not
evaluated in vitro. rAAV2/8 bRHO.hRHOOptimised was prepared using the
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optimised plasmid and purified using the standard protocol incorporating phase
separation. Vector purity was confirmed using SDS-PAGE and a Spyro Ruby
protein stain (supplementary data chapter, Figure 11-14). Unilateral superior and
inferior injections of 1.5l of rAAV2/8 bRHO.hRHO at 1x1011 vg/ml were
performed in 4 Rho-/-Opn.gfp mice at p10 of age. Treated eyes were compared
with untreated fellow eyes.
There was no evidence of rod function with flash intensities below 0.5 cd.s/m2 in
the treated eyes. However, in 3 of the 4 treated eyes the reponse to brighter flash
intensities under scotopic conditions was greater in the treated eyes than in
untreated eyes. In each of these animals photopic ERGs confirmed that cone
function was worse in treated eyes than in untreated fellow eyes. The improved
response in the treated eyes to bright stimuli under scoptopic conditions is
therefore likely to be due to rod responses despite the lack of detectable
responses to low flash stimuli. Example traces from one of the 3 animals
showing this pattern are shown in Figure 8-10. Responses to flashes of 3.0
cd.s/m2 were examined under both scotopic and photopic conditions and were
compared to one another. The mean difference in b-wave amplitude between
treated and untreated eyes under photopic conditions, expressed as a percentage
of function in the untreated eye, was a 24.5% reduction (sd 11.4). Cone function
was therefore reduced in treated eyes, as compared to untreated fellow eyes, by a
similar extent to that seen with injections of control vector. Sub-retinal
injections of a control vector lead to a 33.8% reduction in function to a 10.0
cd.s/m2 flash (Figure 6-5). In contrast under scoptopic conditions the b- wave
amplitude to the same flash intensity caused a mean reduction of just 5.2% (24.2).
A t-test revealed no significant differences in the percentage reduction in
function following treatment seen in scotopic versus photopic conditions (p=0.20)
Further experiments are ongoing to determine if increased doses of the optimised
plasmid improve the rod responses obtained.
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Figure 8-10 ERG function in rAAV2/8 bRHO.hRHOOptimised treated eyes. Example ERG
traces (animal#4) are shown from scoptopic and photopic examinations. Under scotopic
conditions function in the treated eye was greater than that in the untreated eye. Under
photopic conditions the reverse was true. In the lower most graph the percentage change
after treatment is presented for each of the 4 animals (the difference between b-wave
amplitude between treated and untreated eyes as a percentage of the untreated value).
Mean is shown with horizontal bars.
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8.7 Discussion
Gene therapy was used here to induce rhodopsin expression in mice homozygous
for rhodopsin gene disruption. Using rAAV2/8, rhodopsin was expressed
following injections in mice up to P14. Repeatable ERG responses were seen in
a minority of treated animals when exposed to rod-specific stimuli (0.007 and
0.03 cd.s/m2 flashes under scotopic conditions). No responses were seen in
untreated eyes under these conditions. These responses represent rod function
restored by the gene replacement therapy.
Higher flash intensities under scotopic conditions (0.5 and 3.0 cd.s/m2) were used
to stimulate a combination of rod and cone photoreceptor mediated responses.
These stimuli resulted in greater responses in treated eyes than in untreated
fellow eyes in some of the experimental animals. This was despite decreased
cone function in the treated eyes as evidenced by ERG recordings under photopic
conditions where a bright light was used to suppress rod activity. It is therefore
likely that the increased responses to bright flash intensities under scotopic
conditions result from rod activity in treated eyes.
Rod function was detected at low light intensities (0.07 and 0.03 cd.s/m2) with b-
wave amplitudes reaching up to 13% of wild type levels. Earlier injections,
concomitant GDNF gene therapy and modifications of the plasmid with the aim
of improving transgene expression all failed to yield rod function at low light
intensities, though evidence at higher flash intensities (0.5 and 3.0 cd.s/m2) was
variably present. In part this may be due to the lower doses of viral vector used
with the latter modifications, and possibly due to increased iatrogenic damage
with early sub-retinal injections in neonatal mice. Thus despite rhodopsin
expression evident by immunohistochemistry, rod function in the treated eyes
was of greatly reduced amplitude and of reduced sensitivity to low intensity
stimuli in particular. This is in keeping with the histological images showing that
in the treated eyes the rod outer segments were much reduced as compared to
age-matched wildtypes, and that there was evidence of abnormal intra-cellular
distribution of the rhodopsin protein with increased expression within the cell
body.
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Similar levels of rod function, in rhodopsin knockout mice following gene
replacement therapy, was detected by Palfi et al.432 In their study a modified
human rhodopsin cDNA sequence (termed “RHO-BB”) was used so that the
transgene product was resistant to RNAi developed by the same research
group.138 The altered transgene could therefore be used as part of a block and
replace strategy for AdRP. rAAV2/5 containing the construct was injected at P0
resulting in up to 20% of the rod function seen in age-matched controls, at 6
weeks post-injection. Rod function was evaluated by quantifying b-wave
amplitudes in scotopic conditions. A different ERG recording apparatus was
used by Pafi et al. and so the absolute values of b-wave amplitude in treated
rhodopsin knockout mice and controls were greater than in the experiments here.
At 12 weeks following treatment there were 3-4 rows of rod nuclei in the ONL.
This compared favourably to untreated eyes where the ONL was just 1 single
row of nuclei thick, but was reduced as compared to treated eyes evaluated at 6
weeks where the ONL was approximately twice as thick. Likewise rod function
in treated eyes declined in time. Rod-dervied b-wave amplitudes were
approximately 85% lower at week 12 than at week 6 (20.619.3V versus
135.358.5V).
Palfi et al. compared a number of different promoter sequences in order to
improve transgene expression. Differing replacement constructs were injected in
vivo and rhodopsin transgene mRNA levels quantified using qRT-PCR.
Maximal expression levels were found with a 1838 bp promoter containing a
1.7Kb fragment of the murine rhodopsin promoter along with two conserved
regions containing the CRX (Cone-Rod homeobox-containing transcription
factor) and NRL ( Neural Retinal basic Leucine zipper factor) sequences. This
resulted in approximately 40% of the RHO mRNA levels seen in wild type mice.
It is possible that further modification of the bovine rhodopsin promoter used in
the experiments here, in addition to the inclusion of the SV40 intron, could
further increase expression levels. Increased expression levels are likely to be
essential in order to significantly slow the rod degeneration, and in turn slow
secondary cone photoreceptor loss. O’Reilly et al. previously found that
expression of rhodopsin to 70% of wild type levels in transgenic mice was
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sufficient for a normal phenotype, as evaluated with histological and ERG
assessments.456
Injections of rAAV2/5 at P0 reduced cone function in treated eyes by
approximately 67% (mean photopic b-wave amplitudes in the treated and
untreated eyes studied by Palfi et al. were 29V and 89V respectively).432 In
the experiments of this thesis sub-retinal injections of rAAV2/8 at P10, also in
mice homozygous for disruption of the rhodopsin gene, impaired cone function
by approximately 34%. Cone damage was apparently less but still a potential
barrier to clinical application of the treatment. For rhodopsin replacement to be a
viable treatment option for AdRP high levels of rod function will need to be
restored without compromsing the existing cone function of central importance
to patients and their quality of life.
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Chapter 9 Discussion
9.1 Neuroprotection
Clinical trials of memantine for glaucoma,457 GDNF for Parkinson’s disease,458
and CNTF for RP7;459 have to date failed to demonstrate in patients the
magnitude of neuro-protective treatment effects that have previously been seen in
experimental animal models. In part this may be due to the considerable
challenges faced by clinical trials in this field. Neurodegenerations typically
progress only slowly and so without long studies and large numbers of patients a
treatment effect can be hard to detect. This problem is compounded as many
clinical assessments are of limited sensitivity and for many neuro-degenerations
the major phase of cell death is in pre-symptomatic patients. In Parkinsons’s
disease approximately 70% of substantia nigra dopaminergic neurons have died
over a 5-10 year period before patients develop motor symptoms,460 and in
inherited retinal degenerations over 90% of cones may have ceased functioning
before there is a substantial loss in acuity.139 Conducting clinical trials in pre-
symptomatic patients is only possible if the course of disease can be accurately
predicted and the risks of intervention are low. Early phase clinical trials are
therefore typically in patients with advanced disease. Nevertheless the apparent
differences in treatment outcomes between experimental and clinical studies can
serve to highlight the limitations of some of the experimental models used. In
particular the timing of disease progression and potential of confounding
variables (including ageing, genetic heterogeneity and environmental influences)
are often markedly different.
In the field of cone photoreceptor neuroprotection experimental studies are
commonly limited by the challenges of longitudinal follow-up and, in rodent
models, the difficulty with identifying cone-specific outcome measures. The
characterisation and use of the Rho-/-Opn.gfp model is a step towards addressing
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these limitations. Its use in this thesis demonstrated that cone-specific outcome
measures can be assessed repeatedly in individual animals to allow the
magnitude of any treatment effect to be characterised in time. This allows the
identification of potential therapies where the treatment effect soon wanes.
With this model no treatment effect of GDNF was identified, in contrast to
previous studies looking at rod-outcome measures at single timepoints.80;160 If
GDNF were to have a significant and sustained effect on either rods or cones in
the Rho-/-Opn.gfp mouse one would have expected an effect on the cone
photoreceptor outcome measures as cone loss is secondary to rod loss. It is
therefore most likely that GDNF does not have an effect on rods or cones in this
animal model. The value of the rhodopsin knockout phenotype lies not in a
direct similarity to the mutations seen in patients, but in being an experimental
model with which to study rod-cone degeneration and to facilitate the study of
cone-specific outcome measures. It is a more severe phenotype than that seen in
patients and so the absence of an effect in this model does not preclude an effect
in others, or indeed in patients. It would therefore now be of interest to study
GDNF in the presence of other rod mutations also crossed onto the OPN.gfp
background.
The use of this model has also illustrated that in many ways it should be easier
for us to evaluate neuroprotective agents in inherited retinal degenerations than
for researchers studying other neurodegenerations. In contrast to striatal neurons
the anatomy and function of photoreceptors can be comprehensively evaluated
non-invasively in vivo. Furthermore treatments can be delivered to specifically
these cells by translatable and well established techniques. This should mean
that the problems of systemic side-effects seen with treatments targeting the
substantia nigra may be avoidable. The potential clinical impact of even limited
neuroprotective effects is massive, and thus despite the negative findings from
clinical trials and pre-clinical trials to date the search for neuroprotective agents
is highly justified. Improved understanding of the disease mechanisms and
potential therapies should drive this research. Studies of inherited retinal
degenerations are favourable settings to further the study of CNS neuroprotection
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in general and animal models related to the Rho-/-Opn.gfp mouse are likely to
facilitate this.
9.2 Transducing the outer retina
The experiments here in murine models of retinal degeneration and in wild type
mice have demonstrated significant iatrogenic damage to cone function
following sub-retinal injections. This is in keeping with previous findings in
other animal models.343-345;354 Investigators therefore sometimes compare eyes
injected with potential therapies to eyes injected with control solutions or other
vectors.119 The rationale to justify this includes that sub-retinal injections in
humans may not be so damaging to retinal function as those induced
experimentally in rodents; thus only looking for a treatment effect in rodents
sufficient to overcome that damage may be un-necessarily discerning. In
addition, in the RCS rat sub-retinal injections of fluid or injury can themselves
induce a non-specific therapeutic effect; in this situation control injections are
used to quantify these non-specific effects that are not attributable to the
therapeutic agent being evaluated. Nonetheless comparison to un-injected fellow
eyes gives the clearest indication as to whether the intervention is likely to
provide therapeutic benefit.
In the GDNF and XIAP experiments here the outcome measures have been
specifically cone photoreceptor related. There was a 30% loss of function with
sub-retinal injections of control vector alone in the Rho-/-Opn.gfp mouse and so
only highly effective therapies would lead to an improvement in cone function as
compared to untreated fellow eyes. Such an effect was not seen with the GDNF
or XIAP constructs used. It may be that in models with slower degenerations the
detrimental effect of a sub-retinal injection on cone function is less. In addition,
in studies using models with slower degenerations and late outcome measures
there will be a longer time period to allow for cone photoreceptor repair.
Komaromy et al. studied specifically cone function in CNGB3-/- dogs treated
with sub-retinal rAAV.419 Despite a range of transgene expression levels, some
of which were possibly supra-physiological in the missense mutant dogs,
maximal ERG function was still significantly diminished relative to wild types.
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There are multiple potential explanations, including that only a fraction of the
retina was treated or that the kinetics and levels of transgene expression are
critical for proper assembly of CNGB3 and CNGA3 proteins into functional
channels. It is also possible that iatrogenic damage to the cones could be part of
the explanation. Alexander et al. did however restore light-adapted cone
function in the Gnat2cpfl3 murine model of achromatopsia to wild type levels.461
These mice were injected at ages of between P23 and P29, and so at later
timepoints than those in this thesis, but nonetheless these results illustrate that
with highly effective treatments the iatrogenic effects of sub-retinal damage can
be overcome.
Intra-vitreal delivery of therapeutic agents is in some cases an alternative. It
induces less iatrogenic damage but in general requires diffusion of the
therapeutic agent down a concentration gradient to its site of action, with the
inherent risk of side-effects. Bejjani et al. reported gene expression in RPE cells
following the intravitreal delivery of nanoparticles.201 This would present a
favourable alternative to sub-retinal delivery of viral vectors if expression levels
were comparable and sustained. However, in their study expression was only
shown for up to 14 days, and there was no indication as to the number of cells
expressing the reporter gene. One of the principal problems with nanoparticle
technologies such is this is that they contain bacterial DNA, with its
characteristic patterns of methylation. Recognition of bacterial DNA by
eukaryotic cells can lead to short transgene expression, and this is likely to be
one of the contributing factors to the very limited treatment effects obtained to
date with nanoparticles as compared to those with viral vectors.200;202 Viral
vectors are, in contrast, prepared in eukaryotic cells and capable of inducing high
levels of transgene expression for many years after retinal cell transduction.197;198
They are likely to remain the only clinical means of transducing outer retinal
cells in vivo for the near future, and are dependent on sub-retinal injections. The
recent clinical trials of RPE65 gene replacement therapy have demonstrated that
the procedure itself can be performed safely in young patients, despite strong
vitreous attachments and degenerate retina.1-6 Patients will have to be carefully
counselled about the risks involved but these results open the way for further
clinical trials of sub-retinal gene therapy to proceed.
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9.3 Dosing and gene therapy
The experiments in this thesis demonstrated no neuroprotective effect of GDNF
on cone function following intra-vitreal injection of recombinant protein and
following gene therapy that increased endogenous expression between 5 and 232
fold. It is however plausible that there could be a treatment effect with
alternative doses of GDNF.
Erythropoietin is a cytokine that like GDNF has been found to reduce rates of
neuronal cell apoptosis in in vitro and in vivo models of relatively acute cell
death.462;463 As for GDNF, the intracelullar PI-3-K/Akt kinase signalling
pathway and upregulation of XIAP have been implicated in the cellular
mechanisms through which neuroprotective effects are mediated.464-466
Weishaupt characterised the dose-response relationship for EPO supplementation
in in vitro and in vivo models of rat ganglion cell death and found that in both
contexts there was a steep bell-shaped dose response curve such that a
neuroprotective effect of EPO was identified with only a relatively narrow
therapeutic window.464
In the experiments discussed in chapters 4-6 GNDF was expressed with the
constitutively active CMV promoter, or administered at high dose with
intravitreal injections of recombinant protein. rAAV2/2 mediated delivery of
CMV.GDNF following single intra-vitreal injections achieved a 5 fold increase
in expression levels, as compared to basal levels. This was an identical increase
to that reported by Wu et al. using a single injection of rAAV2/2 in wild type
rats,160;308 and likely to be similar to the levels found to mediate rod
photoreceptor neuroprotection in the TgN S334ter-4 rat model of RP.2 In
contrast rAAV2/8 mediated delivery of CMV.GDNF, delivered to the sub-retinal
space, resulted in a much larger (over 200 fold) increase in expression levels that
is likely to be greater than any reported previously using gene therapy.
Until recently one of the principal challenges with ocular gene replacement
techniques has been to achieve levels of expression sufficient to slow
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photoreceptor death. For example gene replacement studies in the rds mouse and
RCS rat have been effective at improving morphological and functional outcome
measures but less successful at halting continued photoreceptor cell death in the
longterm.130;132 This was probably in part due to inadequate levels of protein
being expressed at crucial timepoints. More recent studies using improved
vectors and promoters have increased expression levels and proved effective at
slowing cell death in even fast models of retinal degeneration.133 It is likely that
some gene defects are more readily treated than others with gene replacement
therapy, but to a certain extent recent advances have been through maximising
expression levels. These advances in viral vector technologies may not
necessarily be an improvement for neurotrophic therapies however where bell-
shaped dose-response curves may exist.
Although studies in knockout animal models, or those with null mutations, have
generally sought to maximise transgene expression it also apparent from other
studies that supra-physiological expression can be detrimental. Tan et al. bred
transgenic mice with rhodopsin overexpression.467 Overexpressing rhodopsin by
just 23% lead to photoreceptor degeneration, though of note this increased
expression was present throughout retinal development. Mao et al. evaluated the
effect of overexpression in specifically mature photoreceptors with sub-retinal
injections of rAAV2/5 and cDNA of the rhodopsin gene with the mouse opsin
promoter.423 Injected wild types had reduced amplitude a and b waves compared
to uninjected fellow eyes. Injected eyes were not compared to control vector
injected eyes to determine how much of the loss of function was due to the
effects of sub-retinal injection. However, the negative effect increased between
1 and 3 months post-injection which would be in keeping with progressively
greater, and supra-physiological, levels of rhodopsin expression leading to
photoreceptor degeneration.
Persistent and unregulated overexpression of neuroprotective factors could also
have detrimental and potentially dangerous consequences. In these experiments
the titre of the rAAV2/8 CMV.GDNF (batch#1) was reduced in a step-wise
manner with serial dilutions to reduce the number of transduction units delivered
to the sub-retinal space. This is however a relatively crude means of titrating
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gene therapy as there is likely to be substantial and, more pertinently, largely
unpredictable variation in the number of transfection events and transcribed viral
genomes when working with viral vectors. The strategies under investigation to
enable regulation of gene expression following gene therapy may be broadly
categorised into those using exogenous modifiers and those using endogenous
modifiers (Figure 9-1).
Inducible
Promoter Transgene
Pathology
Endogenous
modifier
Exogenous
modifier
Figure 9-1 Exogenous and endogenous modifiers are used to control gene expression.
Endogenous modifiers can be related to the therapeutic target of the transgene and thus
constitute an endogenous feedback mechanism
Exogenous stimuli, including physical stimuli such as incident light and ambient
temperature, have been used in plant cell technologies to control the activity of
inducible promoters.468;469 Within the mammalian eye, similar promoters have
been used that are sensitive to pharmacological agents, and in particular different
tetracycline drugs.470;471 Administration of these drugs activates gene expression,
and without them the genes are silent, or vice versa. To an extent levels of gene
expression are proportional to the dose of exogenous modifier. The drugs
however must be administered at doses sufficient to transverse the blood brain
barrier, which raises the risks of side-effects and potential drug interactions. In
addition the dosing of these regulators would be dependent on changes in the
indications for treatment being detectable clinically; this would present a
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challenge for both slowly progressive diseases and for pathologies of acute onset
such as neovascularisation where the preceding hypoxia is often not apparent
clinically. An advantageous approach, where possible, has been to directly
couple transgene expression to local tissue changes involved in the pathology to
be treated through endogenous modifiers. Bainbridge et al. demonstrated in vivo
that GFP expression could be driven by a promoter sensitive to HIF-1, such that
transgene expression was localised to areas of neovascularisation and presumed
hypoxia.472 This was demonstrated in two murine models in which
neovascularisation was induced by exposure of newborn mice to hyperoxia or by
laser-induced rupture of Bruch’s membrane. Both models entail an acute
neovascular response that is limited spatially and diminishes in time. GFP
expression, when driven by the hypoxia-responsive element (HRE), was matched
to the spatial and temporal patterns of the neovascularisation. This is of
relevance to the treatment of patients with neovascular disorders where the
hypoxia and neovascular response can be focal and variable in time.
In inherited retinal degenerations the time course of disease is typically slowly
progressive, rather than relapsing and remitting. The principal challenge
therefore is to achieve therapeutic levels but avoid toxicity. To date this has been
best achieved clinically with intra-vitreal implants that slowly release the
therapeutic target over many months and can then be removed in the event of
toxicity or in the absence of a therapeutic benefit. Expression levels from such
implants can be precisely characterised in vitro, and these have been used in the
clinical trials of CNTF.7 Other proteins however are more or only effective if
produced close to or within the target cells, necessitating gene therapy. A major
challenge for any clinical applications of such proteins, including XIAP and
rhodopsin, will be to achieve therapeutic levels and avoid toxicity both in the
short-term and potentially for decades after treatment. Furthermore therapeutic
levels may vary considerably between patients.
9.4 Efficiency of expression
In the experiments of this thesis up to 1.5x1010 rAAV2/8 genomes were delivered
to the sub-retinal space of a mouse eye. This is similar to the doses of rAAV2/2
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used in the recent clinical trials of retinal gene therapy which used between 1.5 ×
1010 vg/eye and 1.0x1012 vg/eye.3;199;473 In the clinical trials these doses were
well tolerated and subsequent trials, aiming to evaluate efficacy rather than safety,
are evaluating larger doses still. The requirement for high vector titres is a
challenge for vector production, but of greater concern is the increased risk of an
immune response. In a clinical trial using AAV2 in patients with haemophilia
the long-term transduction of hepatocytes was compromised by immune
reactions to the rAAV capsid.474 Furthermore, the immune response was dose
related. The doses of viral vector used (up to 2.0x1012 vg/kg) were however
much larger than those employed in ocular gene therapy trials. Of note though,
Stieger and colleagues reported that AAV virions persist in the retinae of dogs
and primates for up to six years after subretinal injection raising the possibility of
immune reactions in the longer-term despite the relative immune priviledged
status of the subretinal space.475 There is therefore a clinical need to optimise the
efficiency of gene expression using viral vectors so that minimum doses can be
used, and minimise their pathogenic potential.
The experiments here with the rhodopsin construct illustrate how changes to the
plasmid may be employed with the aim of maximising transgene expression. As
yet the effects of the in vivo and therapeutic effects are still to be quantified, but
in vitro work suggests that Kozak sequence modifications, codon optimisation
and promoter sequence optimisation are all likely to improve gene expression.
Another approach is to increase the efficiency of vector transduction. This can
be achieved by modifying capsid proteins for example, to remove specific
tyrosine residues and reduce proteasome-mediated degradation of the
vector.476;477 The vectors used in this thesis contained single-stranded DNA.
Synthesis of the second strand in transduced cells has been found to be a rate-
limiting step for transgene expression. In part this is due to the cellular
chaperone protein FKBP52, phosphorylated forms of which interact with the
ITRs of the viral genome preventing second-strand DNA synthesis.478 Self-
complementary (sc) AAV vectors circumvent this step resulting in higher levels
of transgene expression and improved kinetics.194 The principal disadvantage
with sc vectors however is that the size of the expression cassette that can be
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packaged with in the vector is further reduced. An alternative method has been
to co-express enzymes that dephosphorylate FKBP52, which can improve
intracellular trafficking of the vector particles to the nucleus as well as facilitate
second-strand synthesis.479;480
The rAAV2/8 CMV.GDNF vectors produced for this thesis were found to
contain genomes within only about 15% of the capsids. Modifications to vector
production methods to reduce the number of empty capsids would be another
means of reducing vector-related immune reactions without compromising
treatment efficacy. In addition it is the capsid proteins of viral vectors that
primarily interact with the host immune system. Modification of these proteins,
with knowledge of previous sensitisation in the host, is another approach being
used by researchers to improve the efficiency of viral vector mediated gene
therapy whilst minimising the potential for immune reactions.481;482
9.5 Future work
The experiments here have demonstrated that a transgenic animal model, with
cell-specific reporter gene expression, can be used to repeatedly assess in vivo
the function and survival of a specific cell-type. Employing such animal models
should reduce the numbers required to evaluate potential treatments, and allow
the time-scale of treatment effects to be determined in individual animals. The
role of in-vivo imaging as a research tool and outcome measure is likely to be
further advanced by the incorporation of advanced optics technologies. These
systems compensate for optical aberrations in order to further improve the
resolution of retinal imaging systems. This allows individual cells to be
visualised without reporter gene expression,483;484 and is likely to aid the
assessment of cone neuroprotection in future clinical trials.459
It is possible that the greatest value of neuroprotective therapies may lie in an
adjunctive role in which they are combined with other therapies. For example
whilst the effect of GDNF in the RCS rat is transient its expression can be used
to potentiate the effects of gene replacement therapy.154 Similarly XIAP
expression alone was found to confer only structural but not functional protection
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of photoreceptors in the rd10 mouse model of retinal degeneration.413 It would
be interesting to study whether XIAP mediated prolongation of photoreceptor
survival increases the time window during which gene replacement therapy is
viable. Such a role could be of particular value in the treatment of fast retinal
degenerations where high levels of expression can be required at early timepoints.
Alternatively neuroprotective factors may be combined with other
neuroprotective factors to act synergistically and have an additive effect. GDNF
and XIAP have been evaluated together in acute models of neuronal apoptosis.
Straten et al studied co-expression in the adult rat following optic nerve
transection and Eberhardt et al. studied co-expression in 1-Methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP) treated mice which have a degeneration of
dopaminergic striatal neurons similar to that in patients with Parkinson’s
disease.485;486 In both studies expression was induced with adenovirus, and a
treatment effect was seen with expression of either protein alone. When GDNF
and XIAP were co-expressed however there was evidence of a synergistic effect.
The mechanism for this is not known but could be related to the neuroprotective
effects of GDNF being mediated through IAP proteins. Inhibition of XIAP and
the neuronal apoptosis inhibitory proteins (NAIP) using anti-sense mRNA,
prevents the neuroprotective effects of GDNF.293 Co-expression of
neuroprotective proteins with relatively distinct molecular pathways has also
been found to produce synergistic effects, again in the optic nerve transection
model of acute neuronal apoptosis.298;487 Similar synergistic effects between
neurotrophic factors could be of value in inherited retinal degenerations.
The experiments here included modifications to DNA plasmids that can be
expected to increase transgene expression on the basis of related in vitro
experiments. The effects of codon optimisation and intron insertion for example
may however vary in vivo and with the combination of transgene and promoter
used. Further study of the effect of such changes, and quantification of
expression levels in vivo, could have significant consequences for the efficacy
and safety of future gene therapy trials. In the immediate future such trials are
likely to be predominantly for recessive monogenic disorders treatable with gene
replacement therapies. However the focus for the majority of inherited retinal
degeneration patients remains on finding a more widely applicable treatment that
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produces a lasting effect on the cone-photoreceptor mediated vision so important
for normal functional lives
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Chapter 11 Supplementary Data
11.1 Model characterisation
Figure 11-1 Degeneration of the outer retina in the Rho-/-Opn.gfp mouse. The retinal
thickness of mice with the rhodopsin knockout genotype was examined in vivo with
ocular coherence tomography (OCT), and histologically (cryo sections were stained with
H&E). In vivo and histological sections showed loss of the outer retina during the
degeneration. The inner retina is relatively preserved.
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Figure 11-2 The rhodopsin knockout phenotype: rod function as assessed with the
scotopic ERG in 6 week old mice. In the rhodopsin knockout heterozygote (Rho+/-)
there is a significant b wave response to flashes of 0.001 cd.s/m2 or brighter. With
higher flash intensities an a-wave is also discernable (*). In contrast in the rhodopsin
knockout homozygotes there is no consistent response to flash intensities below
approximately 0.5 cd.s/m2. Even at higher flash intensities there is no discernable a-
wave.
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Figure 11-3 The rhodopsin knockout phenotype: cone function as assessed with the
photopic and flicker ERG. In the young mouse homozygous for disruption of the
rhodopsin gene cone function can be quantified with photopic flash or flicker ERG
protocols. This cone function is lost during the course of the retinal degeneration.
11.2 Plasmid maps
All cloning was carried out with the pd10 plasmid.
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11.2.1 CMV.GDNF plasmid
r-pD10/GDNF
5403 bps
1000
2000
3000
4000
5000
SpeI
NsiI
Ppu10I
SplI
EcoRI
Sse8387
EcoRV
SnaBI
EcoRI
BbsI
BstEII
EcoRI
SexAI
SpeI
EcoRI
NotI
MunI
AflII
StuI
AvrIIEcoO109
SspI
ScaI
AflIII
EcoRI
CMV
GDNF
SV40
11.2.2 Null plasmid
6282 bps
1000
2000
3000
4000
5000
6000
SpeI
NsiI
Ppu10I
SplI
Sse8387
Eco47-3
SacII
ApaI
Bsp120I
BstXI
PmaCI
BstEII
BsgI
PshAI
BamHI
MluI
SphI
NotI
XmaIII
BsaBI
MunI
AflII
StuI
Cfr10
CMV
Null-HA
Chapter 11: Supplementary Data
294
11.2.3 CBA.RFP
6478 bps
1000
2000
3000
4000
5000
6000
SmaI
NsiI
SnaBI
ApaI
Bsp120I
HindIII
BamHI
SmaI
AgeI
NotI
MunI
HpaI
AflII
AvrII
SmaI
SmaI
ScaI
AflIII
SmaI
CBA
RFP
SV40
11.2.4 CMV.XIAP
6135 bps
1000
2000
3000
4000
5000
6000
SpeI
NdeI
SnaBI
Asp718
KpnI
BamHI
BstEII
BsgI
PshAI++
SnaBI
MluI
SphI
NotI
XmaIII
BsaBI
MunI
AflII
StuI
Asp718
KpnI
NdeI
Cfr10
NdeI
CMV
hXIAP'
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11.2.5 bRHO.hRHO
This plasmid contains the bovine rhodopsin promoter (bRHO or RhoP) and
human rhodopsin transgene (hRho).
8477 bps
2000
4000
6000
8000
AsuII
NsiI
Ppu10I
SplI
Sse8387
PmaCI
AccI
PflMI
Eco47-3
NcoI
BspMII
SphI
DraIII
BstXI
BsrGI
HpaI
MunI
SexAI
HindIII
AgeI
SspI
ITR
RhoP
h Rho
PolyA
ITR
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11.3 rAAV2/8.CMV.Gdnf
11.3.1 Virus titre
The titre of this virus was 5x10e13. Standards were prepared in duplicate.
Luminance of the 5l and 1l vector samples, and 1012, 1011 and 1010 samples of
both standards was quantified and the titre calculated by comparison of these
luminance values.
Figure 11-4 Genomic titre of the rAAV2/8.CMV.Gdnf vector.
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11.3.2 Protein concentration in samples from rAAV2/8
CMV.GDNF treated eyes
Eyes were enucleated and snap frozen in liquid nitrogen prior to storage at -800C.
On the day of protein assay and GDNF ELISA eyes were removed one by one
from the -800C freezer and crushed in an eppendorf whilst thawing. 120l of
PBS with protease inhibitor (1/100, Sigma) was added and the samples further
homogenised. Centrifugation was performed to separate supernatants that were
used for further analysis.
Total protein concentration in the supernatants from each eye was determined
using a calorimetric protein assay, and comparison to a standard curve using
commercial bovine serum albumin of a known concentration.
Figure 11-5 Total protein concentration in the eyes of six mice that had been
treated with rAAV2/8.CMV.GDNF. Frozen eyes were homogenised. To control
for variability in the degree of homogenisation GDNF concentrations were
compared relative to total eye protein levels.
Chapter 11: Supplementary Data
298
11.4 Control Virus
11.4.1 Titre of control virus
Figure 11-6 Dot-blot titre of rAAV2/8.CMV.HA (no ATG) virus.
11.4.2 Confirmation of absence of transgene expression with
control virus
To determine the effects of sub-retinal injection of virus, infection and
transcription it was important that the control virus was not producing protein
that could independently affect cell function. The plasmid used to generate the
control virus contained a CMV promoter and then a haemagluttin (HA) tag, but
without an intervening ATG sequence.
In vitro evaluation transfections
293 T cells (87 500/well) were transfected with the CMV.HA or CMV.GFP
plasmids, or left untransfected. Transfections were performed using the
lipofectin protocol described in the methods chapter. After 48 hours successful
transfection was confirmed by visualisation of GFP expression in the CMV.GFP
transfected wells. Lysate was drained and the cells collected and disrupted (by
sonification) in RIPA buffer.
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In vivo experiments
AAV2/8 CMV.HA was made and purified using the standard protocols in the
methods chapter. This virus had a titre of 1x1013 vp/ml (Figure 11-6). 3 mice
were injected at P14 of age with superior and inferior injections of 1.5l. Eyes
were enucleated after 6 weeks and snap frozen in liquid nitrogen. They were
then crushed dry and suspended in RIPA buffer. Following a short-spin the
supernatant from each sample was used for further analysis. The treated sample
from one animal was compromised during these steps and so the Western blot
results are for 2 animals.
Western blot
Protein assays were performed on all samples using a bovine serum albumin
(BSA) standard curve. 20g of protein was loaded per well. The primary
antibody used was an anti-HA antibody at a concentration of 1/1000. The
positive control was 20g of HA-tag peptide with a molecular weight of
approximately 55kDa. Both the antibody and HA-tagged protein were supplied
by Abcam, Cambridge, U.K. (product codes ab13834 and ab20896 respectively).
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Figure 11-7 Western blots to validate HA plasmid and control virus.
Chapter 11: Supplementary Data
301
11.5 Rhodopsin constructs
Figure 11-8 The titre of the rhodopsin construct (un-optimised) was determined with a
dot blot as 5x1012 vg/ml.
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11.6 Optimised bRHO.hRHO plasmid
Figure 11-9 Nucleotide sequence before and after optimisation. Changes in the
optimised plasmid are highlighted in red.
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Figure 11-10 Frequency of optimal codons pre and post optimisation. Codon quality
groups are shown on the x-axis with a value of 100 for the codon with the highest usage
frequency for a given amino acid, and 0 for the least used codon. Percentages of
transgene codons within each quality group are shown on the y-axis.
Figure 11-11 The distribution of codon usage frequency along the length of the gene
sequence. A CAI of 1.0 is optimal for gene expression.
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Figure 11-12 Distribution of guanine (G) and cytosine (C) in transgene DNA. G and C
content is shown as a percentage of all nucleotides in 60 base pair sequences.
Figure 11-13 Protein alignment following optimisation (no change to amino acid
sequence)
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Figure 11-14 Protein stain of the bRHO.hRHO (optimised #1) vector. Proteins were
separated by SDS-PAGE and identified with the Spyro Ruby protein stain
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11.7 Quantitative real-time PCR
Quantitative real-time PCR reactions for -actin and XAF1 were performed with
the reaction mixes shown below. Example reaction traces are shown for each.
Gene of interest: -actin
cDNA 1l of 1/10 and 1/100 dilutions
Mastermix FastStart TaqMan Probe Mastermix
Probe #56, Roche. 250 nM
Forward primer AAG GCC AAC CGT GAA AAG AT; 900 nM
Reverse primer GTG GTA CGA CCA GAG GCA TAC; 900 nM
Total volume 30l
Figure 11-15 Examples of -actin quantitative real-time PCR reaction traces.
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Gene of interest: XAF1
cDNA 1l of 1/10 and 1/100 dilutions
Mastermix FastStart TaqMan Probe Mastermix
Probe #2, Roche. 250 nM
Forward primer CTT CCC TTG CCC ATT CTA AA; 900 nM
Reverse primer CCC ACT GGA GTT TCT TTT GG; 900 nM
Total volume 30l
Figure 11-16 Examples of XAF1 quantitative real-time PCR reaction traces.
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11.8 Wild Type ERG
Figure 11-17 Cone function in one year old wild type mice. Three wild type mice were
examined with the phototopic ERG protocol at one year of age. Mean b wave
amplitudes (y axis) are shown with standard deviations at each flash intensity.
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Chapter 12 Abbreviations
AAV adeno-associated virus
Ad adenovirus
adRP autosomal dominant retinitis pigmentosa
AMD age-related macular degeneration
Arr arrestin
arRP autosomal recessive retinitis pigmentosa
b bovine
BDNF brain-derived neurotrophic factor
bFGF basic fibroblast growth factor
BHK baby hamster kidney cells
bp base pair
cAMP cyclic AMP
cDNA complementary DNA
cGMP cyclic GMP
CMV cytomegalovirus
CNS central nervous system
CNTF ciliary neurotrophic factor
CNV choroidal neovascularisation
CORD cone-rod dystrophy
CRALBP cellular retinaldehyde binding protein
CRBP cellular retinol-binding protein
CRX cone-rod otx-like homeobox
DMEM Dulbecco’s Modified Eagle’s Medium
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
ds double stranded
eGFP enhanced green fluorescent protein
Abbreviations
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ERG electroretinogram
ES embryonic stem cell
FACS fluorescence-activated cell sorter
FBS fetal bovine serum
FGF fibroblast growth factor
GC ganglion cell
GCAP guanylate cyclase activator protein
GDNF glial-cell line derived neurotrophic factor
GMP guanosine 5'-monophosphate
GTP guanosine-5'-triphosphate
HEK human embryonic kidney cells
hrGFP human recombinised green fluorescent protein
HSV herpes simplex virus
ILM inner limiting membrane
INL inner nuclear layer
IP intra-peritoneal
IPL inner plexiform layer
IPM inter photoreceptor matrix
IRBP interphotoreceptor retinoid-binding protein
IRD inherited retinal degeneration
IS inner segments
ITR inverted terminal repeats
kb kilobase
kDa kilodalton
l litre
LRAT lecithin-retinol acyltransferase
LTR long tandem repeats
m meter
m- milli
μ-   micro- 
Mertk mer-receptor tyrosine kinase
min minute
Abbreviations
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miRNA micro RNA
mRNA messenger RNA
n- nano-
NF nerve fibre layer
NRL neural retina leucine zipper transcription factor
OD Oculus Dexter (right eye)
OS Oculus Sinister (left eye)
OLM outer limiting membrane
ONL outer nuclear layer
OPL outer plexiform layer
OS outer segments
P postnatal day or photometric units
PCR polymerase chain reaction
PDE phosphodiesterase
PEDF pigment epithelium derived factor
PEG Polyethylene glycol
Pi post injection
Prph2 peripherin2
qRT-PCR quantitative real-time reverse transcription-polymerase
chain reaction
rAAV recombinant AAV
RCS Royal College of Surgeons
rd retinal degeneration
rds retinal degeneration slow
retGC retinal guanylate cyclase
RFP red fluorescent protein
RGC retinal ganglion cells
RGR retinal G-protein-coupled receptor
Rho rhodopsin
Rho-/-Opn.gfp Rhodopsin knockout transgenic mouse with GFP driven
by opsin promoter
RISC RNA induced silencing complex
RK rhodopsin kinase
Abbreviations
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RNA ribonucleic acid
RNAi RNA interference
ROM-1 retinal outer segment membrane protein-1
RP retinitis pigmentosa
RPC retinal progenitor cell
RPE retinal pigment epithelium
RPGR retinitis pigmentosa GTPase regulator
RPGRIP RPGR-interacting protein
rRNA ribosomal RNA
RT reverse transcriptase
shRNA short hairpin RNA
siRNA short interfering RNA
ss single strand
TEM transmission electron microscopy
UTR untranslated regions
vg viral genomes
w/v weight/volume
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